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ABSTRACT 
Heather Ashley Vincent: Regulation of mRNA Translation by Human Cytomegalovirus 
pTRS1 
(Under the direction of Nathaniel Moorman) 
 
Human cytomegalovirus (HCMV) is a major public health burden. Acute infection 
during pregnancy can lead to congenital birth defects, and reactivation of a latent 
infection in immune compromised individuals can cause significant morbidity and 
mortality. HCMV does not encode its own ribosomes, and is therefore completely reliant 
on the host translation machinery for viral protein synthesis. HCMV also does not 
induce host translational shutoff upon infection, thus viral mRNAs must compete with 
cellular mRNAs to efficiently translate viral proteins. The HCMV protein TRS1 (pTRS1) 
plays an integral role in translation regulation during HCMV replication by antagonizing 
the antiviral kinase PKR. Activated PKR phosphorylates eIF2α, which causes an overall 
inhibition of protein synthesis that inhibits HCMV replication. pTRS1 also increases 
overall levels of protein synthesis and enhances the translation of reporter mRNAs in a 
PKR-independent manner, showing that pTRS1 regulates mRNA translation through 
multiple mechanisms. In this dissertation I sought to define the mechanisms used by 
pTRS1 to stimulate translation. In chapter 1 I show that pTRS1 inhibits PKR activation 
by binding to PKR and inhibiting PKR kinase activity. pTRS1 binds PKR residues that 
are conserved across eIF2α kinases, suggesting that pTRS1 can antagonize multiple 
eIF2α kinases. In chapter 2 I show that pTRS1 stimulates cap-independent translation. 
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pTRS1 enhances the activity of both host and viral internal ribosome entry sites (IRESs) 
and stimulates translation of a circular mRNA reporter. These pTRS1 functions were 
independent of its ability to antagonize PKR, but dependent on its ability to bind double-
stranded RNA. To understand how pTRS1 stimulates translation, in chapter 4 I identify 
ribosome-associated, cellular proteins that bind pTRS1. I found that pTRS1 interacts 
with active protein phosphatase 1 (PP1) catalytic subunits. Rather than affect PP1 
catalytic activity, pTRS1 changes the complement of proteins that interact with the PP1 
alpha catalytic subunit, possibly to regulate PP1 substrate specificity. Together these 
data further characterize the mechanisms used by pTRS1 to regulate mRNA translation 
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CHAPTER 1: INTRODUCTION1 
Herpesvirus replication and pathogenesis 
Herpesviruses are double-stranded DNA viruses that infect and cause disease in 
many animal species, including humans (1-3). Several different herpesviruses infect a 
majority of the human population (4-6). Thus, nearly every person is infected with at 
least one herpesvirus. The host immune response initially controls acute infection, and 
the virus then enters a latent state and is harbored by the host for the remainder of their 
life. The majority of herpes infections are latent and therefore asymptomatic (6-8). 
However, lytic herpesvirus replication after primary infection, or reactivation of a latent 
infection, in an immune-compromised or immune naïve individual can cause significant 
morbidity and mortality (7, 9, 10). There are no vaccines for herpesviruses, and current 
antiviral drugs have toxic side effects (11). Therefore, herpesvirus infections are a 
significant global public health burden.        
There are nine types of human herpesviruses (HHVs) (1). HHV-1 and HHV-2 are 
both herpes simplex viruses (HSV-1 and HSV-2, respectively). Both HSV-1 and HSV-2 
are transmitted through contact with infected skin or via fluid exchange, and establish 
lifelong latency in the neural ganglia. Reactivation of an HSV-1 or HSV-2 infection can 
lead to cold sores or genital warts depending on the site of infection (4, 7). Primary 
infection with HHV-3, or varicella zoster virus (VZV), causes chickenpox, while 
																																																								
1 Part of this chapter previously appeared as an article in Virology. The original citation 
is as follows: Vincent HA, Ziehr B, Moorman NJ. “Human Cytomegalovirus Strategies to 
Maintain and Promote mRNA Translation.” Virology. 2016 Apr 13;8(4):97. 
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reactivation of latent VZV from trigeminal or basal root ganglia leads to shingles (12). 
Epstein-Barr virus (EBV), or HHV-4, infects a majority of the population. Nearly 90% of 
adults in the United States have been infected with EBV, and primary infection during 
adolescence can lead to infectious mononucleosis. Reactivation of latent EBV infection 
from B cells in immune-compromised individuals is associated with several cancers 
including Hodgkin’s lymphoma, Burkitt’s lymphoma, and nasopharyngeal carcinoma (6, 
13). HHV-5, or human cytomegalovirus (HCMV), also infects a majority of the 
population. The virus establishes latency in hematopoietic progenitor cells, however 
HCMV can infect many different cell types during a lytic infection. Thus, reactivation of 
HCMV in immune-compromised individuals can lead to disease in multiple organ 
systems, and even result in death (8, 14). In addition, lytic HCMV infection can be 
spread from mother to child during pregnancy causing congenital birth defects (10). The 
roseolovirus genus contains three herpesviruses, HHV-6A, HHV-6B, and HHV-7, which 
infect nearly 100% of the human population. Infection with HHV-6A, HHV-6B or HHV-7 
infection as a child can cause roseola rash and fever, and lead to transplant 
complications in adults (15). While initial infection with Kaposi’s sarcoma-associated 
herpesvirus (KSHV or HHV-8) is typically asymptomatic, reactivation of KSHV is the 
causative agent of Kaposi’s sarcoma, multicentric Castleman’s disease, and primary 
effusion lymphoma (9). Because herpesvirus infection is ubiquitous, the disease burden 
caused by human herpesviruses is staggering, and highlights the need for development 
of herpesvirus vaccines and more efficient therapeutics. 
The nine herpesviruses are further classified into three subfamilies: alpha-, beta- 
and gammaherpesviruses. These classifications were originally based on the speed of 
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replication and range of cell types infected by each virus (2). However, herpesviruses 
are now classified based on the sequence and structure of their viral genome (16). 
Alphaherpesvirus genomes contain a unique long (UL) and unique short (US) region that 
is flanked by short inverted terminal repeat regions. Betaherpesvirus genomes also 
contain both a UL and US region, but are flanked by long inverted terminal repeat 
regions. Gammaherpesvirus genomes contain tandem direct repeat regions at the 
terminal ends of the genome, and in the case of EBV, tandem direct repeat regions 
interspersed throughout the genome (1). Each subfamily contains conserved genes that 
are not present within the other two subfamilies. Thus viruses are classified into 
subfamilies based on these conserved features. Each virus also contains unique genes 
that distinguish it from other viruses within that subfamily (17).  
All herpesviruses have a large, double-stranded DNA genome that is packaged 
in the viral nucleocapsid. A layer of protein and RNA, the tegument, surrounds the 
nucleocapsid, and together the nucleocapsid and tegument layer are packaged within a 
phospholipid bilayer envelope (3). Viral glycoproteins in the virion envelope mediate cell 
entry by binding receptors on the cell surface, and promoting fusion of the viral 
envelope and cell plasma membrane. Following fusion, the viral tegument and 
nucleocapsid are released into the cytosol. The nucleocapsid transits to the nuclear 
envelope, and the viral DNA is then released into the nucleus (17, 18). 
After deposition of the viral DNA in the nucleus, the virus can enter into a phase 
of lytic replication. A large number viral proteins are expressed during lytic infection that 
blunt the host immune response, replicate the viral genome, and produce progeny virus. 
Herpesvirus genes are transcribed in three classes: immediate early (IE), early (E), and 
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late (L). Immediate early genes are the first transcribed and encode viral proteins that 
block innate immune responses and transactivate expression of early genes (19, 20). 
Early viral proteins are involved in replication of the viral genome, induction of metabolic 
changes necessary for efficient viral replication, and transactivation of late viral gene 
expression (21). Late viral proteins primarily function in virion assembly and release (22-
24). This coordinated expression of viral proteins allows herpesviruses to efficiently 
hijack multiple cellular pathways to ensure the production of progeny virus. 
Following an initial lytic infection the virus establishes a latent infection within 
specific cell types. During latency, viral gene expression is very limited as compared to 
lytic replication. Only genes that encode viral proteins that antagonize the host immune 
response and maintain the virus as a chromatinized episome are expressed (6, 8, 25). 
In addition, several herpesviruses express non-coding RNAs and miRNAs that blunt the 
innate immune response during latency (26-28). Repressive chromatin structure on IE 
gene promoters ensures that lE genes are not expressed, and many infections will 
remain latent for the remainder of the host’s lifespan. However conditions that remove 
the repressive chromatin structure from IE promoters, such as stress, can induce IE 
expression and reactivation of lytic replication (29, 30).  
Although this general replication program is conserved, herpesviruses vary 
widely in their cellular tropism, which greatly impacts the specific disease caused by 
each virus. In cell culture, alphaherpesviruses infect a wide range of cell types (31). In 
vivo, however, HSV-1 or HSV-2 lytic replication occurs in epithelial cells at mucosal 
surfaces or areas of broken skin, and latency is established in trigeminal ganglion (7). 
VZV initially infects epithelial cells in the upper respiratory mucosa, and then infects T 
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cells, which disseminate the virus to large areas of skin epithelium, causing chickenpox. 
VZV establishes latency in dorsal root ganglia (32, 33). Reactivation of 
alphaherpesviruses leads to anterograde transport of virions to initial sites of infection, 
where lytic replication ensues (34).  
The betaherpesviruses show a more limited range of cell tropism than 
alphaherpesviruses in vitro, though they infect many cell types in vivo (35, 36). Initial 
lytic HCMV infection is thought to occur within epithelial cells of the genital tract or upper 
respiratory tract. The infection then spreads to the epithelium of multiple organ systems 
including the salivary glands, liver and spleen, and latency is established within myeloid 
progenitor cells (14). HHV-6 and HHV-7 replicate in CD4+ lymphocytes, but can also 
infect epithelial cells. HHV-6 DNA has been found in lymph nodes, macrophages, the 
salivary gland and the central nervous system (37). HHV-6B is thought to establish 
latency in hematopoietic progenitor cells, though the exact cell types supporting HHV-
6A and HHV-7 latency are unknown (15).  
Gammaherpesviruses have the most limited cell tropism (6). KSHV replicates in 
epithelial cells and B cells after primary infection, and establishes latency within B cells 
and monocytes (38). KSHV infection of endothelial cells is also the cause of Kaposi 
sarcoma (39). Similarly, EBV infects both epithelial cells and B cells and establishes 
latency in memory B cells (40).  
 
Human cytomegalovirus pathogenesis 
Human cytomegalovirus (HCMV) is a pervasive herpesvirus that infects nearly 
100% of individuals in developing countries and >60% of individuals in developed 
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nations (5, 41). Primary infection generally occurs during childhood and is transmitted 
via the saliva and urine of infected individuals, most often toddlers. Primary infection in 
children is largely asymptomatic, but may lead to fever and malaise (42). In rare cases 
primary infection of healthy teenagers and adults can cause infectious mononucleosis, 
hepatitis, thrombosis, retinitis and colitis (43-47). Infection can be spread through close 
contact with infected bodily fluids (e.g. saliva, urine, breast milk, semen and cervical 
secretions) (48-51).  When this is the case, epithelial cells in the upper respiratory 
mucosa or genital tract are thought to be the initial site of HCMV lytic replication. 
Infiltrating neutrophils and monocytes are then infected and aid in the dissemination of 
the virus to vascular endothelial cells. Infection can then spread to multiple organ 
systems, including the kidney, salivary gland, liver, inner ear, and central nervous 
system (CNS) (41, 44).  In immune competent individuals, lytic replication in tissues is 
controlled and resolved by virus-specific CD8+ T cells (52, 53). Latency is then 
established within bone marrow resident CD34+ myeloid progenitor cells (54-56). 
Differentiation of latently infected myeloid progenitor cells into macrophages or dendritic 
cells leads to reactivation of lytic replication, likely due to changes in chromatin structure 
that result in expression of immediate early genes (29, 57-59). Reactivation events seed 
further CD34+ progenitor cells with virus, and are cleared by the host immune system, 
often causing no disease. However, reactivation of HCMV lytic replication in immune-
compromised individuals can lead to disease in multiple organ systems (8, 44). 
Reactivation of lytic HCMV replication is a major issue for whole organ transplant 
recipients. Kidney and cardiac allografts are often rejected as a result of HCMV 
infection, with a higher rate in seronegative recipients who receive organs from 
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seropositive donors (60, 61). HCMV disease is most common, averaging 50%, in 
patients receiving bone marrow transplants. In addition, immunosuppressive therapy 
administered before transplant leads to reactivation in ~40% of patients (41, 62, 63). 
This often leads to not only graft rejection, but also the disease states described above. 
Another population highly affected by HCMV reactivation is cancer patients undergoing 
immunosuppressive chemotherapy and AIDS patients, as diminishment of protective T 
cells results in reactivation of lytic replication (64). Active HCMV replication in these 
populations can lead to retinitis, pneumonia, CNS damage, and even death (65, 66).  
HCMV infection is also one of the leading causes of congenital birth defects. A 
primary infection, reinfection with an additional strain, or reactivation of a latent HCMV 
infection during pregnancy can lead to infection of the uterus and the fetus (10, 42). 
Approximately 4-5 children out of every 1,000 live births worldwide have congenital 
HCMV infection, and approximately 1 out of 5 infected children will develop disease as 
a result of the infection (67, 68). Hearing loss is the most common sequela of congenital 
HCMV infection. However congenital infection can also cause vision loss, microcephaly, 
and CNS damage leading to severe developmental and learning disabilities (69, 70).  
There is currently no vaccine to prevent HCMV infection. Further, the drug most 
commonly used to treat HCMV disease (acyclovir and its derivatives) is highly toxic, and 
drug-resistant HCMV strains are becoming increasingly common (11, 71). Thus more 
research defining the molecular mechanisms that regulate HCMV replication are 
needed to define novel targets for antiviral therapeutics and new strategies for the 
design of HCMV vaccines. 
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Human cytomegalovirus replication 
HCMV cell entry is mediated by the viral glycoproteins gH, gB, and gL, which 
mediate fusion of the virion envelope with the envelope of the cell. Upon membrane 
fusion the viral nucleocapsid and tegument are released into the cytoplasm (72-75). 
Several tegument proteins function to blunt initial immune responses (19, 76). The 
HCMV proteins pTRS1 and pIRS1 are both packaged within the tegument and inhibit 
activation of the antiviral kinase PKR (77-79). Additionally, the viral protein UL83 inhibits 
activation of the innate DNA sensor IFI16 (80). The viral nucleocapsid then transits to 
the nuclear envelope and the HCMV genome is released into the nucleus.  
The HCMV genome is the largest of the human herpesviruses (>230kb) and 
encodes multiple miRNAs, long non-coding RNAs (lncRNAs), and >750 ORFs (1, 81-
86). Viral mRNAs are transcribed from both strands of the viral genome, and throughout 
the course of lytic infection almost the entirety of the HCMV genome is transcribed (87). 
Immediately after deposition of the viral genome in the nucleus, viral DNA is circularized 
and chromatinized, at which time the transcription of immediate early (IE) genes begins 
(19). IE genes are defined as genes that are transcribed in the absence of de novo viral 
protein synthesis (i.e. in the presence of the protein synthesis inhibitor cycloheximide) 
(88, 89). Expression of the IE genes IE1 and IE2 initiates lytic replication (90, 91). IE1 
also inhibits cellular histone deacetylases (HDACs) and transactivates promoter 
elements, and IE2 acts as a general transcription factor and regulates cell cycle 
progression (92-96). Thus together IE1 and IE2 promote the expression of early viral 
genes.  
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Early (E) viral genes are primarily responsible for replication of the viral genome, 
and are defined as genes whose expression requires prior IE protein synthesis (21, 88). 
Thus, immediate early viral proteins must be expressed for early viral genes to be 
transcribed. The viral DNA polymerase (UL54), ssDNA binding protein (UL57), and DNA 
polymerase processivity factor (UL44) are all expressed with early kinetics and are 
necessary for viral DNA replication (97-100). In addition viral proteins that prevent 
apoptosis (UL36), promote DNA replication (UL21.5), and regulate cell cycle 
progression (UL33) are also expressed with early kinetics (101-105). 
Early viral proteins then transactivate the expression of late (L) viral genes (22). 
DNA replication is necessary for true late gene expression, as transcription of these 
genes is inhibited in the presence of phosphoacetic acid (PAA), a viral DNA polymerase 
inhibitor (88). Expression of some late viral genes is dampened in the presence of PAA, 
but not prevented; these genes are characterized as “leaky late” genes (106). Late gene 
products (e.g. UL32 and UL52), in general, regulate the formation and egress of mature 
virions (107, 108). 
 
Regulation of mRNA translation during HCMV infection 
Although much is known about the transcriptional regulation of HCMV genes, 
relatively little is known about the translational regulation of viral mRNAs (19, 21, 22, 29, 
88, 106). Viruses are completely reliant on the host translation machinery for the 
synthesis of viral proteins, since no virus encodes a ribosome. As a result, viral and host 
mRNAs must compete for access to ribosomes. This is especially relevant to HCMV, as 
unlike most viruses, HCMV does not induce any host transcriptional or translation shut-
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off. Therefore, both host and viral mRNAs are translated throughout infection (86, 109-
113). Translation initiation, the rate-limiting step of translation, is heavily regulated (113-
115). Multiple antiviral signaling pathways inhibit translation initiation once activated, 
preventing the synthesis of viral proteins (116). Therefore HCMV must simultaneously 
counteract host defenses that inactivate the translation machinery upon sensing viral 
infection, and compete with host mRNAs for limited translation machinery. HCMV 
effectively antagonizes host defenses that limit viral protein expression (113, 117). In 
addition, HCMV manipulates multiple host signaling pathways to ensure the continued 
synthesis of both host and viral proteins needed for virus replication (80, 118, 119). 
Thus, the interface between viral mRNAs and the host translation machinery serves as 
a critical determinant for successful HCMV infection. 
This thesis focuses on understanding the regulation of translation by the HCMV 
protein TRS1 (pTRS1). Therefore a brief overview of the steps in translation, especially 
those most relevant to infection, is provided below. 
 
Overview of translation regulation 
Translation of mRNAs occurs in three steps: initiation, elongation and termination 
(120, 121). Translation initiation begins with the assembly of the eukaryotic initiation 
factor 4F (eIF4F) translation initiation complex on the 7-methyl guanosine cap (m7G 
cap) at the 5’ end of the mRNA. ((122-124) reviewed in (121)). The bound eIF4F 
complex recruits the 43S preinitiation complex (PIC), consisting of the 40S ribosomal 
subunit, the ternary complex and multiple initiation factors, to form the 48S initiation 
complex. The 48S complex then scans the 5’ untranslated region (UTR) of the mRNA 
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until reaching the translation start codon, whereupon multiple initiation factors are 
released and the 60S ribosomal subunit is recruited (125). Joining of the 40S and 60S 
ribosomal subunits to form the 80S ribosome marks the end of the initiation phase, and 
the beginning of elongation. Elongation is regulated by the eukaryotic elongation factor 
1 (eEF1), which promotes binding of aminoacyl-tRNAs to the A-site of the ribosome, 
and eukaryotic elongation factor 2 (eEF2), which facilitates the translocation of peptidyl-
tRNA from the A-site to the P-site of the ribosome (126-128). Peptide elongation 
continues until a translation termination codon is encountered, whereupon translation 
ceases, the nascent peptide chain is displaced from the ribosome, and the ribosome 
disassembles (129, 130). The first step of translation, initiation, is the most regulated 
step ((131-133) reviewed in (134)) and is described in more detail below. 
Formation of the eIF4F complex, which consists of eukaryotic initiation factors 4E 
(eIF4E), 4G (eIF4G) and 4A (eIF4A), mediates the initiation of translation (121, 135). 
eIF4F assembly begins with binding of eIF4E to the m7G cap (122, 136). After binding 
the m7G cap, eIF4E recruits eIF4G, which acts as a scaffold protein that mediates the 
recruitment of the eIF4A RNA helicase, completing the assembly of the eIF4F complex 
(137, 138). eIF4G also coordinates the interaction of the eIF4F complex with additional 
factors bound to the mRNA, such as the poly(A) binding protein (PABP), that enhance 
translation initiation (121, 135, 137-139). Prior to binding the eIF4F complex, multiple 
initiation factors associate with the 40S ribosomal subunit to prepare for translation 
initiation. Together, the 40S subunit and its associated factors are referred to as the 43S 
PIC ((140, 141) reviewed in (115)). The 43S PIC contains the 40S ribosomal subunit, 
multiple initiation factors (e.g., eIF1, eIF1A, eIF3, and eIF5), and a ternary complex 
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composed of the eukaryotic initiation factor 2 (eIF2), guanosine triphosphate (GTP) and 
a charged methionyl-tRNA (tRNAMet) (142). eIF3 plays a critical role during 43S 
assembly, acting as a scaffold to recruit multiple initiation factors to the 40S ribosomal 
subunit (143). These factors affect ribosome scanning, eIF4A helicase activity, and 
fidelity of start codon recognition once associated with the eIF4F complex on the 5’UTR 
of the mRNA (143, 144). 
Recruitment of the 43S PIC to the mRNA is mediated via an interaction between 
the eIF4G subunit of the eIF4F complex and eIF3 within the 43S PIC (145). Together, 
the 43S PIC, the eIF4F complex, and the bound mRNA constitute the 48S initiation 
complex. Once assembled, the 48S complex scans the 5’UTR of the mRNA until 
reaching the translation “start” codon (146). The eIF4A helicase, whose activity is 
stimulated by binding to eIF4B (147, 148), unwinds RNA structures that would otherwise 
impede 48S scanning (146, 149). Additional RNA helicases such as DDX3, DHX9 and 
DHX29 also facilitate scanning through areas with high RNA secondary structure (150-
153). Scanning ceases upon recognition of a translation start site, which almost always 
consists of an AUG methionine codon in a favorable sequence context (i.e., Kozak 
sequence (154)). The combined actions of the eIF1, eIF1A and eIF5 initiation factors 
position the tRNAMet over the AUG codon, triggering hydrolysis of eIF2-bound GTP and 
release of a subset of initiation factors (125). eIF5 directs subsequent joining of the 40S 
and 60S ribosomal subunits to form a functional 80S ribosome, after which peptide 
elongation commences (155). Elongation continues until a translation termination or 
“stop” codon is encountered, at which point eukaryotic release factor 1 (eRF-1) together 
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with eukaryotic release factor 3 (eRF-3) terminates elongation by displacing the nascent 
peptide from the ribosome (129, 130). 
The target of rapamycin (TOR) kinase is conserved throughout eukaryotes, 
where it plays a critical role in modulating protein synthesis in response to the 
intracellular and extracellular environment ((156, 157) reviewed in (120)). In mammalian 
cells, mTOR (mammalian TOR) is found in two complexes: the mTORC1 and mTORC2 
complexes (158, 159). While the two complexes share several subunits, each complex 
has unique defining components. mTORC1 contains the regulatory-associated protein 
of mTOR (raptor), while the presence of rapamycin-insensitive companion of mTOR 
(rictor) defines the mTORC2 complex (160, 161). mTORC1 plays a central role in 
regulating translation initiation by controlling the assembly of the eIF4F complex (162). 
In the hypo-phosphorylated state, the eIF4E-binding protein 1 (4EBP1) binds eIF4E and 
prevents binding to eIF4G, thereby limiting eIF4F formation (163). Phosphorylation of 
4EBP1 by mTORC1 reduces the affinity of 4EBP1 for eIF4E, allowing efficient eIF4F 
complex formation and increasing overall levels of protein synthesis (Figure 1A) (164). 
mTORC1 also promotes protein synthesis by phosphorylating and activating the 
70 kDa ribosomal protein S6 kinase (p70S6K). Active p70S6K phosphorylates several 
factors involved in translation, such as eIF4B and eukaryotic elongation factor 2 kinase 
(eEF2K) (165, 166). When phosphorylated, eIF4B binds eIF4A and increases its 
helicase activity, resulting in more efficient 48S scanning through 5’UTRs with 
significant secondary structure (167). Like mTORC1 itself, p70S6K also phosphorylates 
and deactivates a translation repressor, eEFK2 (166, 168). eEFK2 phosphorylates and 
inactivates eukaryotic elongation factor 2 (eEF2), which stimulates the incorporation of 
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amino acids into the growing peptide chain (169, 170). eEF2K phosphorylation of eEF2 
prevents its association with the ribosome, thereby slowing the rate of elongation (126). 
Thus, protein synthesis is induced through multiple mechanisms upon mTORC1 
activation. 
Protein synthesis is one of the most energy intensive cellular processes. 
Therefore mTORC1 is unsurprisingly subject to both positive and negative regulation in 
response to environmental cues. This regulation converges on the tuberous sclerosis 
(TSC) complex, which negatively regulates mTORC1 activity (171, 172). The 
heterodimeric TSC consists of the tuberous sclerosis 1 (TSC1) and tuberous sclerosis 2 
(TSC2) proteins that together act as a GTPase activating protein (GAP) for the 
mTORC1 cofactor Rheb (173). mTORC1 is activated by association with Rheb-GTP 
and repressed by Rheb-GDP. Increased TSC GAP activity stimulates hydrolysis of GTP 
bound to Rheb, and therefore inhibits mTORC1 activity (174). Decreased nutrient 
availability leads to elevated AMP to ATP ratios that activate the AMP-regulated protein 
kinase (AMPK) (175). Active AMPK phosphorylates TSC2, stimulating TSC GAP activity 
and inhibiting mTORC1 activity (176). Conversely, when nutrients are plentiful, growth 
factor receptor signaling activates the phosphoinositide 3-kinase (PI3K), which 
phosphorylates and inhibits the TSC complex, thereby promoting mTORC1 activity and 
eIF4F assembly (177). Thus the TSC complex integrates upstream signaling pathways 
to modulate mTORC1 activity and protein synthesis to match the nutrient availability 
within the cellular environment. 
Translation of some viral mRNAs does not require 40S ribosomal subunit scanning. 
Instead, ribosomes are recruited to the site of translation initiation, often with limited or 
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no ribosome scanning, by specific RNA sequences/structures called internal ribosome 
entry sites (IRESs) ((178, 179) reviewed in (180)). Ribosome recruitment to IRESs often 
requires only a subset of translation initiation factors. For example, translation initiation 
from the poliovirus IRES is independent of the eIF4E cap binding protein, but requires 
eIF4A, eIF4G and the 43S PIC (181). On the other end of the spectrum, the cricket 
paralysis virus (CrPV) IRES requires only 40S and 60S ribosomal subunits to initiate 
translation (182, 183). Although these and other IRESs require differing factors to 
initiate translation, RNA secondary and tertiary structure is indispensable for the 
recruitment of ribosomal subunits to IRES elements (184). 
In addition to initiation factors, IRES activity can be enhanced through binding of 
IRES trans-activating factors, or ITAFs (185). Two cellular factors consistently function 
as ITAFs, the polypyrimidine tract binding protein (PTB) and the lupus autoantigen (La). 
PTB is an RNA binding protein that directly interacts with RNA secondary structures to 
promote RNA folding and maintain IRES structures (186, 187). The La protein binds the 
5’UTR of multiple viruses, including poliovirus, human immunodeficiency virus (HIV), 
hepatitis C virus (HCV), and influenza virus (188). Binding of La to IRES sequences 
stimulates recruitment of the 40S ribosomal subunit, possibly to promote correct start 
codon usage (189). Both proteins are critical for the activity of multiple viral IRESs 
((190, 191) reviewed in (192)) and promote IRES driven translation during HCV, 
poliovirus and rhinovirus infection (193, 194). 
The length of the 5’UTR and the extent of RNA secondary structure also affect 
mRNA translation efficiency. mRNAs that contain very short 5’UTRs (<20 nucleotides) 
are not efficiently translated, as the AUG start codon is too close to the cap structure, 
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and initiation is inhibited by eIF1 (146, 179, 195-197). Lengthening of an mRNA 5’UTR 
does not inhibit translation efficiency, but increases the likelihood that the UTR will 
contain RNA secondary structures that can impede 43S PIC scanning (149, 198). The 
RNA helicases DHX29, DDX3 and eIF4A are crucial for the efficient translation of 
cellular mRNAs containing highly structured 5’UTRs (199-202). In addition to complex 
RNA secondary structure, the presence of upstream ORFs (uORFs) in the 5’UTR can 
inhibit translation of the downstream protein coding region (203). Translation initiation 
on the uORF produces a short peptide and inhibits initiation at the main, downstream 
ORF. When levels of ternary complex are limiting, such as when eIF2α is 
phosphorylated in response to stress (see below), leaky scanning through the uORF 
occurs and allows for translation initiation at the downstream ORF (204). Nearly 50% of 
cellular mRNAs contain uORFs, potentially allowing for complex regulation of translation 
of these mRNAs in response to changes in the cellular environment (205, 206).  
Another focal point in the regulation of translation initiation is the phosphorylation 
of the alpha subunit of eukaryotic initiation factor 2 (eIF2α). eIF2α is part of the trimeric 
eIF2 complex, which together with GTP and tRNAMet, form the ternary complex that 
associates with the 43S PIC (207). Recognition of the AUG initiation codon by tRNAMet 
stimulates the hydrolysis of eIF2-associated GTP. The resulting release of free 
phosphate triggers eIF2-GDP release from the ribosome (208). Eukaryotic initiation 
factor 2B (eIF2B) then exchanges GDP for GTP in the eIF2 complex, allowing eIF2-
GTP to form a new ternary complex and participate in subsequent rounds of initiation 
(209). Phosphorylation of eIF2α by one of four eIF2α kinases (see below) greatly 
increases the affinity of eIF2B for eIF2, preventing eIF2B release and GTP exchange 
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(210, 211). As eIF2α is present at a much higher concentration than eIF2B, even small 
increases in eIF2α phosphorylation can sequester essentially all of the available eIF2B, 
preventing the formation of new ternary complexes and leading to a dramatic (>80%) 
decrease in protein synthesis (212). 
Similar to the mTOR signaling pathway, eIF2α kinases play a critical role in 
matching the cell’s protein synthesis capacity to the cellular environment. Four eIF2α 
kinases have been identified, each of which are activated in response to a distinct 
cellular stress (reviewed in (213)). The heme-regulated inhibitor (HRI) kinase 
phosphorylates eIF2α in response to high levels of reactive oxygen species, linking the 
rate of protein synthesis to the respiratory capacity of the cell (214). Accumulation of 
unfolded proteins within the endoplasmic reticulum (ER) activates the PKR-like 
endoplasmic reticulum kinase (PERK) (215), temporarily inhibiting protein synthesis to 
allow the cell to properly fold or degrade accumulated unfolded proteins. The eIF2α 
kinase general control nonderepressible 2 (GCN2) is activated by binding to uncharged 
tRNAs that accumulate during amino acid deprivation, directly linking amino acid 
availability to the rate of protein synthesis (216, 217). Particularly relevant to viral 
infections is protein kinase R (PKR), which is activated by binding to viral double 
stranded RNAs (dsRNAs) (218-221) and potently inhibits viral protein synthesis, and 
thus virus replication (211). As discussed above, eIF2α phosphorylation can enhance 
the translation of mRNAs containing uORFs in the 5’UTRs. For example, a uORF in the 
5’UTR of the GADD34 mRNA allows for efficient GADD34 protein synthesis when eIF2α 
is phosphorylated (222). GADD34 binds and recruits protein phosphatase (PP1) to 
eIF2α to mediate eIF2α dephosphorylation. This regulation ensures that eIF2α 
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phosphorylation is reversed after stress is resolved, and inhibition of translation initiation 
is relieved (223).  
The mechanisms used by HCMV to regulate mRNA translation during infection, 
and the signaling pathways that control translation, are discussed below. 
 
Overview of translation regulation during HCMV infection 
Unlike many viruses, HCMV does not limit host translation. Instead, overall levels 
of protein synthesis are maintained in HCMV-infected cells (114). As both host and viral 
mRNAs rely on the same pool of ribosomes for their translation, HCMV mRNAs must 
efficiently compete with host transcripts for access to the translation machinery to 
ensure synthesis of viral proteins. A recent ribosome profiling study showed both host 
and viral mRNAs are efficiently translated as infection progresses. However the overall 
translation efficiency of viral mRNAs exceeds that of host mRNAs late in infection (86, 
109). This suggests that viral mRNAs compete more efficiently for cellular translation 
machinery than host mRNAs. Additionally, HCMV must circumvent antiviral defenses 
that otherwise limit protein synthesis upon infection. Infection activates both antiviral 
defenses and stress response pathways, yet viral protein synthesis and replication 
remain unaffected (see below). While the full spectrum of strategies employed by 
HCMV to regulate host responses is beyond the scope of this introduction, examples of 
the strategies HCMV uses to maintain viral protein synthesis by counteracting host 




The role of the eIF4F complex in HCMV replication 
As discussed above, the eIF4F complex plays a critical role in translation 
initiation by recruiting the 43S PIC to the 5’ end of the mRNA. Recruitment of the eIF4F 
complex, particularly binding of the eIF4E subunit to the mRNA m7G cap, is thought to 
be the rate-limiting step of translation initiation (224). Overall levels of eIF4F often 
directly correlate with the total level of protein synthesis within the cell. The sustained 
eIF4F-dependent translation of host mRNAs during HCMV infection suggests that the 
virus manipulates cellular signaling pathways to maintain eIF4F activity (Figure 1A). 
Consistent with this idea, Walsh et al. found that HCMV infection increases the 
abundance of eIF4F subunits and promotes eIF4F complex formation (114). In addition, 
elevated levels of PABP stimulate eIF4F formation during infection (225). The increase 
in eIF4F abundance is important for virus replication, as disrupting or inhibiting the 
eIF4F complex early during infection profoundly limits virus replication (113, 119, 226). 
Similarly, an eIF4A helicase inhibitor suppresses HCMV replication in vitro when added 
at the time of infection (113). This reflects the necessity for eIF4F-dependent translation 
of host mRNAs during infection, as depletion of several host proteins that require eIF4F 
for their expression reduces the production of progeny virus (227). 
In addition to increasing the abundance of eIF4F subunits, HCMV activates 
signaling pathways that stimulate eIF4F complex formation. mTORC1 activity is 
increased in HCMV infected cells, promoting eIF4F formation by phosphorylating and 
inactivating the 4EBP family of translational repressors (Figure 1A) (114, 226, 228). 
During infection, mTORC1 activity is refractile to cellular stresses such as AMPK 
activation that typically decrease its activity (229-231). In fact HCMV paradoxically 
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requires increased activation of both AMPK and mTOR during infection for efficient 
replication (118). Thus HCMV uncouples mTORC1 activity from negative regulatory 
cues to promote virus replication. The dichotomy of continued mTORC1 activity despite 
AMPK activation is explained by the fact that the HCMV UL38 protein (pUL38) binds 
and inhibits the host TSC2 protein, thus preventing inhibition of mTORC1 by activated 
AMPK (80). pUL38 also stimulates mTORC1 activity in a TSC2-independent manner, 
although the mechanism remains unclear (Figure 1A) (232). Thus HCMV pUL38 severs 
the connection between AMPK and mTOR signaling, allowing for eIF4F formation and 
maintained levels of protein synthesis.  
HCMV infection also stimulates additional signaling pathways that potentially 
enhance translation during infection. The PI3K signaling pathway is stimulated during 
infection and increases mTORC1 activity (233, 234). Chemical inhibitors of PI3K limit 
HCMV replication (233), suggesting that PI3K signaling could play a role in stimulating 
translation in infected cells. HCMV infection also activates the MNK kinases (114), 
which phosphorylate eIF4E (Figure 1A). Phosphorylation of eIF4E is suggested to 
increase the rate of translation through an unknown mechanism. Inhibitors of the MNK 
kinase reduce HCMV replication (114), suggesting that MNK-dependent eIF4E 
phosphorylation regulates protein synthesis in infected cells. Infection also increases 
the abundance of the critical translation elongation factor eEF2 in a UL38-dependent 
manner (Figure 1B). While the role of the above signaling changes in HCMV translation 
has not been demonstrated, their association with the control of translation in other 
contexts suggests a potential role in translation regulation during HCMV infection. 
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As suggested by the multiple mechanisms HCMV employs to induce and 
maintain mTORC1 activity, decreased mTOR activity or expression inhibits virus 
replication (113, 119, 226). Depletion of mTOR, rictor or raptor decreases HCMV 
replication, as do ATP-competitive inhibitors of mTOR kinase activity (228, 235). 
However, mTOR inhibitors also prevent metabolic remodeling induced by HCMV during 
infection, thus the effects of the inhibitors are likely pleiotropic (236).  
Interestingly, mTOR inhibitors have little effect on viral protein synthesis when 
added later in infection (119, 235). The association of viral mRNAs with polysomes is 
largely unaffected by treatment with Torin1, which inhibits mTOR activity and prevents 
the formation of the eIF4F complex. In contrast, the translation efficiency of most host 
mRNAs is greatly reduced in infected cells treated with Torin1. In addition, hippuristanol, 
an inhibitor of the RNA helicases eIF4AI and eIF4AIII, does not affect viral replication 
later in infection, nor does it inhibit IE1 and IE2 protein expression at immediate early 
times after infection. These data suggest that HCMV uses a unique set of factors (viral 
and/or host) to regulate translation initiation during infection and ensure that viral 
mRNAs remain efficiently translated when eIF4F availability is limited. 
 
Alternate modes of translation initiation during infection  
Many viruses use IRES elements to ensure translation of viral mRNAs under 
stress conditions that limit host protein synthesis. The best characterized IRES-like 
element identified to date in the HCMV genome is located adjacent to the UL138 open 
reading frame (ORF). The UL138 ORF is the most 3’ of four ORFs encoded on a 
polycistronic mRNA, suggesting that cap-mediated translation initiation of UL138 would 
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be exceedingly inefficient. The UL138 IRES-like element directs internal initiation on the 
polycistronic pUL138 transcript and allows for increased UL138 protein synthesis under 
conditions of cell stress (237). While the role of the UL138 IRES during infection is 
unknown, it likely plays a role in regulating HCMV latency, as pUL138 acts as a 
molecular switch that regulates virus reactivation (238). A recent study identified ~100 
HCMV 5’UTRs that contain IRES activity (239). However, whether or not these IRES-
like elements allow for non-canonical translation initiation during infection events 
remains to be determined.  
HCMV also stimulates the translation of at least one IRES-containing cellular 
mRNA encoding a protein needed for virus replication. Cells induce a coordinated 
response to the accumulation of unfolded proteins in the ER, aptly named the unfolded 
protein response (UPR). While induction of the UPR generally suppresses protein 
synthesis, the translation of a subset of mRNAs involved in resolving cell stress is 
selectively increased. HCMV infection induces the UPR, but selectively modulates 
downstream signaling pathways to support virus replication (240, 241). Induction of the 
UPR leads to increased levels of the ER chaperone BiP (binding immunoglobulin 
protein) in infected cells, which likely supports HCMV replication by increasing the 
protein folding capacity of the ER (242, 243). The BiP mRNA contains an IRES element, 
and HCMV stimulates BiP mRNA translation in part by increasing the expression of the 
La protein, a known ITAF for the BiP IRES (244). Given the increase in La abundance 
during infection and the wide range of cellular and viral mRNAs that La interacts with, 
HCMV infection may stimulate the translation of additional IRES-containing cellular 
mRNAs. 
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HCMV and eIF2α  kinases 
HCMV infection generates cellular stresses that are potent activators of eIF2α 
kinases. However very little eIF2α phosphorylation is observed in infected cells, and 
only during the late stage of the virus lytic cycle (245), suggesting that HCMV actively 
prevents eIF2α kinase activation. The mechanism(s) used by HCMV to inhibit or 
counteract activation of two eIF2α kinases, PKR and PERK, is well described (78, 117, 
245-248). The potential role of the other eIF2α kinases, HRI and GCN2, during HCMV 
infection is less clear, however they could play beneficial or inhibitory roles in virus 
replication. 
The antiviral kinase PKR is the best characterized eIF2α kinase during HCMV 
infection. PKR is activated upon binding to double-stranded RNAs (dsRNAs) generated 
during the early stage of HCMV infection (249). Binding to dsRNA induces PKR 
homodimerization and subsequent activating autophosphorylation. Activated PKR then 
binds and phosphorylates eIF2α, leading to a significant decrease in the translation of 
both cellular and viral mRNAs, and thus decreased virus replication. dsRNA ligands for 
PKR accumulate during HCMV replication (250), likely due to transcription from 
overlapping regions of both strands of the viral genome. Yet PKR activation and eIF2α 
phosphorylation are not observed, suggesting HCMV actively prevents PKR activation.  
 Almost all viruses express factors that inhibit PKR activation or limit eIF2α 
phosphorylation in infected cells. Some viruses produce RNAs that bind PKR and 
prevent its recognition of dsRNA ligands, such as the adenovirus VAI RNA (251) and 
Epstein-Barr virus (EBV) EBER RNAs (252). Other viruses encode proteins that inhibit 
PKR activation or reverse eIF2α phosphorylation. The herpes simplex virus 1 (HSV-1) 
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US11 protein prevents PKR activation (250, 253), while the HSV-1 ICP34.5 protein 
recruits the host protein phosphatase 1 (PP1) to de-phosphorylate eIF2α in order to 
maintain sufficient levels of active ternary complex (254). Thus inhibition of PKR is a 
conserved strategy used by many viruses to ensure efficient viral protein synthesis and 
virus replication.   
Using a screen to identify HCMV genes that rescue growth of a vaccinia virus 
mutant lacking its PKR antagonist E3L, the laboratory of Dr. Adam Geballe identified the 
HCMV TRS1 and IRS1 proteins (pTRS1 and pIRS1, respectively) as potent PKR 
antagonists (79). Expression of either pTRS1 or pIRS1 is necessary for HCMV 
replication, as a recombinant virus lacking both proteins fails to replicate (249). 
Replication of a ΔTRS1/ΔIRS1 double mutant is rescued through depletion of PKR 
mRNA or disruption the PKR gene expression (77, 78). Thus a major function of 
pTRS1/pIRS1 during infection is to prevent inhibition of viral protein synthesis by PKR 
(Figure 1B). Despite pTRS1/pIRS1 inhibition of PKR, phosphorylated eIF2α 
accumulates in infected cells during the late stage of HCMV infection (240, 255).  
The eIF2α kinase PERK also plays a critical role in HCMV replication. High levels 
of protein synthesis, as during the late phase of HCMV infection, can overwhelm the 
folding capacity of the endoplasmic reticulum (ER). The presence of unfolded proteins 
in the ER initiates a coordinated cellular response, called the unfolded protein response 
(UPR). The UPR is activated when unfolded proteins accumulate in the ER, competing 
the ER chaperone BiP away from its normal binding partners, the ER sensors ATF6, 
IRE-1 and PERK (256). Loss of BiP binding activates each sensor and initiates a series 
of events designed to re-establish cellular homeostasis. Dissociation from BiP also 
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activates PERK, which then phosphorylates eIF2α. This results in a global reduction in 
translation, preventing the synthesis of new proteins into the already overtaxed ER. In 
addition eIF2α phosphorylation enhances the translation of a specific subset of mRNAs 
that encode proteins involved in resolving ER stress (257). Thus eIF2α phosphorylation 
by PERK allows the cell to both prevent further accumulation of unfolded proteins and 
reduce their levels within the ER.  
As mentioned above, HCMV manipulates many aspects of the UPR, including 
the activity of the eIF2α kinase PERK. PERK levels increase during infection, and 
PERK expression is necessary for efficient HCMV replication (240). Depletion of PERK 
prevents the increase in lipid synthesis observed during infection, and inhibits viral 
growth (248). Despite activation of the UPR and increased PERK abundance, PERK 
remains inactive until late in infection. The factors responsible for the regulation of 
PERK activity during HCMV infection are not known. However PERK activation is not 
responsible for eIF2α phosphorylation late in infection, as eIF2α phosphorylation is 
observed when PERK expression is knocked down (258).  These data again 
demonstrate how HCMV manipulates complex signaling pathways to ensure successful 
virus replication. 
HCMV-induced ER stress also increases the levels of reactive oxygen species 
(ROS) and overall levels of oxidative stress, which activate the eIF2α kinase heme-
regulated inhibitor kinase (HRI) (259). Infection also stimulates NADPH oxidase, the 
enzyme responsible for production of superoxide (231). As HCMV induces oxidative 
stress and limits eIF2α phosphorylation, it seems likely that the virus regulates HRI 
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activation or its ability to phosphorylate eIF2α. However the effect of HCMV-induced 
oxidative stress on HRI expression and activity has not been examined.  
High levels of translation increase the levels of deacetylated, or uncharged, 
tRNAs in the cell. The eIF2α kinase general control nonderepressible 2 (GCN2) is 
activated by binding to uncharged tRNAs (259). Thus as levels of translation and 
uncharged tRNAs increase, so do the levels of eIF2α phosphorylation. The resulting 
inhibition of translation allows the cell to restore a sufficient pool of charged tRNAs to 
support normal levels of protein synthesis. The high levels of viral protein synthesis 
together with the ongoing synthesis of host proteins would be expected to decrease the 
available pool of charged tRNAs, resulting in GCN2 activation. To date the role of GCN2 
during HCMV infection has not been examined, however it seems likely that HCMV 
regulates GCN2 signaling to allow for continued viral protein expression. The related 
murine cytomegalovirus (MCMV) causes more severe disease in mice lacking GCN2 
compared to wild type mice (260), demonstrating an antiviral role for GCN2 in vivo. 
Because HCMV induces multiple stresses that could activate GCN2, and GCN2 plays 
an antiviral role in MCMV infection, it is likely that HCMV has mechanisms in place to 
limit GCN2 activation.  
While infection induces stress that should activate multiple eIF2α kinases, eIF2α 
is not phosphorylated until late in infection (261, 262). Interestingly, both host and viral 
mRNAs are translated efficiently at this time despite eIF2α phosphorylation (86, 109). It 
is unclear if eIF2α phosphorylation no longer restricts translation initiation late in 
infection, or if the extent of eIF2α phosphorylation is insufficient to suppress protein 
synthesis. Perhaps the increased abundance and activity of the host PP1 and PP2A 
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phosphatases during infection (263) in conjunction with viral inhibitors of eIF2α kinases 
allow for efficient translation in the presence of multiple eIF2α stresses. Regardless, 
continued protein synthesis in the face of significant cellular stress suggests that HCMV 
encodes viral proteins that limit eIF2α kinase activity, or actively limit eIF2α 
phosphorylation in response to virus-induced stress. 
 
Role for HCMV pTRS1 in translation regulation 
 As stated above, HCMV has multiple mechanisms in place to antagonize antiviral 
signaling events that inhibit translation initiation to ensure the continued synthesis of 
viral proteins. Two viral proteins involved in this process, pTRS1 and pIRS1, antagonize 
activation of the antiviral kinase PKR (78, 117). This prevents phosphorylation of PKR’s 
substrate, eIF2α, to ensure continued translation initiation. Thus pTRS1 and pIRS1 are 
pivotal in the regulation of translation during HCMV infection.  
 HCMV pTRS1 and pIRS1 were first shown to enhance the transactivation of viral 
promoters by IE1 and IE2 in vitro (264-266). However, when the TRS1 gene was 
removed from HCMV (HCMVΔTRS1), viral genomes and mRNAs accumulated to 
similar levels as wild-type virus. A defect in the amount of cell-free virus released late in 
infection was observed when primary human foreskin fibroblasts (HFFs) were infected 
with HCMVΔTRS1 at a low multiplicity of infection (267). It was later shown that pTRS1 
played a minor role in the proper formation of DNA-containing capsids (268).  
Later studies by Geballe et. al. demonstrated a role for pTRS1 and pIRS1 in 
blocking antiviral signaling. Either protein alone was sufficient to rescue replication of a 
vaccinia virus mutant lacking its PKR antagonist, E3L (VVΔE3L). Expression of pTRS1 
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or pIRS1 restored overall levels of protein synthesis, inhibited phosphorylation of eIF2α, 
and prevented activation of an additional antiviral protein, RNaseL following VVΔE3L 
infection (79). E3L binds and sequesters dsRNA ligands to prevent activation of PKR, 
suggesting pTRS1 might prevent PKR activation through a similar mechanism (269). 
The subsequent finding that pTRS1 and pIRS1 both contain a non-canonical RNA 
binding domain in their conserved amino terminus further supported this hypothesis. 
pTRS1 binds both poly(I:C), a dsRNA ligand that activates PKR, and dsRNA hairpins of 
varying size (20, 29, and 39bp) (270). Three amino acids in the pTRS1 RNA binding 
domain (R121, R124, K125) are necessary for pTRS1 binding to poly(I:C). A pTRS1 
mutant with these residues mutated to alanines (pTRS1 triple) did not rescue replication 
of VVΔE3L, suggesting that in this system the ability of pTRS1 and pIRS1 to bind 
dsRNA is important to inhibit PKR activation. Although the affinity of pTRS1 for dsRNA 
is much lower than that of PKR, the molar ratio of pTRS1 and pIRS1 together is greater 
than PKR across infection, suggesting that together pTRS1 and pIRS1 could efficiently 
compete with PKR for dsRNA ligands (246).    
An HCMV mutant lacking both TRS1 and IRS1 (ΔTRS1/ΔIRS1) does not 
replicate in human foreskin fibroblasts (HFFs). Robust eIF2α phosphorylation is seen 
early after infection with ΔTRS1/ΔIRS1, which correlates with reduced overall levels of 
protein synthesis (271). dsRNA accumulates in HCMV infected cells, leading to the 
assumption that PKR was activated in the absence of pIRS1 and pTRS1. This would 
then lead to eIF2α phosphorylation and reduced protein synthesis (249). However this 
was not shown, as the authors did not measure PKR activation or demonstrate that 
PKR was required for eIF2α phosphorylation or inhibition of protein synthesis. 
 29 
Subsequently we found that loss of both pIRS1 and pTRS1 during HCMV infection 
leads to activation of PKR and phosphorylation of eIF2α. We generated cells expressing 
an shRNA against IRS1 (HFF-shIRS1), and infected these cells with HCMV mutants 
lacking either the entire pTRS1 ORF (HCMVΔTRS1), or the pTRS1 PKR binding 
domain (HCMVΔPBD). The absence of pIRS1 in these cells allowed us to specifically 
test the role of pTRS1 in PKR inhibition during HCMV infection. Infection of HFF-shIRS1 
with HCMVΔTRS1 caused robust PKR and eIF2α phosphorylation, reduced overall 
levels of protein synthesis, and decreased virus replication. Importantly each of these 
phenotypes could be rescued by depletion of PKR prior to infection. Identical results 
were found after infection with HCMVΔPBD, which importantly contains the pTRS1 
dsRNA binding domain. These data suggest that the ability of pTRS1 to bind PKR, 
rather than dsRNA, is necessary for inhibition of PKR activation (77). Similar results 
were concurrently reported by another group (78); mutation of four amino acids in the 
pTRS1 PKR binding domain, that disrupt the interaction between pTRS1 and PKR, 
significantly attenuated HCMV replication in HFFs, even though the pTRS1 dsRNA 
remained intact. Further, mutant virus replication was rescued when PKR expression 
was ablated in using CRISPR/Cas9.  
Interestingly, when our group infected IRS1 knockdown cells with HCMV 
TRS1ΔPBD we found that stress granules accumulated during infection (77). Stress 
granules form when pre-initiation complexes stall on mRNAs in response to eIF2α 
phosphorylation (272). The stalled mRNAs are redistributed into protein-RNA 
aggregates called stress granules until cellular stress is resolved. Stress granules do 
not form during wild-type HCMV infection, suggesting that pTRS1, specifically through 
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an interaction in its carboxyl-terminus, prevents stress granule formation during HCMV 
infection. This is likely due to reduced eIF2α phosphorylation resulting from the 
inhibition of PKR. However, we also found that pTRS1 inhibits stress granule formation 
in response to an HRI agonist, arsenite, in PKR-deficient cells. This result demonstrates 
two things: (1) that pTRS1 inhibits eIF2α phosphorylation resulting from activation of 
multiple eIF2α kinases and (2) that it does so in a PKR-independent manner. Although 
the main function of pTRS1 during HCMV infection of HFFs appears to be PKR 
antagonism, the role for additional PKR-independent functions of pTRS1 in other cell 
types has yet to be determined.  
One additional function for pTRS1 that we identified was the ability of pTRS1 to 
promote mRNA translation independent of PKR inhibition. We identified pTRS1 in a 
proteomics screen of m7G cap-binding proteins during HCMV infection. I found that 
pTRS1 directly interacts with m7G cap, independent of the presence of any other 
translation initiation factors or other viral proteins (273). pTRS1 also associates with 
40S ribosomal subunits (273) and interacts with ribosomal subunit proteins (our 
unpublished data). Our group also showed that exogenous expression of pTRS1 in 
transfected cells increases overall levels of protein synthesis by 50%, and stimulates 
the translation of reporter mRNAs containing viral or cellular 5’UTRs. To determine if the 
ability of pTRS1 to stimulate translation was simply due to PKR inhibition, we repeated 
these experiments in cells where we disrupted PKR expression using CRISPR/Cas9 
mutagenesis. We found that pTRS1 maintained the ability to increase protein synthesis 
and stimulate the translation of reporter mRNAs, although to lower levels that in wild 
type cells (273). These data show that while inhibition of PKR contributes to the 
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increase in translation, pTRS1 also has a PKR-independent mechanism to promote 
translation. These data suggest that pTRS1 may recruit ribosomal subunits directly to 
mRNAs to stimulate their translation. Additionally, pTRS1 may play a role in the 
regulation of viral mRNA translation during HCMV infection.  
 
Outstanding questions in the field 
The current data show that the primary function of pTRS1 during HCMV infection 
of HFFs, the cell type commonly used to study lytic HCMV replication, is to inhibit PKR 
activation. Inhibition of PKR by pTRS1/pIRS1 prevents phosphorylation of eIF2α and 
inhibition of viral protein synthesis. Additionally, the ability of pTRS1 to antagonize PKR 
is dependent on a direct interaction (274). However, the molecular mechanism by which 
pTRS1 prevents PKR activation remains unknown.  
 The PKR-independent role of pTRS1 in translation regulation during HCMV 
infection has not been examined. Our group has shown that translation of HCMV 
transcripts, but not cellular transcripts, becomes resistant to eIF4F disruption late in 
infection (113). This suggests that HCMV utilizes a non-canonical translation initiation 
complex to promote the translation of viral mRNAs late in infection. Could pTRS1 be 
responsible for this eIF4F-independent translation initiation? We have shown that 
pTRS1 preferentially stimulates the translation of reporter mRNAs containing viral 
5’UTRs compared to reporter mRNAs containing cellular 5’UTRs (273). Thus it is 
possible that pTRS1 is promoting the recruitment of ribosomal subunits to viral mRNAs 
and ensuring their efficient translation under conditions of limiting translation initiation 
factors. 
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Another unresolved question is how does pTRS1 stimulate translation in a PKR-
independent manner? In addition to binding PKR, pTRS1 also binds dsRNA. We have 
shown the pTRS1 RNA binding domain (amino acids 84-246) is dispensable for the 
inhibition of PKR activation, but it is necessary for the stimulation of translation of 
reporter mRNAs in transfected cells (273). The molecular mechanism(s) underlying this 
function remains unknown. pTRS1 may be functioning as a viral initiation factor that 
promotes the recruitment of ribosomes to target mRNAs. Alternatively pTRS1 may be 
antagonizing additional signaling pathways that inhibit translation. In any case, further 
work is needed to understand how pTRS1 stimulates translation in a PKR-independent 
manner. 
  In this thesis I explored the molecular mechanism by which pTRS1 antagonizes 
PKR, and how pTRS1 stimulates translation in a PKR-independent manner. In Chapter 
2 I showed that the ability of pTRS1 to bind dsRNA is dispensable for its ability to inhibit 
PKR activation, in vitro. However, the ability to bind PKR is necessary. pTRS1 interacts 
with conserved residues within the PKR kinase domain that mediate the interaction of 
PKR with eIF2α. pTRS1 binding to PKR mediates inhibition of PKR kinase activity, thus 
preventing PKR from undergoing activating autophosphorylation. In addition, pTRS1 
interacts with HRI and limits the accumulation of eIF2α phosphorylation in response to 
arsenite treatment in PKR KO cells, suggesting that pTRS1 inhibits the activation of 
multiple eIF2α kinases. 
 In Chapter 3, I examined the ability of pTRS1 to stimulate cap-independent 
translation. I found that pTRS1 increases the activity of both the poliovirus IRES and 
KSHV vFLIP IRES in a bicistronic reporter assay by promoting IRES-dependent 
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translation. To address technical caveats of bicistronic reporter assays, I also tested the 
ability of pTRS1 to stimulate translation of a circular mRNA reporter whose translation is 
driven by an IRES. This mRNA reporter contains neither a m7G cap nor a poly(A) tail, 
thus translation of the reporter mRNA is driven solely by the IRES element. I showed 
that pTRS1 stimulates cap-independent translation driven by both viral and cellular 
IRES elements. The ability of pTRS1 to stimulate cap-independent translation is PKR-
independent, but requires the pTRS1 dsRNA binding domain, suggesting that pTRS1 
binds RNA secondary structures to promote the translation of specific mRNAs. 
 To understand how pTRS1 promotes translation independent of PKR inhibition, 
in Chapter 4 I identified ribosome-associated proteins that interact with pTRS1 using the 
BioID approach. BioID works by generating a fusion protein consisting of your gene of 
interest fused to a promiscuous biotin ligase (BirA) domain. Proteins that interact with 
the BioID fusion protein are covalently biotinylated, and can be recovered with 
streptavidin affinity chromatography and identified by mass spectrometry. Using a 
pTRS1-BioID fusion protein, I identified proteins that specifically interact with pTRS1 
and also associate with ribosomes. 114 binding partners were consistently identified in 
the screen, and multiple interactions were confirmed both in transfection and during 
HCMV infection. I found that pTRS1 interacts with all isoforms of protein phosphatase 1 
(PP1) catalytic subunits in transfected cells, and with the PP1β catalytic subunit during 
infection. pTRS1 immune complexes isolated from infected cells have associated 
phosphatase activity, and pTRS1 does not change the activity of PP1 catalytic subunits. 
Additionally, we showed that pTRS1 changes the complement of proteins that interact 
with PP1. Thus pTRS1 does not inhibit PP1 activity, but likely targets PP1 to specific 
 34 
substrates. As phosphorylated eIF2α is a PP1 target, this data suggests that pTRS1 
may limit eIF2α phosphorylation through the recruitment of PP1 to eIF2α. 
 Lastly, in the Discussion (Chapter 5) I describe how my findings have advanced 
our understanding of the role of pTRS1 in regulating mRNA translation, and what 
remains to be done to understand how pTRS1 functions and how those functions affect 





















Figure 1. Schematic of human cytomegalovirus (HCMV) manipulation of 
translation initiation and elongation. (A) HCMV stimulates eIF4F formation and 
activity through multiple mechanisms. Infection increases levels of eIF4F components 
(eIF4E, eIF4G, eIF4A) and poly(A) binding protein (PABP). HCMV also promotes eIF4F 
assembly by activating mTORC1, which phosphorylates and inhibits the eIF4F 
 36 
antagonist 4EBP1. The HCMV UL38 protein prevents inactivation of mTORC1 by 
inhibiting the tuberous sclerosis complex (TSC). pUL38 also stimulates mTORC1 
activity through a TSC2-independent mechanism. mTORC1 activates p70S6K, which 
phosphorylates eIF4B to increase eIF4A helicase activity. HCMV infection activates the 
PI3K pathway to promote mTORC1 activation, and may also regulate translation 
through activation of MNK kinases. (B) Translation initiation and elongation are 
maintained during HCMV infection. Inhibition of eIF2α phosphorylation ensures the 
regeneration of ternary complexes and continued rounds of translation initiation. Levels 
of eEF2 increase during infection through a pUL38-dependent mechanism and may 
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CHAPTER 2: MECHANISM OF PKR INHIBITION BY HCMV PTRS11 
OVERVIEW 
Double stranded RNAs (dsRNA) produced during human cytomegalovirus 
(HCMV) infection activate the antiviral kinase PKR, which potently inhibits virus 
replication. The HCMV pTRS1 and pIRS1 proteins antagonize PKR to promote HCMV 
protein synthesis and replication, however the mechanism by which pTRS1 inhibits PKR 
is unclear. PKR activation occurs in a three-step cascade. First, binding to dsRNA 
triggers PKR homodimerizaton. PKR dimers then autophosporylate, leading to a 
conformational shift that exposes the binding site for the PKR substrate eIF2α. 
Consistent with previous in vitro studies, we found that pTRS1 bound and inhibited 
PKR. pTRS1 binding to PKR was not mediated by an RNA intermediate, and mutations 
in the pTRS1 RNA binding domain did not affect PKR binding or inhibition. Rather, 
mutations that disrupted the pTRS1 interaction with PKR ablated the ability of pTRS1 to 
antagonize PKR activation by dsRNA. pTRS1 did not block PKR dimerization, and could 
bind and inhibit a constitutively dimerized PKR kinase domain. In addition, pTRS1 
binding to PKR inhibited PKR kinase activity. Single amino acid point mutations in the 
conserved eIF2α binding domain of PKR disrupted pTRS1 binding, and rendered PKR 
resistant to inhibition by pTRS1. Consistent with a critical role for the conserved eIF2α 
																																																								
1 This chapter previously appeared as an article in the Journal of Virology. The original 
citation is as follows: Vincent HA, Ziehr B, Moorman NJ. “Mechanism of PKR inhibition 
by HCMV pTRS1.” J Virol. 2017 Feb 14;91(5). 
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contact site in PKR binding, pTRS1 bound an additional eIF2α kinase, HRI, and 
inhibited eIF2α phosphorylation in response to an HRI agonist. Together our data 
suggest that pTRS1 inhibits PKR by binding to conserved amino acids in the PKR eIF2α 
binding site and blocking PKR kinase activity. 
 
INTRODUCTION 
Protein kinase R (PKR) plays a critical role in the cellular intrinsic antiviral 
response (1). Double stranded RNAs (dsRNAs) produced during viral infection activate 
PKR, leading to phosphorylation of its only known substrate, the alpha subunit of the 
eIF2 translation initiation factor (eIF2α (2-4). Phosphorylation of eIF2α reduces 
formation of the ternary complex, which is composed of eIF2α, GTP and a charged 
methionyl tRNA (tRNAMet) (5). Since the ternary complex is required for translation 
initiation, activation of PKR limits the synthesis of both cellular and viral proteins and 
inhibits virus replication (6, 7). Active PKR further limits virus replication by increasing 
type I interferon expression, stimulating apoptosis, inducing autophagy and possibly 
activating inflammasomes (8-14). Together these functions make PKR a potent antiviral 
effector capable of inhibiting the replication of many viruses. 
Both RNA and DNA viruses generate dsRNA ligands that activate PKR during 
infection. Structured regions of RNA virus genomes and dsRNA replicative 
intermediates are the most likely triggers of PKR activation during RNA virus infection 
(15-17). dsRNAs produced by overlapping transcriptional units during DNA virus 
replication likely drive PKR activation (18, 19). While PKR exists as an inactive 
monomer in uninfected cells, binding to dsRNA, mediated by two amino terminal dsRNA 
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binding domains (dsRBDs), results in a conformational shift that allows for PKR 
dimerization. Dimerization results in PKR autophosphorylation on multiple serine and 
threonine residues, however only phosphorylation on threonine 446 (Thr446) and 451 
(Thr451) in the PKR kinase domain (KD) activation loop are necessary for PKR 
activation (16, 20-23). Following autophosphorylation, conserved residues within the αG 
helix in the C-lobe of the PKR kinase domain mediate its interaction with eIF2α (3, 4). 
PKR binding to dsRNA ligands thus leads to a catalytically active PKR capable of 
binding and phosphorylating eIF2α, resulting in inhibition of protein synthesis and 
decreased viral replication. 
Almost every virus encodes a PKR inhibitor, underscoring the critical role of PKR 
in the antiviral response (1). In several cases a single virus employs multiple proteins to 
limit PKR activation or mitigate the effects of eIF2α phosphorylation. For example, 
herpes simplex virus (HSV) encodes three proteins that limit PKR activation and eIF2α 
phosphorylation to facilitate virus replication. The vhs protein degrades viral dsRNAs 
that otherwise activate PKR, while the US11 protein binds PKR and prevents PKR-
dependent eIF2α phosphorylation (12, 24). In addition, the ICP34.5 protein recruits the 
cellular protein phosphatase 1 (PP1) to dephosphorylate eIF2α and ensure continued 
synthesis of viral proteins (25). Similarly, the murine cytomegalovirus (MCMV) m142 
and m143 proteins and the vaccinia virus (VV) K3L and E3L proteins each function to 
limit PKR activation (15, 26-33). Other viruses including orthomyxoviruses, flaviviruses 
and retroviruses each encode at least one PKR antagonist, highlighting the important 
role of PKR antagonism for successful viral replication (15, 17, 34). 
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Like the above viruses, human cytomegalovirus (HCMV) encodes PKR 
antagonists that are necessary for virus replication. The HCMV TRS1 and IRS1 proteins 
(pTRS1 and pIRS1, respectively) each inhibit PKR activation (7, 35-37). The amino 
terminal two thirds of both pTRS1 and pIRS1 are conserved and contain a noncanonical 
RNA binding domain that competitively inhibits PKR binding to dsRNA ligands in vitro 
(38, 39). While the carboxyl-terminal third of pTRS1 and pIRS1 differ in sequence, both 
proteins contain a C-terminal PKR binding domain and both can inhibit PKR activation 
(6, 7, 37). Expression of either pTRS1 or pIRS1 is sufficient to prevent PKR activation 
during HCMV infection of human fibroblasts, and viral protein synthesis and HCMV 
replication are dramatically reduced in the absence of both proteins (6, 7, 18). pTRS1 
and pIRS1 have additional functions, including promoting mRNA translation and limiting 
autophagy (40-49). However, the viral replication defect observed in the absence of 
both pTRS1 and pIRS1 is largely reversed through inhibition of PKR expression (6, 7). 
Though the other functions of pTRS1 and pIRS1 may play important roles in other cell 
types, inhibiting PKR activation appears to be the predominant role for pTRS1 and 
pIRS1 during HCMV infection of primary human fibroblasts.  
While the role of pTRS1 and pIRS1 as PKR antagonists is well established, 
questions remain concerning the mechanism by which they inhibit PKR. pTRS1 binds 
both dsRNA and PKR, but the relative importance of these two functions for PKR 
antagonism is unknown. In this study we performed a series of molecular biology and 
biochemical experiments to further elucidate the molecular mechanism(s) by which 
pTRS1 prevents PKR activation.  We found that pTRS1 binding to both dsRNA and 
PKR contribute to PKR antagonism, although pTRS1 binding to PKR is the predominant 
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mechanism that mediates PKR inhibition by the full-length TRS1 protein. Our results 
suggest that pTRS1 does not block PKR dimerization, but rather prevents activating 
autophosphorylation of PKR dimers. pTRS1 binding to PKR is mediated through 
interactions with conserved amino acids in the PKR eIF2α contact site, and results in 
inhibition of PKR kinase activity. We also found that pTRS1 binds the HRI kinase and 
inhibits eIF2α phosphorylation in response to the HRI agonist arsenite in PKR-deficient 
cells. Together our results provide further insight into the mechanism of PKR 
antagonism by pTRS1. 
 
MATERIALS AND METHODS 
Cells and viruses. HEK293T cells and MRC-5 fibroblasts were cultured in 
Dulbecco’s Modified Eagle Medium (Sigma) supplemented with 10% fetal bovine serum 
(Sigma) and 100 U/ml penicillin-streptomycin (Sigma) at 37°C and 5% CO2. PKR-
deficient HeLa cells (PKR KO), HEK293T cells containing an inducible TRS1 expression 
cassette (293T-pTRS1i), and PKR-deficient cells containing an inducible TRS1 
expression cassette (PKR KO-pTRS1i) were maintained in 1 µg/ml puromycin in normal 
growth media. PKR-deficient HeLa cells have been previously described (35). The 
HCMV AD169inGFP strain was used for all infections. This strain is derived from a 
bacterial artificial chromosome (BAC) and contains a green fluorescent protein (GFP) 
reporter driven by the SV40 promoter. 
Generation of recombinant plasmids. Vectors expressing full-length TRS1 or 
TRS1 truncation mutants fused to a carboxyl-terminal 6XHis epitope were a kind gift 
from Dr. Adam Geballe (University of Washington;(39)). To generate full-length TRS1 
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containing arginine to alanine mutations that disrupt dsRNA binding 
(R121,124,125A;(38)) the full-length TRS1 expression plasmid was amplified with 
primers Triple F and Triple R (Table 1), and recircularized using Gibson cloning (NEB). 
The R121A,R124A,R125A point mutations were introduced into the 1-550 TRS1 
expression vector, as above, using the pcDNATRS1 1-550 plasmid as a template. Point 
mutations within the pTRS1 PKR binding domain that disrupt PKR binding (R658A, 
D660,661A, E662A;(7)) were incorporated into full-length TRS1 and TRS1triple using 
primers Mut1 F and Mut1 R (Table 1) followed by recircularization using a Gibson 
reaction (New England BioLabs), in which a mixture of DNA exonuclease, DNA 
polymerase and DNA ligase anneal overlapping complementary DNA ends into a 
contiguous double stranded DNA molecule. The portion of each clone containing the 
TRS1 open reading frame (ORF) was sequenced to ensure the absence of unintended 
mutations. 
The human protein kinase R (PKR) ORF containing homology arms to the 
pcDNA3.1 V5 His expression vector was ordered as a gBlock Gene Fragment (IDT; 
Table 1). The pcDNA3.1 vector was digested with BamHI and XhoI, and the full-length 
PKR ORF was inserted using a Gibson cloning reaction according to the manufacturer’s 
directions. The kinase-dead PKR (K296R) ORF containing homology arms to the 
pcDNA3.1 expression vector was also ordered as a gBlock Gene Fragment (Table 1) 
and introduced into pcDNA3.1 by Gibson cloning as above. A flag epitope was fused to 
the N-terminus of PKR K296R by amplification of the PKR ORF with primers PKRflag F 
and PKR R (Table 1) followed by Gibson cloning into the pcDNA3.1 vector digested with 
BamHI and XhoI as above. An N-terminal myc tag was added to both wild type PKR 
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and PKR K296R as above using the primers PKRmyc F and PKR R. The following point 
mutations were introduced into PKR: E375V, T446A, A473T, D486V, T487A, E490A 
and F495R using the following primer pairs: PKR_E375V F and PKR_E375V R, 
PKR_A446T F and PKR_ A446T R, PKR_T473A F and PKR_T473A R, PKR_D486V F 
and PKR_ D486V R, PKR_T487A F and PKR_ T487A R, PKR_E490A F and PKR_ 
E490A R, PKR_F495R F and PKR_ F495R R, respectively. All primer sequences are 
listed in Table 1. The full-length PKR expression plasmid was amplified from both myc-
tagged wild type and myc-tagged PKR K296R, in pcDNA3.1 backgrounds, with the 
above primer pairs, gel extracted and circularized using Gibson cloning. For each PKR 
mutant, the portion of each vector containing the PKR ORF was sequenced to confirm 
the absence of additional mutations. 
The PKR kinase domain (KD) fused to glutathione-S-transferase (GST) was 
created by first amplifying GST from pET-41 b(+) using primers GST-pCW F and GST R 
(Table 1). The PKR KD (amino acids 259-551) was then amplified from the full-length 
PKR expression vector using primers KDGST F and KDGSTpCW R (Table 1). The 
plasmid pCW-Cas9 (Addgene #50661) was digested with NheI and BamHI to remove 
the Cas9 open reading frame. The GST ORF and PKR KD were then cloned into the 
digested pCW vector using a three part Gibson reaction. Full-length TRS1 was 
introduced into the pCW plasmid by amplifying the TRS1 ORF using primers TRS1ind F 
and TRS1ind R (Table 1), followed by Gibson assembly into pCW-Cas9 previously 
digested with NheI and BamHI. Sanger sequencing was used to confirm the absence of 
unintended mutations. 
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The heme-regulated inhibitor (HRI) ORF was amplified from the pJP1563 vector 
(DNASU #38827) using primers HRImyc F and HRImyc R (Tale 1). The HRI ORF was 
then cloned into the pcDNA3.1 vector digested with BamHI and XhoI via Gibson 
reaction. The complete HRI ORF was sequenced to ensure no unintended mutations. 
Production of lentivirus stocks and pTRS1-inducible cell lines. Lentivirus 
stocks were generated by transfecting HEK293T cells with the pCW TRS1 expression 
plasmid (described above) and Lentivirus Packaging Mix (Sigma) using 
polyethylenimine (PEI; Polysciences). The media was collected at 48 hours and 72 
hours after transfection and clarified by passage through a 0.22 µm filter. The virus was 
then stored at -80oC until use. 293T-pTRS1i and PKR KO-pTRS1i cells were generated 
by transduction with the pCW TRS1 lentivirus in the presence of 8 µg/ml polybrene. 
After bulk selection in 1 µg/ml puromycin for 48 hours, clonal cell lines were isolated by 
limiting dilution in media containing puromycin. Clonal cells lines were assayed for 
minimal basal expression of pTRS1 and maximal induction of pTRS1 expression after 
treatment with 1 µg/ml doxycycline by Western blot.   
PKR and HRI activation assays. The ability of pTRS1 or pTRS1 mutants to 
inhibit PKR was measured in HEK293T cells. Cells were transfected with 1 µg of either 
a GFP or TRS1 expression plasmid using PEI and harvested at 36 hours after 
transfection. Cells were washed with PBS, pelleted and lysed in 120 µl of PKR lysis 
buffer (50 mM Tris-HCl, pH 7.5; 150 mM NaCl; 0.5% NP-40; 10% glycerol; 1 mM EDTA, 
with protease and phosphatase inhibitors (Roche)) on ice for 15 min. Insoluble debris 
was removed by centrifugation at 21,000xg for 10 min at 4oC. Unless otherwise 
indicated, 1 mg/ml of poly(I:C) (LMW, Invivogen) was added to 100 µl of supernatant for 
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30 min at 30°C to activate PKR. To examine PKR KD activation, HEK293T cells were 
transfected with 500 ng of GST-KD expression plasmid together with 500 ng of either 
GFP, TRS1 or TRS1mut1 expression plasmid for 36 hours. Doxycycline (1 µg/ml) was 
added to cells overnight prior to harvest to induce GST-KD expression. Cells were 
washed once with PBS, pelleted and stored at -80oC until processed. To measure 
activation of PKR mutants in PKR KO cells, PKR KO-pTRS1i, cells were co-transfected 
with 500 ng of PKR expression plasmid and 500 ng of either GFP or TRS1 expression 
plasmid. Twenty hours after DNA transfection, cells were transfected with 20 µg of 
poly(I:C) using Lipofectamine2000 (Thermo Fisher) for four hours. Cells were washed 
once in PBS, pelleted and stored at -80oC until processed. 
PKR KO-pTRS1i cells were used to measure the effect of pTRS1 on arsenite-
induced HRI activation. Cells were treated overnight with doxycycline (1 µg/ml) to 
induce pTRS1 expression. The next day, cells were treated with 0.05, 0.25 or 0.5 mM 
sodium arsenite (Sigma) for two hours to activate HRI (50). Cells were then washed 
once with PBS, pelleted and stored at -80oC until processed. 
Analysis of protein expression. Unless otherwise stated, cells were lysed in 
RIPA buffer (50 mM Tris-HCl, pH 7.4; 150 mM NaCl; 1% NP-40; 0.25% deoxycholate; 1 
mM EDTA containing protease and phosphatase inhibitors (Roche). Protein 
concentration was determined using a Bradford assay. Equal amounts of protein were 
resolved on 10% SDS-PAGE gels, transferred to nitrocellulose membranes (Amersham) 
and blocked in 5% non-fat milk in TBS-T (50 mM Tris, pH 7.4; 150 mM NaCl; 0.1% 
Tween-20) for 1 hour at room temperature (RT) or overnight at 4oC. For mouse 
monoclonal antibodies, membranes were incubated with primary antibodies for either 1 
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hour at RT or overnight at 4oC in 1% BSA in TBS-T. For rabbit polyclonal antibodies, 
membranes were blocked as above and incubated at 4oC overnight in 5% BSA in TBS-
T, with the exception of the aHis antibody which was diluted in 1% BSA in TBS-T. 
Membranes were incubated in appropriate secondary antibodies (KPL) at a 1:10,000 
dilution in 1% BSA in TBS-T for 1 hour at RT. A modified protocol was used for total and 
phosphorylated eIF2α blots. Membranes probed for total eIF2α were blocked and 
incubated in primary antibody as above, and then incubated in secondary antibody 
(1:10,000) in 5% milk in TBS-T for 1 hour at RT before being developed. Membranes 
probed for phospho-eIF2α (Ser51) were blocked in 5% BSA in TBS-T overnight at 4oC 
prior to an overnight incubation in primary antibody at 4oC. Membranes were then 
incubated in secondary antibody (1:10,000) in 1% BSA in TBS-T for 1 hour at RT. The 
following antibodies were used: pTRS1 (1:100; (43)), His (1:1,000; CST #2365S), PKR 
Total (1:1,000; Santa Cruz sc-707), phospho-PKR (Thr446) (1:1,000; Abcam ab32036), 
Myc (1:1,000; CST #2276S), Flag (1:1,000; Sigma F3165), eIF2α (1:1,000; CST 
#9722S), phospho-eIF2α (Ser51) (1:1,000; CST #3398S), HRI (1:1,000; Abcam 
ab28530), Tubulin (1:20,000; Sigma T6199).  
Immunoprecipitation. HEK293T cells were transfected with 5 µg of the 
indicated plasmid for a total of 36 hours. Where indicated, doxycycline (1 µg/ml) was 
added 18 hours prior to harvest to induce pTRS1 expression. Cells were lysed in 1 ml of 
PKR lysis buffer for 15 min on ice. Insoluble debris was removed by centrifugation for 
10 min at 21,000xg at 4oC. 100 µl of protein A/G sepharose beads (Santa Cruz) in PKR 
lysis buffer (20 µl packed bead volume) was added to each sample and nutated at 4oC 
for 30 minutes to pre-clear the lysate. Where indicated, 2,000 units of microccocal 
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nuclease (NEB) and 5 µl of 0.5M CaCl2 were added to each sample prior to the pre-
clear step, and incubated at 37oC for 30 min to digest nucleic acid species. The beads 
were then removed and the lysate was transferred to a new tube containing 1 µg of the 
indicated antibody, or 1 µg of either mouse IgG or tubulin antibody as a negative 
control. Samples were nutated with antibody at 4oC for 4 hours whereupon 100 µl of 
protein A/G beads in PKR lysis buffer (20 µl packed bead volume) was added to each 
sample. For the αTRS1 immunoprecipitation, antibodies were pre-conjugated to protein 
A/G beads overnight before addition to sample lysates. Samples were nutated for 90 
minutes after the addition of the beads. The beads were collected by brief centrifugation 
and washed three times with 1 ml of PKR lysis buffer before addition of 30 µl of 1X 
sample buffer (0.1 M Tris-HCl, pH 6.8; 6% glycerol; 2% SDS; 0.1 M DTT; 0.002% 
bromophenol blue). The samples were boiled at 95oC for 10 minutes, briefly centrifuged 
at 21,000xg and stored at -20oC prior to analysis by Western blot.  
For the glutathione sepharose pull-down, HEK293T cells were co-transfected 
with 2.5 µg of inducible GST-PKR kinase domain (GST-KD) expression plasmid and 2.5 
µg of either TRS1 or TRS1mut1 expression plasmid for 36 hours. GST-KD expression 
was induced by addition of 1 µg/ml doxycycline 18 hours before harvest. Upon harvest, 
cells were washed once with PBS, pelleted and lysed in 500 µl Wash buffer (20 mM 
Hepes, pH 7.0; 100 mM NaCl; 1 mM DTT; 1% glycerol) for 15 min on ice. Insoluble 
debris was removed by centrifugation at 21,000xg for 10 min at 4oC. 100 µl of washed 
glutathione sepharose 4B (GE) (15 µl packed sepharose volume) was added to each 
sample. Samples were nutated at RT for 1 hour, and then washed three times with 1 ml 
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of Wash buffer. 30 µl of 1X sample buffer was added to the beads, whereupon samples 
were boiled, briefly centrifuged and stored at -20oC until analysis by Western blot.   
PKR Kinase assay. HEK293T cells were transfected with 5 µg of the indicated 
plasmids for 36 hours. For co-transfections, 2.5 µg of each plasmid was transfected. 
Immunoprecipitation using αMyc or mouse IgG was performed as described above. 
After washing in PKR lysis buffer, beads were re-suspended in 25 µl of 1X kinase 
reaction buffer (40 mM Tris, pH 7.5; 20 mM MgCl2; 0.1 mg/ml BSA; 500 µM ATP 
(Promega)) containing 7.5 µg of histone H2A peptide (NEB) as a substrate. The kinase 
reaction was run for 30 min at RT. The ADP-GloTM kinase assay (Promega) was then 
used to determine PKR kinase activity. Briefly, 25 µl of ADP-Glo reagent was added to 
each kinase reaction and incubated at RT for 40 min. 50 µl of Kinase Detection Reagent 
was added to each sample and incubated at RT for an additional 40 minutes, 
whereupon the luminescence of each sample was read using a luminometer (Molecular 
Devices). Fold change in luminescence compared to the IgG control 
immunoprecipitation was calculated and statistical significance was determined using 
an unpaired students’ t-test. 
 
RESULTS 
pTRS1 inhibits PKR activation by dsRNA. We began by examining the ability 
of pTRS1 to inhibit PKR activation in transfected cells. Increasing amounts of a 
synthetic dsRNA (poly(I:C)) were added to lysates of cells transfected with either a GFP 
or pTRS1 expression plasmid, and PKR activation was measured by Western blot. PKR 
is activated by autophosphorylation on Thr446 (T446) and Thr451 (T451), although 
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phosphorylation of T451 is dependent upon T446 phosphorylation (23, 51). We 
therefore used PKR T446 phosphorylation as a marker of PKR activation. Low levels of 
phosphorylated PKR were present in the absence of poly(I:C) in cells expressing GFP, 
likely due to stress from transfection. Poly(I:C) activated PKR in cells expressing GFP 
(Fig 1A). In contrast, the presence of pTRS1 completely suppressed PKR activation, 
even at the highest doses of poly(I:C). Thus pTRS1 is sufficient to prevent PKR 
activation by dsRNA in cell culture.  
We next examined the regions of pTRS1 necessary for PKR antagonism. In 
these experiments we used a series of plasmids expressing amino or carboxyl terminal 
truncations of pTRS1, as they have previously been characterized in vitro (37, 39)(Fig 
1B, Table 2) and measured PKR T446 phosphorylation after poly(I:C) treatment (Fig 
1C). It is important to note that truncation mutants may unintentionally affect protein 
folding, and thus negative results using these mutants should be interpreted with 
caution. As before, full-length pTRS1 blocked activation of PKR by poly(I:C) treatment. 
However, pTRS1 lacking its amino terminal 240 or 390 amino acids (240-795 and 390-
795, respectively), which contain the dsRNA binding domain, did not inhibit PKR 
activation. Similarly, a pTRS1 mutant lacking the final 116 amino acids (1-679), 
containing the PKR binding domain, also failed to antagonize PKR. Curiously, the 
removal of an additional 180 amino acids from the C-terminus (1-550) restored PKR 
inhibition, but further deletion (1-370) again led to an inability to inhibit PKR activation.  
Purified pTRS1 and PKR directly interact in vitro, and deletion or mutation of the 
PKR binding domain ablates the ability of pTRS1 to inhibit PKR during HCMV infection 
(6, 7, 37). These results suggest that pTRS1 interaction with PKR is critical for PKR 
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antagonism. We therefore tested the ability of each pTRS1 mutant to bind PKR in 
transfected cells (Fig 1D). Cells were transfected with vectors expressing pTRS1 
mutants together with kinase-dead PKR (K296R), and the presence of pTRS1 in PKR-
specific immune complexes was determined by Western blot. Only full-length pTRS1 
bound to PKR. None of the pTRS1 truncation mutants co-purified with PKR, even 
pTRS1 240-795 and pTRS1 390-795, which both contain the previously described PKR 
binding domain. Interestingly, pTRS1 1-550 inhibited PKR activation (Fig 1C), but did 
not bind PKR. These data suggest that pTRS1 binding to PKR is sufficient, but not 
necessary, to prevent PKR activation by dsRNA. However as noted above, negative 
results in this assay should be interpreted cautiously due to the potential effect of the 
truncations on protein folding. 
Relative role of dsRNA and PKR binding by pTRS1 in PKR antagonism. 
Amino acids 84-246 of pTRS1 contain a noncanonical double stranded RNA binding 
domain (RBD) that allows purified pTRS1 to competitively inhibit the binding of purified 
PKR to dsRNA (39). This function suggests that in addition to inhibiting PKR via a direct 
interaction, pTRS1 may also inhibit PKR by preventing recognition of its dsRNA ligands 
(38, 39). Consistent with this idea, the pTRS1 1-550 mutant, which lacks the PKR 
binding domain, did not co-purify with PKR but could still prevent PKR activation in 
response to dsRNA treatment. To determine if pTRS1 1-550 inhibits PKR by binding to 
dsRNA, we introduced three amino acid changes in the dsRBD of pTRS1 1-550 (1-
550triple) that prevent binding of purified pTRS1 to dsRNA (38). We then measured the 
ability of this mutant to prevent poly(I:C)-induced PKR activation (Fig 2A). pTRS1 1-
550triple could not prevent PKR activation in response to poly(I:C) treatment. Thus in 
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the context of the truncated pTRS1 protein (1-550), RNA binding is necessary for PKR 
antagonism.  
In contrast we found that pTRS1 could still inhibit PKR activation when the same 
dsRBD mutations were introduced into full-length pTRS1 (pTRS1triple) (Fig 2A). We 
reasoned this could be due to pTRS1 binding to PKR through the previously defined 
PKR binding domain (PBD). We therefore mutated amino acids in pTRS1 necessary for 
binding to PKR (7) either alone (pTRS1mut1) or in combination with the dsRBD 
mutations (pTRS1mut1.triple). Mutation of the pTRS1 PBD ablated both binding to PKR 
(Fig 2C) and the ability to inhibit poly(I:C)-induced PKR activation, even when the 
dsRBD was intact (Fig 2B), suggesting that the primary mechanism of PKR antagonism 
by full-length pTRS1 is mediated through interactions with PKR. To further explore this 
hypothesis, we tested if pTRS1 associated with PKR via an RNA intermediate (Fig 2D). 
Micrococcal nuclease treatment had no effect on pTRS1 binding to PKR. We also 
demonstrated that pTRS1 interacts with PKR in HCMV infected cells, which had not 
been previously demonstrated (Fig 2E). Together these data suggest that pTRS1 has 
two distinct mechanisms to inhibit PKR activation. In some circumstances pTRS1 may 
prevent PKR activation by sequestering dsRNA from PKR, independent of binding to 
PKR. However, at least in this system, the primary mechanism of PKR inhibition by full-
length pTRS1 requires an RNA-independent interaction with PKR. 
pTRS1 blocks PKR activation at a step after PKR dimerization. Binding to 
dsRNA induces PKR dimerization, which is necessary for PKR activation (3, 52). We 
thus hypothesized that pTRS1 might block PKR activation by preventing PKR 
dimerization. To test this hypothesis, cells expressing pTRS1 were co-transfected with 
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plasmids encoding myc- and flag-tagged PKR K296R. Catalytically inactive PKR was 
used in these experiments to limit toxicity. Poly(I:C) was added to cell lysates to induce 
PKR dimerization, and the ability of flag-tagged PKR to co-purify with myc-tagged PKR 
was measured by immunoprecipitation followed by Western blot (Fig 3). As expected, 
flag-tagged PKR co-purified with myc-tagged PKR in the absence of pTRS1. Similar 
amounts of flag-PKR associated with myc-PKR in the presence of pTRS1, suggesting 
that pTRS1 does not affect PKR homodimer formation. In addition, we detected pTRS1 
in the myc-PKR immune complexes suggesting that pTRS1 might bind to PKR dimers. 
These data show that pTRS1 does not inhibit PKR activation by preventing PKR 
dimerization and suggest that pTRS1 may in fact bind to PKR dimers.  
To further test if pTRS1 prevents PKR activation at a step after dimerization, we 
determined if pTRS1 could bind and inhibit a constitutively dimerized, active PKR. The 
glutathione-S-transferase (GST) protein constitutively forms dimers; replacing the amino 
terminal dsRBD of PKR with GST results in a constitutively dimerized, and thus 
constitutively active, PKR kinase domain (GST-KD) (53). We asked if pTRS1 co-purified 
with GST-KD to determine if pTRS1 could bind the dimerized PKR kinase domain (Fig 
4A). As long-term expression of GST-KD is toxic, a doxycycline-inducible promoter was 
used to regulate GST-KD expression. Wild type pTRS1 co-purified with glutathione 
resin from cells expressing GST-KD, while the PKR binding domain mutant 
(pTRS1mut1) did not. We next determined if pTRS1 could inhibit the activity of a 
constitutively dimerized PKR KD by measuring the effect of pTRS1 expression on GST-
KD autophosphorylation (Fig 4B). pTRS1 expression decreased GST-KD 
autophosphorylation as compared to GFP and pTRS1mut1 controls. Together these 
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results suggest that pTRS1 binds and inhibits dimerized PKR, and that pTRS1 binds 
PKR through an interaction with the PKR KD. 
Amino acids in the PKR eIF2α contact site are important for pTRS1 binding. 
Previous studies identified key amino acids in the αG helix of the PKR kinase domain 
that are necessary for binding of PKR to its substrate eIF2α (Fig 5A)(3, 4). To determine 
if pTRS1 interacted with the PKR eIF2α binding site, we examined the ability of pTRS1 
to bind and inhibit previously characterized PKR mutants with single amino acids 
changes in the αG helix (Table 2). Mutation of PKR residues Thr487 and Phe495 to 
alanine and arginine (T487A and F495R, respectively) ablate PKR phosphorylation of 
eIF2α, but do not affect PKR catalytic activity or autophosphorylation (3). Two amino 
acids within the PKR αG helix, T487 and Glu490 (E490), are conserved in all 
eIF2α kinases (4). Therefore, we generated plasmids expressing PKR T487A, F495R or 
E490A, and measured their binding to pTRS1 (Fig 5B). While pTRS1 efficiently co-
purified with wild type PKR, very low levels of pTRS1 were recovered with the T487A 
and E490A PKR mutants, which were only visible after overexposure of the blot. pTRS1 
co-purified with the PKR F495R mutant, but at reduced levels. pTRS1 also maintained 
the ability to bind a PKR mutant in which the activating phosphorylation site had been 
mutated to alanine (T446A) (Fig 5B). These data suggest that amino acids in the PKR 
eIF2α contact site are important for pTRS1 binding and that PKR activation is not 
necessary for its interaction with pTRS1. 
We next tested the ability of pTRS1 to prevent activation of each of the above 
PKR mutants. pTRS1 and the PKR mutants were expressed in PKR-deficient cells, and 
PKR autophosphorylation was measured after poly(I:C) transfection (Fig 5C). 
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Consistent with previous results, poly(I:C) induced the autophosphorylation of each 
PKR mutant in control cells expressing GFP, demonstrating that each PKR mutant was 
catalytically active (4, 27, 54). Though PKR F495 was activated to lower levels than wild 
type PKR in control cells, pTRS1 prevented PKR F495R autophosphorylation. In 
contrast the PKR T487A and E490A mutants were resistant to inhibition by pTRS1, 
consistent with the inability of pTRS1 to bind these mutants. From these data, we 
conclude that binding of pTRS1 to the PKR αG helix is necessary for inhibition of PKR 
activation.   
The vaccinia virus PKR antagonist, K3L, also binds PKR at an eIF2α contact 
residue within the αG helix, Asp486 (D486). Recently, PKR mutants resistant to K3L 
binding and inhibition were identified (Fig 5A) (27). To determine if pTRS1 bound PKR 
in a structurally similar manner as K3L, we tested the ability of pTRS1 to bind and inhibit 
three PKR mutants (E375V, A473T and D486V) that escape inhibition by K3L (Fig 5D). 
We found that pTRS1 efficiently bound both PKR E375V and A473T, but showed 
decreased binding to PKR D486V. pTRS1 prevented autophosphorylation of PKR 
E375V and A473T and reduced autophosphorylation of PKR D486V (Fig 5E). These 
data suggest that while pTRS1 and K3L interact with the same region of PKR, these 
interactions occur in a structurally distinct manner.  
pTRS1 inhibits PKR kinase activity. The inhibition of PKR autophosphorylation 
by pTRS1 at a step after PKR dimerization suggested that pTRS1 might inhibit PKR 
kinase activity. To test this hypothesis we measured PKR kinase activity in the presence 
of pTRS1 (Fig 6). Cells were transfected with a myc-PKR expression plasmid together 
with plasmids expressing the control protein GFP, wild type pTRS1, or pTRS1mut1, 
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which cannot bind PKR. We then measured PKR kinase activity in myc-specific immune 
complexes using a peptide from histone H2A as a substrate. The histone H2A peptide 
has previously been shown to be a substrate for PKR in vitro (3). PKR kinase activity 
was significantly lower in pTRS1 expressing cells as compared to control cells 
expressing GFP or cells expressing kinase-dead PKR K296R. The pTRS1mut1 protein 
did not inhibit PKR kinase activity, consistent with its inability to bind PKR and prevent 
PKR autophosphorylation. In fact in some experiments slightly elevated PKR kinase 
activity was found in cells expressing pTRS1mut1, though the difference was not 
statistically significant. Together with the above data, these results suggest that pTRS1 
binding to the PKR kinase domain inhibits PKR kinase activity, preventing activating 
autophosphorylation of PKR and subsequent phosphorylation of its substrate eIF2α.  
pTRS1 binds and inhibits an additional eIF2α kinase. Our results show that 
pTRS1 binds and inhibits PKR through interactions with amino acids in the PKR 
eIF2α contact site. Interestingly, two of the amino acids in the PKR αG helix important 
for pTRS1 binding are conserved in other eIF2α kinases. To further test the hypothesis 
that interaction with the PKR eIF2α contact site is critical for pTRS1 binding, we 
determined if pTRS1 could also bind an additional eIF2α kinase, HRI. We found that 
HRI co-purified with pTRS1 in transfected 293T cells (Fig 7A) and in HCMV infected 
fibroblasts (Fig 7B). Treating cells with arsenite leads to an accumulation of reactive 
oxygen species (ROS), which activates the HRI kinase, resulting in eIF2α 
phosphorylation (50). To determine if pTRS1 could prevent HRI-dependent eIF2α 
phosphorylation, we measured eIF2α phosphorylation after arsenite treatment in PKR-
deficient cells (Fig 7C). Arsenite induced a dose-dependent increase in eIF2α 
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phosphorylation, which was decreased in cells expressing pTRS1. This result is 
consistent with our previous study showing that pTRS1 inhibits stress granule formation 
in PKR-deficient cells treated with arsenite (6). As HRI activation does not require an 
interaction with dsRNA, these data further confirm that pTRS1 can inhibit eIF2α kinases 
independent of its ability to bind RNA. In addition these data further support the 
conclusion that residues in the eIF2α contact site are critical for pTRS1 interaction with 
PKR, and may mediate interactions with additional eIF2α kinases.  
 
DISCUSSION 
In this study we sought to examine the mechanism by which HCMV pTRS1 
inhibits the antiviral kinase PKR. Our results suggest that pTRS1 employs two 
mechanisms to block PKR activation. In isolation, the amino terminal 550 amino acids of 
pTRS1, which contain the RNA binding domain, can prevent PKR activation 
independent of binding to PKR (Fig 1). However in the context of full-length pTRS1, 
mutations that disrupt pTRS1 RNA binding do not affect its ability to prevent PKR 
activation (Fig 2). Rather, binding of pTRS1 to PKR appears to be essential for PKR 
antagonism. pTRS1 did not block PKR dimerization (Fig 3), but instead could bind and 
inhibit a constitutively dimerized PKR kinase domain (Fig 4). pTRS1 binding to PKR 
inhibits PKR kinase activity (Fig 6) and is mediated through interactions with conserved 
amino acids in the PKR eIF2α contact site. Mutation of these residues rendered PKR 
resistant to pTRS1 antagonism (Fig 5). Consistent with this finding, pTRS1 interacted 
with an additional eIF2α kinase, HRI, and limited HRI activation in PKR-deficient cells 
(Fig 7). Together our data suggest that inhibition of PKR kinase activity, mediated by 
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pTRS1 binding to conserved residues within the PKR eIF2α contact site, is the 
dominant mechanism of PKR antagonism.  
Both pTRS1 and pIRS1 contain a noncanonical RNA binding domain in their 
conserved N-terminus. Although the affinity of pTRS1 for dsRNA is lower than that of 
PKR, the higher abundance of pTRS1 and pIRS1 in relation to PKR during infection 
may allow for competition for dsRNA binding (38, 39). Our data show that in some 
contexts, dsRNA binding by pTRS1 contributes to PKR antagonism. pTRS1 1-550 did 
not bind PKR (Fig 1D) but maintained the ability to inhibit PKR activation in response to 
poly(I:C) treatment (Fig 1C). Mutations within pTRS1 1-550 that disrupt dsRNA binding 
(1-550triple) ablated the ability of pTRS1 1-550 to inhibit PKR (Fig 2A) suggesting that 
in the context of the truncated protein, dsRNA binding is necessary for PKR inhibition. 
Interestingly, this truncation mutant comprises the conserved region between pTRS1 
and pIRS1 suggesting that dsRNA binding by both proteins may contribute to PKR 
antagonism during infection, although the function of dsRNA binding by pTRS1/pIRS1 
during infection has not been examined. It is also possible that pTRS1 1-550 has a 
higher binding affinity for dsRNA than full-length pTRS1 allowing for efficient binding 
and sequestration of poly(I:C) in vitro. Nevertheless, these data suggest that in some 
contexts dsRNA binding by pTRS1 contributes to PKR antagonism. 
While dsRNA binding was necessary for the pTRS1 1-550 mutant to inhibit PKR, 
the ability of full-length pTRS1 to bind dsRNA was dispensable for PKR antagonism (Fig 
2B). Consistent with this result, pTRS1 binding to PKR was not dependent on an RNA 
intermediate (Fig 2D) and pTRS1 inhibited the activation of a constitutively active PKR 
kinase domain lacking its dsRNA binding domains (Fig 4B). Instead, we found that an 
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interaction between PKR and full-length pTRS1 was necessary for PKR antagonism 
(Fig 2). Thus, at least in this system, pTRS1 binding to PKR, rather than competition for 
dsRNA ligands, is the primary mechanism by which pTRS1 prevents PKR activation. 
This is consistent with previous studies showing that the pTRS1 PKR binding domain is 
necessary for PKR inhibition during HCMV infection in primary human fibroblasts (7, 
35). However, as discussed above, our results suggest that dsRNA binding by pTRS1 
does play a role in PKR inhibition. Previous studies have shown that a pTRS1 mutant 
incapable of binding dsRNA (pTRS1triple) did not rescue replication of a vaccinia virus 
lacking its PKR antagonist, even though pTRS1triple maintained the ability to bind PKR 
(38). While dsRNA accumulates in HCMV infected cells (18), the signals driving PKR 
activation during HCMV infection are unknown. Perhaps these two functions of pTRS1, 
binding to dsRNA and PKR, are most important for PKR inhibition in different settings, 
or in response to different PKR activating signals. 
We also identified the domain of PKR necessary for its association with pTRS1. 
Our finding that pTRS1 could bind and inhibit a constitutively active PKR kinase domain 
(GST-KD) suggested that an interaction between pTRS1 and the PKR kinase domain is 
necessary for PKR antagonism (Fig 4A,B). Using a series of previously described PKR 
point mutants that retain PKR catalytic activity (3, 4, 27), we found pTRS1 interacts with 
specific amino acids in the αG helix of the PKR kinase domain that are necessary for 
binding to its substrate eIF2α (Fig 5). pTRS1 did not co-purify with PKR mutants 
containing αG helix mutations (PKR T487A or E490A), and weakly interacted with an 
additional αG helix mutant, PKR D486V (Fig 5B, D). The loss of binding correlated with 
a decrease in the ability of pTRS1 to inhibit activation of these PKR mutants (Fig 5C,E). 
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PKR T487A and E490A were completely resistant to inhibition by pTRS1, while D486V 
was partially resistant. In contrast, mutations in PKR residues more distal to the eIF2α 
contact site (E375V and A473T) had a minimal effect on pTRS1 binding, and pTRS1 
prevented activation of both mutants in response to poly(I:C) treatment (Fig 5D,E). Thus 
our data suggest that inhibition of PKR by pTRS1 requires an interaction with the eIF2α 
contact site in the PKR kinase domain. 
These results were reminiscent of PKR inhibition by the vaccinia virus K3L 
protein. K3L binds the PKR αG helix and functions as a PKR pseudosubstrate (26, 27, 
55). Mutation of PKR E375 or A473 to valine and threonine, respectively, confers 
resistance of PKR to K3L inhibition (27). We found that pTRS1 bound both the E375 
and A473 PKR mutants (Fig 5D), and prevented their autophosphorylation in response 
to poly(I:C) treatment (Fig 5E). These results are again consistent with a model in which 
pTRS1 binding mediates PKR antagonism. In addition, these data suggest that pTRS1 
inhibition of PKR activation occurs in a manner structurally distinct from that of other 
viral PKR antagonists. 
In addition to a distinct binding modality, we found that pTRS1 also differs from 
K3L in its mode of PKR inhibition. K3L does not inhibit PKR catalytic activity, but rather 
prevents phosphorylation of eIF2α by acting as a PKR pseudosubstrate (26, 55). Our 
data show that pTRS1 binds PKR and inhibits PKR kinase activity (Fig 6). Importantly, 
the kinase assay used measures the conversion of ATP to AMP as a result of kinase 
activity. In the presence of pTRS1, AMP accumulation is reduced, indicating a loss of 
PKR catalytic activity. Thus, unlike K3L, pTRS1 does not act as a PKR 
pseudosubstrate, but rather inhibits PKR kinase activity towards the histone H2A 
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substrate. Together these results suggest that pTRS1 binds the PKR kinase domain 
and inhibits its catalytic activity. 
When considered in sum, our data suggests that pTRS1 inhibits PKR activation 
and subsequent eIF2α phosphorylation at multiple levels. In some scenarios pTRS1 
may sequester dsRNA ligands to prevent PKR dimerization and activation. In addition, 
we find that pTRS1 inhibits PKR at a step after dimerization through an interaction with 
the αG helix of the PKR kinase domain. pTRS1 binding to the kinase domain inhibits 
PKR catalytic activity, thus preventing autophosphorylation of dimerized PKR and 
subsequent phosphorylation of eIF2α. While not addressed herein, the fact that pTRS1 
binds to PKR residues necessary for its interaction with eIF2α suggests that pTRS1 
could also prevent eIF2α recognition by PKR. Thus inhibition of PKR kinase activity by 
pTRS1 ensures that eIF2α is not phosphorylated, even when PKR has bound activating 
dsRNA ligands. 
As the two residues in PKR recognized by pTRS1 are conserved across all 
eIF2α kinases, we reasoned that pTRS1 might bind and inhibit additional eIF2α 
kinases. We previously found that pTRS1 can prevent stress granule formation in 
response to arsenite treatment in PKR-deficient cells, suggesting that pTRS1 has the 
ability to block HRI-dependent eIF2α phosphorylation (50). Here we found that pTRS1 
binds HRI (Fig 7A and B) and limits eIF2α phosphorylation in response to arsenite 
treatment in PKR-deficient cells (Fig 7C). These data further support the conclusion that 
residues in the PKR αG helix necessary for eIF2α binding are critical for interaction of 
pTRS1 with PKR. In addition these data suggest that pTRS1 could have a more general 
role in suppressing cellular stress responses during HCMV infection, allowing for 
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efficient cellular and viral protein synthesis in the face of robust cellular stress induced 
by infection.  
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Figure 2.1. Domains of pTRS1 necessary for PKR binding and inhibition. (A) 
Lysates from HEK293T cells transfected with either a GFP or pTRS1 expression vector 
were treated with poly(I:C) to induce PKR activation. Levels of phosphorylated PKR 
(T446) were measured by Western blot. (B) Schematic showing location of pTRS1 
functional domains and pTRS1 truncation mutants (RBD = dsRNA binding domain; PBD 
= PKR binding domain) Areas shaded grey are conserved between pTRS1 and pIRS1. 
(C) HEK293T cells were transfected with GFP, full-length TRS1 or the indicated TRS1 
mutants. Lysates were treated with poly(I:C) and PKR phosphorylation (T446) was 
measured by Western blot. (D) HEK293T cells were co-transfected with myc-tagged 
kinase-dead PKR (K296R) and either full-length TRS1 or the indicated TRS1 mutants. 
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Cell lysates were immunoprecipitated with αMyc (PKR) or IgG (specificity control) 
antibodies. The presence of pTRS1 in the immune complexes was determined by 
Western blot. Representative results from one of at least three independent 
experiments are shown for each panel. 
 
Figure 2.2. PKR binding by full-length pTRS1 is necessary for inhibition of PKR 
activation. (A) Lysates from HEK293T cells transfected with full-length TRS1 (WT) or 
the indicated TRS1 mutants. pTRS1 1-550 (1-550) expresses only the first 550 amino 
acids of pTRS1. pTRS1triple (Triple) contains mutations that disrupt dsRNA binding. 
pTRS1.1-550.triple (1-550 Triple) expresses the 1-550 truncation mutant containing 
mutations in the dsRNA binding domain. Lysates were incubated with poly(I:C) to 
activate PKR. PKR phosphorylation (T446) was examined by Western blot. (B) Same 
as in A, except with different TRS1 mutants. pTRS1mut1 (Mut1) contains mutations that 
disrupt PKR binding. (C) HEK293T cells were transfected with myc-tagged kinase dead 
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PKR (K296R) together with full-length TRS1 or the indicated TRS1 mutants. 
pTRS1mut1.triple (Mut1-triple) contains point mutations in both the PKR and dsRNA 
binding domainsCell lysates were immunoprecipitated with αMyc (PKR) or IgG 
(specificity control) antibodies. The presence of pTRS1 in the immune complexes was 
determined by Western blot. (D) As in C, except lysates were treated with micrococcal 
nuclease prior to immunoprecipitation. (E) MRC-5 fibroblasts were infected with HCMV 
at an MOI of 3 for 24 hours. The presence of PKR in pTRS1 or IE1 specific immune 
complexes was determined by Western blot. Representative results from one of at least 
three independent experiments are shown for each panel. 
 
Figure 2.3. pTRS1 does not prevent PKR dimerization. HEK293T cells expressing 
pTRS1 from an inducible promoter (293T-pTRS1i) were co-transfected with flag- and 
myc-tagged PKR K296R expression vectors. pTRS1 expression was induced with 
doxycycline treatment. Cell lysates were treated with poly(I:C) and PKR was 
immunoprecipitated with αMyc antibody. The interaction of flag- and myc-tagged PKR 
was examined by Western blot. Representative results from one of at least three 
independent experiments are shown. 
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Figure 2.4. pTRS1 binds and inhibits a constitutively active PKR kinase domain. 
(A) HEK293T cells were co-transfected with a doxycycline-inducible GST-tagged PKR 
kinase domain (GST-KD) expression vector and an expression vector encoding either 
pTRS1 or pTRS1 Mut1. GST-KD expression was induced with doxycycline treatment. 
Glutathione resin was used to capture the GST-KD, and the co-purification of pTRS1 or 
pTRS1mut1 (Mut1) was examined by Western blot. (B) Cells were transfected as in (A) 
with the addition of cells co-transfected with a GFP expression vector and the GST-KD 
expression vector. GST-KD expression was induced with doxycycline treatment, and 
levels of GST-KD autophosphorylation (T446) were determined by Western blot 
analysis. Representative results from one of at least three independent experiments are 
shown for each panel. 
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Figure 2.5. pTRS1 interacts with the PKR kinase domain to prevent PKR 
autophosphorylation. (A) PyMOL image of the PKR kinase domain and eIF2α (PDB: 
2A1A). The PKR αG helix is represented in cyan. Amino acids required for eIF2a 
binding are shown in magenta, while mutations that confer resistance to inhibition by 
K3L are shown in blue. (B) 293T-pTRS1i cells were transfected with myc-tagged PKR 
K296R or the indicated myc-tagged PKR mutants. pTRS1 expression was induced with 
doxycycline treatment before lysates were immunoprecipitated with αMyc (PKR) or IgG 
(specificity control) antibodies. The presence of pTRS1 in the immune complexes was 
determined by Western blot. (C) PKR-deficient HeLa cells (PKR KO) were transfected 
with the indicated PKR mutants together with vectors expressing either GFP or TRS1. 
Cells were transfected with poly(I:C) to activate PKR and PKR autophosphorylation 
(T446) was measured by Western blot. (D and E) As in B and C, except cells were 
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transfected with the indicated PKR mutants. Representative results from one of at least 
three independent experiments are shown for each panel. 
 
Figure 2.6. pTRS1 inhibits PKR kinase activity. HEK293T cells were transfected with 
the indicated expression vectors (PKR K296R = kinase dead PKR; Mut1 = pTRS1 
containing PKR binding domain mutations). PKR was immunoprecipitated with αMyc 
antibody and re-suspended in kinase buffer. The kinase reaction was performed “on 
bead” as described in Materials and Methods, using histone H2A peptide as a 
substrate. PKR kinase activity was measured using the ADP-Glo™ kinase assay. The 
amount of kinase activity is normalized to the background activity associated with non-
specific (IgG) immunoprecipitates, which was set to one. Statistical significance was 
determined using an unpaired Student’s t-test (n=3; * = p<0.05). 
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Figure 2.7. pTRS1 binds HRI and limits its activation. (A) 293T-pTRS1i cells were 
transfected with myc-tagged HRI, and pTRS1 expression was induced with doxycycline. 
Lysates were immunoprecipitated with αMyc (PKR) or control antibody (αTubulin), and 
the presence of HRI the immune complexes was determined by Western blot. (B) MRC-
5 fibroblasts were infected with HCMV at an MOI of 3 for 72 hours. The amount of HRI 
co-purifying with pTRS1 specific immune complexes or with beads alone (control) was 
determined by Western blot. (C) PKR KO-pTRS1i cells were treated with doxycycline to 
induce pTRS1 expression and subsequently treated with increasing concentrations of 
arsenite (ARS) to activate HRI. Levels of eIF2α phosphorylation were measured by 
Western blot. The ratio of phosphorylated eF2α to total eIF2a levels (P/total) was 
calculated by densitometry. Representative results from one of at least three 








Table 2.1. Primer and gBlock Gene Fragment Sequences 
Primer Name Sequence (5' à  3') 
Triple F GCGGCCATGGCCGCCTGGTCGCAGCGCGACGCGGGCAC 
Triple R GACCAGGCGGCCATGGCCGCGCCCGTGCTGTTGGCCAGAA 
Mut1 F CTTTGGCCCGGGCCGCCGCCGATTGGAAACCGCCACGTCTCCCTGGGGAAG 
Mut1 R CAATCGGCGGCGGCCCGGGCCAAAGCACGTCCCAAACTGGCTTGGGGAGTC 
PKRflag F TAAGCTTGGTACCGAGCTCGCCACCATGGACTACAAGGACGACGACGACAAGGCTGGTGATCTTTCAGCAGG 
PKR R CGCGGGCCCTCTAGACTCGATCAACATGTGTGTCGTTCATTTT 
PKRmyc F TAAGCTTGGTACCGAGCTCGCCACCATGGAACAAAAACTCATCTCAGAAGAGGATCTGGCTGGTGATCTTTCAGCAGG 
PKR_E375V F AGGGACCTTGGTACAATGGATTGAAAAAAGAAGAGGCGAGAAAC 
PKR_E375V R CAATCCATTGTACCAAGGTCCCTTTATCACAGAATTCCATTTGG 
PKR_A473T F GTGGACCTCTACACTTTGGGGCTAATTCTTGCTGAACTTCTTC 
PKR_A473T R CCCAAAGTGTAGAGGTCCACTTCCTTTCCATAGTCTTGCG 
PKR_T446A F GATGGAAAGCGAGCAAGGAGTAAGGGAACTTTGCGATACA 
PKR_T446A R CTCCTTGCTCGCTTTCCATCATTTTTCAGAGATGTTACAAG 
PKR_D486V F CTTCATGTATGTGTCACTGCTTTTGAAACATCAAAGTT 
PKR_D486V R AGCAGTGACACATACATGAAGAAGTTCAGCAAGAATTAGCC 
PKR_T487A F GTATGTGACGCTGCTTTTGAAACATCAAAGTTTTTCACAGACCTACGG 
PKR_T487A R GTTTCAAAAGCAGCGTCACATACATGAAGAAGTTCAGCAAGAATTAGCC 
PKR_E490A F GACACTGCTTTTGCAACATCAAAGTTTTTCACAGACCTACGGGATG 
PKR_E490A R CTTTGATGTTGCAAAAGCAGTGTCACATACATGAAGAAGTTCAG 
PKR_F495R F CAAAGTTTCGCACAGACCTACGGGATGGCATCATCTCAG 
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PKR_F495R R TAGGTCTGTGCGAAACTTTGATGTTTCAAAAGCAGTGTCAC 
GST_pCW F CAGATCGCCTGGAGAATTGGCTAGCgccaccATGTCCCCTATACTAGGTTATTGG 
GST R TGGAGGATGGTCGCCACCAC 





TRS1ind F CAGATCGCCTGGAGAATTGGCTAGCgccaccATGGCCCAGCGCAACGGCAT 
TRS1ind R CGCAACCCCAACCCCGGATCCTTATTGAGCATTGTAATGGT 
HRImyc F TAAGCTTGGTACCGAGCTCGgccgccaccATGGAACAAAAACTCATCTCAGAAGAGGATCTGCAGGGGGGCAACTCCGGGGTC 




























































































Table 2.2. pTRS1 and PKR Mutations and Functional Descriptions 
PKR expression vectors 
Plasmid 
Name Mutation Description Ref 
PKR T446A T446A Mutation in activating phosphorylation site (23) 
PKR E375V E375V 
Confers resistance to 
inhibition by VV K3L (27) PKR A473T A473T 
PKR D486V D486V 
PKR T487A T487A Disrupts PKR 
phosphorylation of eIF2α (3) PKR E490A F495R 
PKR F495R E490A Mutation in conserved eIF2α αG helix residue (4) 
PKR K296R 
FLAG K296R 
Kinase dead PKR with 




Kinase dead PKR with 




fusion of GST to the 
PKR kinase domain (aa 
259-551) 
HRI-myc NA HRI expression vector, C-terminal myc tag NA 
pTRS1 expression vectors 
Plasmid 
Name Mutation Description Ref 





lacking final 425 aa 
Contains RNA binding 





lacking final 245 aa 
Contains RNA binding 





lacking final 116 aa 
Contains RNA binding 





lacking the first 239 
aa 
Lacks RNA binding 





lacking the first 299 
aa 
Lacks RNA binding 
domain. Contains PKR 
binding domain 
Triple 
Full length pTRS1 
containing point 




Lacks ability to bind 
dsRNA (38) 
Mut1 
Full length pTRS1 
contatining point 





Lacks ability to bind PKR (7) 
Triple/Mut1 
Full length pTRS1 
containing point 
mutations in the 
RNA 
(R121A,R124A,R12





Lacks ability to bind both 
dsRNA and PKR (7, 38) 
1-550.Triple 
pTRS1 deletion 
mutant lacking final 
245 aa and 
containing point 
mutations in RNA 
Lacks ability to bind both 
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Human cytomegalovirus (HCMV) significantly manipulates multiple cellular 
processes, including the control of mRNA translation of host and viral mRNAs. While 
translation of host and viral mRNAs is thought to occur in a cap-dependent manner, 
HCMV mRNAs are efficiently translated when cap-dependent translation is inhibited late 
in HCMV infection. This suggests that viral mRNAs use a non-canonical translation 
initiation complex to ensure viral protein synthesis. The viral protein TRS1 (pTRS1) has 
been shown to associate with the mRNA cap, 40S ribosomal subunits, and double-
stranded RNA (dsRNA), and to inhibit the antiviral kinase PKR. Exogenous expression 
of pTRS1 increases overall levels of protein synthesis and promotes cap-dependent 
mRNA translation. However, the effect of pTRS1 on cap-independent translation has 
not been examined. Here we show that pTRS1 enhances cap-independent translation. 
pTRS1 increases internal ribosome entry site (IRES) activity from both a bicistronic 
reporter and also a circular RNA reporter, which lacks an mRNA cap and poly(A) tail. 
pTRS1 expression also stimulates the activity of cellular IRESs that control the 
expression of proteins needed for HCMV replication. While its effect on PKR contributes 
to the enhancement of cap-independent translation, we find that pTRS1 also promotes 
cap-independent translation in PKR deficient cells. Stimulation of cap-independent 
translation is dependent on the ability of pTRS1 to bind dsRNA. Together these data 
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show that pTRS1 stimulates cap-independent translation, and suggest that pTRS1 may 
play a role in translation regulation during HCMV infection.  
 
INTRODUCTION 
Control of protein synthesis is key to the regulation of multiple cellular processes 
including metabolism, cell cycle progression, and antiviral responses (1-3). Translation 
initiation is the rate-limiting step of protein synthesis and is highly regulated (4, 5). 
Factors such as the availability of nutrients, the presence of unfolded proteins, or virus 
infection affect how efficiently translation initiation occurs. In fact, activation of many 
cellular stress response pathways leads to inhibition of translation initiation. Therefore, 
by regulating the rate of translation initiation, overall levels of protein synthesis can be 
tuned to match the cellular environment (6).       
Translation initiation on the majority of cellular mRNAs occurs in a cap-
dependent manner. The 7-methylguanosine mRNA cap (m7G) is bound by the eIF4F 
complex, which consists of the cap-binding protein eIF4E, the RNA helicase eIF4A, and 
the scaffold protein eIF4G (7-9). Nucleation of the eIF4F complex on an mRNA leads to 
the recruitment of the 43S preinitation complex (PIC), consisting of eIF3, eIF2-GTP, an 
initiator methionyl tRNA (Met-tRNAi) and the 40S ribosomal subunit, to form the 48S 
complex (10-12). The 48S complex scans the mRNA 5’ untranslated region (UTR) until 
the translation start codon is recognized, at which time the 60S ribosomal subunit is 
recruited and translation elongation begins (13).  
While most translation requires the mRNA cap for initiation, translation initiation 
can also occur through cap-independent mechanisms. Internal ribosome entry sites, or 
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IRESs, are RNA structures that directly recruit ribosomal subunits and/or translation 
initiation factors to allow for translation initiation independent of the m7G cap (5, 14-16). 
This allows for efficient translation of IRES-containing mRNAs under conditions of cell 
stress where eIF4F abundance is limited and cap-dependent translation is inhibited (17, 
18). In fact, most mRNAs containing IRES elements encode proteins that are involved 
in stress response and cell death pathways (18, 19). Thus IRES-mediated translation 
provides an alternative to cap-dependent translation to allow for ongoing protein 
synthesis during periods of cellular stress. 
 Cap-independent translation was first described for viral mRNAs (14), as viruses 
commonly inhibit cap-dependent translation initiation. IRESs present on viral mRNAs 
allows for ongoing viral protein synthesis despite inhibition of cap-dependent translation. 
The IRES controlling expression of the poliovirus polyprotein provides an excellent 
example (20-22). Poliovirus encodes a viral protease that cleaves eIF4G during 
infection, inhibiting cap-dependent translation. However, stem loop structures within the 
poliovirus IRES (located in the 5’UTR) directly bind the carboxyl-terminus of cleaved 
eIF4G, which then recruits eIF4A and the 43S PIC. The 48S complex then scans 
through an additional stem loop within the poliovirus 5’UTR and initiates translation at 
the proper AUG (23-27). eIF4E is not necessary for the translation of poliovirus RNA, as 
the presence of a cap is not necessary for eIF4G recruitment. Rhinovirus, picornavirus, 
flavivirus, and pestivirus RNAs contain IRESs to ensure the synthesis of viral proteins 
during infection (28-31). Thus viral IRESs allow for the continued expression of viral 
proteins under conditions with limited cap-dependent translation initiation.  
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While cap-independent translation has been well characterized in the context of 
RNA virus infections, its role in the translation of DNA viruses mRNAs has been studied 
in less detail. Human cytomegalovirus (HCMV), a double-stranded DNA virus of the β-
herpesvirus family, transcribes its capped mRNAs in the nucleus, which are then 
transported to the cytoplasm and translated by host ribosomes (32, 33). Unlike most 
viruses, HCMV infection does not induce translational shut-off, and both cellular and 
viral mRNAs are translated throughout infection (34, 35). The ongoing translation of 
host mRNAs encoding proteins needed for HCMV replication is due in part to an 
increase in eIF4F levels in infected cells (36, 37). However, the translation of HCMV 
mRNAs becomes increasingly resistant to eIF4F disruption as infection progresses (38). 
While only a single HCMV IRES has been described in detail, ~100 HCMV 5’UTRs have 
been shown to promote cap-independent translation in a bicistronic mRNA reporter 
screen (39, 40). These data suggest that HCMV uses an eIF4F-independent 
mechanism to initiate translation of viral mRNAs, but the mechanism(s) controlling 
translation initiation on HCMV mRNAs is currently unknown.  
 We previously found that the HCMV TRS1 protein (pTRS1) increases overall 
levels of protein synthesis and stimulates cap-dependent translation. pTRS1 increases 
the translation of monocistronic mRNAs containing both cellular and HCMV 5’UTRs, 
though pTRS1 preferentially enhances the translation of mRNAs containing viral 
5’UTRs (41). pTRS1 binds double-stranded (dsRNA) and the m7G cap, and inhibits 
activation of the antiviral kinase PKR, which dramatically inhibits translation initiation 
during infection (41-46). However, pTRS1 also stimulates mRNA translation in cells 
lacking PKR (41). Thus pTRS1 enhances translation independent of PKR inhibition. 
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While pTRS1 has been shown to stimulate cap-dependent translation, its effect on cap-
independent translation has not been examined.  
Here we show that HCMV pTRS1 enhances cap-independent translation. pTRS1 
increased the activity of both the poliovirus and KSHV vFLIP IRESs in a bicistronic 
reporter assay. To avoid technical issues associated with bicistronic reporters, we 
developed a new assay to measure IRES activity from circular RNAs. pTRS1 enhanced 
translation of circular mRNAs containing the poliovirus or KSHV IRES, as well as the 
cellular BiP and c-myc IRES elements. pTRS1 also stimulated cap-independent 
translation of bicistronic and circular mRNAs in cells lacking PKR, showing that the 
ability of pTRS1 to stimulate cap-independent translation was separable from its ability 
to antagonize PKR. A pTRS1 mutant that cannot bind dsRNA did not enhance cap-
independent translation, suggesting that pTRS1 directly binds RNAs to promote 
ribosome recruitment. Together these data show that pTRS1 stimulates cap-
independent translation, and may drive the eIF4F-independent translation of viral 
transcripts during HCMV infection. 
  
MATERIALS AND METHODS 
Cells and viruses. HeLa cells and HEK293T cells were maintained in 
Dulbecco’s Modified Eagle Medium (Sigma) supplemented with 10% fetal bovine serum 
(Gibco) and 1% penicillin/streptomycin solution (Sigma). HeLa cells lacking PKR 
expression (PKR KO, (45)) were maintained in media as above supplemented with 1 
ug/ml puromycin.  
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Generation of recombinant plasmids. The poliovirus and KSHV vFLIP 
bicistronic reporters were a kind gift from Dr. Felicia Goodrum at the University of 
Arizona (39). The circular GFP reporter (TR-circGFP) was a kind gift from Dr. Aravind 
Asokan at the University of North Carolina at Chapel Hill (47). To clone IRES elements 
into the circular RNA reporter, the circular GFP reporter plasmid was amplified using 
circGFP F and circGFP R (Table 1). The poliovirus IRES element was amplified from 
the bicistronic reporter above using poliocirc F and poliocirc R (Table 1). The KSHV 
vFLIP IRES was amplified from the bicistronic reporter above using KSHVcirc F and 
KSHVcirc R (Table 1). The IRES elements were ligated into the amplified circular GFP 
reporter using Gibson cloning (NEB). The BiP and c-myc IRES elements were ordered 
as gBlock gene fragments (IDT; Table 1) and ligated to the amplified circular GFP 
reporter using Gibson cloning. The sequences of all circular GFP constructs were 
confirmed by Sanger sequencing. The pTRS1 mutants have been described previously 
(46).       
Luciferase assays. HeLa cells were seeded into 12-well plates (150,000 
cells/well) and transfected with the indicated plasmids using polyethylenimine (PEI, 
Polysciences). Twenty-four hours after transfection cells were washed in 1 ml 1X PBS 
(Sigma) and lysed in 150 µl 1X Passive Lysis Buffer (Promega) for 10 min with rocking 
at room temperature. After lysis supernatants were cleared of debris by centrifugation at 
10,000 x g for 1 min. For firefly luciferase, 40 µl of luciferase reagent (Promega) was 
added to 8 µl of sample, and luciferase activity was measured using a luminometer 
(Molecular Devices). For experiments using bicistronic reporters, 40 µl of Stop and Glo 
reagent was added to each sample after measuring firefly luciferase levels.  40 µl of 
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renilla luciferase reagent (Promega) was then added, and luciferase activity was again 
measured. The amount of luciferase activity was normalized to the amount of protein 
present in each sample as determined by Bradford assay (Amresco). 
Western blot analysis. Cells were washed once in 1X PBS before scraping, and 
cell pellets were stored at -80˚C until analysis. Cell pellets were lysed in RIPA buffer (50 
mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP40, 1% sodium deoxycholate) 
containing protease and phosphatase inhibitors (Roche) for 10 min on ice. Cell debris 
was removed by centrifugation at 10,000 x g for 10 min. The protein concentration of 
the lysate was then determined by Bradford assay, and equal amounts of protein loaded 
onto SDS-PAGE gels. The resolved proteins were transferred to 0.45 µm nitrocellulose 
membranes (Amersham) and blocked in 5% non-fat milk in TBS-T (20 mM Tris-HCl, pH 
7.6, 140 mM NaCl, 0.1% Tween 20) for 1 hour at room temperature. For mouse primary 
antibodies, membranes were incubated with the appropriate antibody diluted in 1% BSA 
in TBS-T for one hour at room temperature. For rabbit primary antibodies, membranes 
were incubated in the appropriate antibody diluted in 5% BSA in TBS-T overnight. 
Secondary antibodies were diluted 1:10,000 in 1% BSA in TBS-T and incubated with 
the membrane for 1 hour at room temperature. Proteins were visualized by 
chemiluminesence using WesternBlot ECL (Advansta) and an imager (ChemiDoc; 
BioRad). The following antibodies were used: anti-GFP (1:10,000; Sigma G1544), anti-
tubulin (1:20,000; ThermoScientific A11126), anti-TRS1 (1:100; (48)), anti-His (1:1,000; 
CST #2365).  
Quantitative real-time PCR (qRT-PCR). RNA was extracted from cells using 
Trizol essentially as described previously (41). Briefly, 100 µl of cell lysate was mixed 
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with 1 ml of Trizol and incubated at room temperature for 10 min. 200 µl of chloroform 
was then added, and samples were shaken for 60 sec before centrifugation at 10,000 x 
g for 10 min. The aqueous layer was removed and an equal volume of isopropanol was 
added. Samples were incubated at -20oC overnight, and the RNA was pelleted by 
centrifugation at 10,000 x g for 30 min at 4oC. RNA pellets were washed once in 70% 
ethanol, resuspended in 1X DNase buffer containing 20U DNase (Turbo DNase free kit; 
Ambion), and incubated at 37oC for 30 min. DNase was inactivated according to the 
manufacturer’s directions. RNA concentrations were determined using a 
spectrophotometer (NanoDrop) and equal amounts of RNA were reverse transcribed to 
cDNA using the High Capacity cDNA Reverse Transcription Kit (ThermoFisher). 2 µl of 
cDNA was added to 1X SYBR Green Master Mix with the appropriate primers, and real-
time PCR was performed using the following conditions: 95oC 5 minutes, followed by 40 
cycles of 95oC 10 for seconds, 55oC for 30 seconds, 72oC for 90 seconds. Changes in 
RNA levels were determined by the ∆∆Ct method as before using GAPDH as the 
reference gene (41). The following primer pairs were used (sequences listed in Table 
1): GAPDH (GAPDH F and GAPDH R), renilla luciferase (RLUC F and RLUC R), firefly 
luciferase (FLUC F and FLUC R), circular GFP (qcircGFP F and qcircGFP R). All 
experiments were performed at least in triplicate and statistical significance was 
determined using a Student’s paired t-test.    
 
RESULTS 
pTRS1 enhances the activity of the poliovirus IRES. We previously found that 
pTRS1 increases the translation of monocistronic luciferase reporters regulated by cap-
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dependent translation (41). To determine if pTRS1 could also enhance cap-independent 
translation, we measured the effect of pTRS1 expression on the translation of a 
bicistronic mRNA reporter containing the well-characterized poliovirus IRES (20, 22, 
49). Translation of the first cistron of the bicistronic mRNA (renilla luciferase) is cap-
dependent, while translation of the downstream cistron (firefly luciferase) is driven by an 
IRES element in a cap-independent manner (Fig 1A). The effect of pTRS1 on cap-
dependent and cap-independent translation was determined by comparing the effect of 
pTRS1 expression on renilla and firefly luciferase activity, respectively, from a 
bicistronic reporter containing no IRES element (control) or the poliovirus IRES (polio) 
(Fig 1B). The bicistronic reporter containing the poliovirus IRES showed a 10-fold 
increase in firefly luciferase levels compared to the control when co-transfected with 
GFP, consistent with previous results (39). pTRS1 expression increased both renilla 
and firefly luciferase levels from the control vector as compared to the GFP control (4- 
and 5.6-fold, respectively). While polio renilla levels were increased 2.2 fold in the 
presence of pTRS1, firefly luciferase levels were increased by 28.2-fold. Using the 
same data we also analyzed the effect of pTRS1 on IRES activity, defined as the ratio 
of firely to renilla luciferase activity (Fig 1A). pTRS1 expression did not affect IRES 
activity from the control reporter (Fig 1C), as levels of renilla and firefly luciferase were 
similar (Fig 1B). However, pTRS1 increased poliovirus IRES activity by 13-fold 
compared to the control. In addition, pTRS1 increased poliovirus IRES activity in a 
dose-dependent manner (Fig 1D), consistent with a specific role for pTRS1 in 
enhancing cap-independent translation. 
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KSHV vFLIP IRES activity is enhanced in the presence of pTRS1. To 
determine if the effect of pTRS1 on cap-independent translation was specific to the 
poliovirus IRES, we examined the effect of pTRS1 on the activity of an additional IRES 
from the Kaposi’s sarcoma-associated herpersvirus (KSHV) vFLIP mRNA (50). pTRS1 
increased the activity of the KSHV vFLIP IRES by 29-fold as compared to the control 
(Fig 2A). Analyzing the effect of pTRS1 expression on renilla and firefly luciferase levels 
separately, we found that pTRS1 expression had little to no effect on renilla luciferase 
activity (Fig 2C), but significantly increased firefly luciferase activity (Fig 2D). 
Importantly, pTRS1 expression did not result in a significant change to firefly or renilla 
RNA levels (Fig 2B). Thus the increase in poliovirus and KSHV vFLIP IRES activity in 
the presence of pTRS1 was not due to cryptic promoter activity or cryptic RNA splicing 
within the reporter plasmid or mRNA.  These data suggest that pTRS1 can enhance 
cap-independent translation driven by multiple IRESs. 
pTRS1 promotes translation of a circular mRNA. Translation of the firefly 
open reading frame (ORF) in the bicistronic reporter requires an IRES element. 
However the bicistronic RNA encoding the firefly ORF contains a 7-methygluanosine 
(m7G) mRNA cap, which pTRS1 is known to bind (41). Thus pTRS1 could promote 
translation of the firefly ORF by bridging an interaction with cap-associated proteins and 
the IRES element. This would mean that the ability of pTRS1 to stimulate IRES activity 
is not truly independent of the m7G mRNA cap. To assess this possibility, we 
determined the effect of pTRS1 on the translation of a circular reporter RNA. The 
circular RNA reporter consists of a single exon minigene containing split GFP in the 
reverse order (Fig 3A). Backsplicing of the primary transcript produces a circular RNA 
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(circRNA), which lacks both a m7G RNA cap and poly(A) tail, and contains the GFP 
coding sequence in the correct order. The inclusion of an IRES upstream of the GFP 
start codon allows the circRNA to be efficiently translated (47, 51). As the circRNA GFP 
reporter lacks an m7G mRNA cap and poly(A) tail, and translation is solely driven by the 
IRES element, this system is ideal for assessing IRES activity.  
We first cloned the poliovirus and KSHV vFLIP IRES into the circular GFP 
reporter (polio circGFP and KSHV circGFP, respectively). We then measured GFP 
expression from the circular RNA reporters. GFP was expressed in cells transfected 
with polio circGFP or KSHV circGFP, showing that both the poliovirus and KSHV vFLIP 
IRESs promote circGFP translation (Fig 3B). We next examined the effect of pTRS1 
expression on polio circGFP and KSHV circGFP (Fig 3B). GFP expression increased 
when the circGFP reporters were co-transfected with pTRS1 and these changes 
mirrored the increase in IRES activity in the presence of pTRS1 from the bicistronic 
reporters. In addition, pTRS1 did not change the levels of circGFP RNA (Fig 3C). These 
data suggest that pTRS1 promotes mRNA translation independent of the m7G mRNA 
cap or factors associated with a poly(A) tail. 
We also tested the ability of pTRS1 to stimulate the translation of circRNA 
reporters containing cellular IRES elements. We examined the effect of pTRS1 on 
translation driven by the binding immunoglobulin protein (BiP) and c-myc IRES 
elements (16, 17, 19) (Fig 4). BiP IRES activity and protein levels, and c-myc RNA 
levels increase during HCMV infection (52-57). pTRS1 enhanced BiP IRES activity, as 
shown by increased GFP protein expression from the BiP circRNA reporter, though the 
effect was less pronounced than observed with the poliovirus and vFLIP IRESs. We 
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saw undetectable levels of GFP from the c-myc circRNA in the absence of pTRS1, 
suggesting that the c-myc IRES sequence normally has very low IRES activity. However 
as with the other IRESs, pTRS1 expression increased GFP protein expression driven by 
the c-myc IRES. Thus, in addition to increasing the activity of viral IRESs, pTRS1 also 
enhances translation driven by cellular IRES elements.  
pTRS1 stimulates IRES activity independent of its ability to antagonize 
PKR. pTRS1 enhances translation in part by preventing PKR activation. However, 
pTRS1 also promotes cap-dependent translation, independent of PKR antagonism (41, 
45). To determine if the increase in cap-independent translation in the presence of 
pTRS1 was due to inhibition of PKR activation, we measured the effect of pTRS1 on 
IRES activity in cells where CRISPR/Cas9 mutagenesis was used to ablate PKR 
expression (PKR KO cells, (45)). Using bicistronic reporters, we found that the 
poliovirus and KSHV vFLIP IRESs had increased activity in PKR KO cells, 
demonstrating that PKR inhibits poliovirus and KSHV vFLIP IRES activity. In addition 
pTRS1 increased the activity of both IRESs in PKR KO cells compared to cells 
expressing GFP (Fig 5A & 5B). We confirmed these results using the circGFP reporter 
containing the KSHV vFLIP IRES. pTRS1 expression increased GFP protein levels in 
PKR KO cells, showing that pTRS1 stimulates KSHV vFLIP IRES activity in a PKR-
independent manner (Fig 5C). Thus pTRS1 stimulates cap-independent translation 
independent of its ability to inhibit PKR activation. 
The ability of pTRS1 to bind RNA is necessary to stimulate cap-
independent translation. pTRS1 has a non-canonical RNA binding domain that 
preferentially binds double-stranded RNA (dsRNA) (43, 44). While this function is 
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dispensable for pTRS1 to antagonize PKR in transfected cells, we hypothesized it may 
be important to enhance cap-independent translation (46). To determine if pTRS1 
binding to dsRNA was necessary to enhance cap-independent translation, we 
compared the ability of wild type pTRS1 and a TRS1 mutant that cannot bind dsRNA 
(Triple) to increase GFP protein expression from the KSHV vFLIP circRNA (Fig 6). Wild 
type pTRS1 increased GFP expression compared to the control. However, no GFP 
expression was observed in cells transfected with pTRS1 triple. These results show that 




In this study we found that HCMV pTRS1 enhances cap-independent translation. 
pTRS1 stimulates the activity of multiple IRESs in both a bicistronic reporter assay, and 
in a novel circular RNA assay of IRES activity. pTRS1 stimulates cap-independent 
translation independent of its ability to inhibit PKR, as it increases the activity of multiple 
IRESs in PKR deficient cells. The ability of pTRS1 to bind dsRNA is necessary to 
stimulate cap-independent translation, suggesting that pTRS1 may bind specific mRNA 
sequences or structures to facilitate ribosome recruitment.  
Our results raise the question of how pTRS1 enhances cap-independent 
translation. While pTRS1 binds the m7G mRNA cap (41), this function is dispensable to 
stimulate IRES activity as pTRS1 enhances translation of circRNA reporters lacking an 
mRNA cap and a poly(A) tail. Our group and others have shown that pTRS1 binds RNA, 
with a preference for binding to double-stranded RNA (dsRNA) (43, 58). The 
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requirement for the pTRS1 dsRNA binding domain to stimulate cap-independent 
translation suggests that pTRS1 directly interacts with the IRES to recruit ribosomes. 
The fact that pTRS1 stimulates the activity of multiple IRESs with minimal sequence 
homology suggests that pTRS1 likely binds common IRES RNA structures. As pTRS1 
also associates with 40S ribosomal subunits (41), these data suggest a model wherein 
pTRS1 binds to double-stranded RNA structures in IRESs and facilitates the recruitment 
of ribosomal subunits, resulting in enhanced cap-independent translation. 
 pTRS1 potently antagonizes the antiviral kinase PKR, which inhibits both cap-
dependent and -independent translation by limiting the availability of active ternary 
complexes (42, 45, 46, 59, 60). Our results show that the inhibition of PKR by pTRS1 
contributes to increased cap-independent translation. However pTRS1 also enhances 
cap-independent translation in PKR deficient cells, possibly reflecting a role for pTRS1 
in recruiting ribosomes as discussed above. Multiple host RNA binding proteins 
recognize viral RNA elements and activate restriction pathways that limit viral protein 
synthesis (3). Therefore it is possible that pTRS1 also antagonizes additional restriction 
factors that recognize and inhibit the translation of viral RNA. If so, the requirement for 
the pTRS1 RNA binding domain would suggest that pTRS1 competes with antiviral 
sensors to limit their detection of dsRNA structures. 
How might the enhancement of cap-independent translation by pTRS1 impact 
HCMV replication? HCMV infection increases eIF4F abundance, and the eIF4F 
complex is required for the synthesis of several cellular proteins needed for virus 
replication (36-38). Although, inhibiting the activity or formation of the eIF4F complex 
does not limit the association of HCMV mRNAs with polysomes, especially during the 
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later stages of infection (38). Our results showing that pTRS1 enhances the translation 
of a circRNA reporter suggests that pTRS1 may help recruit ribosomes to HCMV 
mRNAs independent of the eIF4F complex. The increase in cap-independent translation 
caused by pTRS1 may also promote the expression of cellular proteins necessary for 
HCMV replication. BiP IRES activity and protein levels increase during HCMV infection, 
and BiP expression is necessary for efficient HCMV replication (52-55). Perhaps the 
stimulation of cap-independent translation by pTRS1 allows for the efficient translation 
of BiP and other pro-viral cellular factors during infection to allow for successful HCMV 
replication  
Our results add to the growing list of functions ascribed to pTRS1 (41, 44-46, 58, 
61, 62). While antagonism of PKR is an important role of pTRS1 during infection of 
primary fibroblasts, the enhancement of cap-independent translation may be more 
important in other cell types relevant to HCMV disease, such as CD34+ progenitor cells, 
epithelial cells or placental cells (63, 64). Further studies to define the mechanism 
behind the ability of pTRS1 to stimulate translation will therefore be critical to fully 
understand the role of pTRS1 in HCMV pathogenesis. 
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Figure 3.1. pTRS1 stimulates poliovirus IRES activity. (A) Schematic of bicistronic 
mRNA reporter. IRES activity is determined by comparing the level of firefly luciferase 
(FLuc) to the level of renilla luciferase (RLuc). (B) HeLa cells were transfected with a 
bicistronic reporter containing no IRES element (EV) or a reporter containing the 
poliovirus IRES (Polio) in the presence of GFP or TRS1. Fold change of renilla 
luciferase (black bars) and firefly luciferase (white bars) compared to EV co-transfected 
with GFP are shown. (C) As in (B), IRES activity is represented as fold change 
compared to EV or Polio reporters co-transfected with GFP. (D) HeLa cells were 
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transfected with the Polio reporter and increasing amounts of TRS1 DNA. Fold change 
in IRES activity compared to reporter in the absence of TRS1 is shown.  
 
 
Figure 3.2. pTRS1 increases the activity of multiple viral IRESs. (A) HeLa cells 
were co-transfected with a bicistronic reporter containing no IRES element (EV), the 
KSHV vFLIP IRES (KSHV) or the poliovirus IRES (Polio) and either GFP or TRS1. The 
fold change in IRES activity in reporters co-transfected with TRS1 compared to co-
transfection with GFP is shown. (B) RNA was extracted from cells transfected as in (A). 
Renilla and fireflly luciferase RNA levels were determined by qRT-PCR. The ratio of 
firefly luciferase (FLuc) to renilla luciferase (RLuc) RNA in cells transfected with TRS1 
compared to cells transfected with GFP is shown for each bicistronic reporter. (C) As in 
(A), the fold change in renilla luciferase levels in cells transfected with TRS1 compared 
to cells transfected with GFP is shown for each reporter. (D) As in (C), except levels of 
firefly luciferase are shown. 
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Figure 3.3. pTRS1 stimulates the translation of a circular GFP mRNA. (A) Cartoon 
of the circular GFP reporter and the backsplicing event that results in the formation of a 
circular GFP mRNA. (B) HeLa cells were transfected with circular RNA reporters 
containing either the poliovirus IRES (Polio) or the KSHV vFLIP IRES (KSHV). GFP 
protein levels were determined by Western blot 48 hours post transfection. (C) As in (B), 
except following transfection, RNA was extracted and circular GFP mRNA levels were 
determined by qRT-PCR. The fold change in GFP RNA levels in cells transfected with 




Figure 3.4. pTRS1 stimulates cellular IRES activity. (A) HeLa cells were co-
transfected with a circular GFP reporter containing either the BiP IRES (BiP) or the c-
myc IRES (c-myc) with either a vector control (EV) or TRS1. GFP levels were 
determined by Western blot 72 hours post transfection. 
 
 
Figure 3.5. Stimulation of IRES activity by pTRS1 is not dependent on PKR 
antagonism. (A) WT HeLa cells were co-transfected with a bicistronic reporter 
containing the KSHV vFLIP IRES (KSHV) or the poliovirus IRES (Polio) with either GFP 
or TRS1. IRES activity of each reporter (FLuc/RLuc) is shown. (B) As in (A), but in PKR 
KO cells. (C) WT and PKR KO HeLa cells were co-transfected with a circular GFP 
reporter containing the KSHV vFLIP IRES and either a vector control (EV) or TRS1. 
Levels of GFP expression were determined by Western blot. 
 130 
 
Figure 3.6. pTRS1 dsRNA binding is necessary to promote cap-independent 
translation. (A) HeLa cells were co-transfected with a circular GFP reporter containing 
the KSHV vFLIP IRES (KSHV circGFP) and either a vector control (EV) or the indicated 
TRS1 construct. TRS1 triple (Triple) lacks the ability to bind dsRNA. Levels of GFP 
















Table 3.1. Primer and gBlock Gene Fragment Sequences 
Primer Name Sequence (5' à  3') 
circGFP F ACCATGGTGAGCAAGGGCGA 
circGFP R GTCGACTGCAGAATTCAGAT 
poliocirc F ATCTGAATTCTGCAGTCGACTTAAAACAGCTCTGGGGTTGTTCC 
poliocirc R TCGCCCTTGCTCACCATGGTATATCTTAACAATGAGGTAATTCC 
KSHVcirc F ATCTGAATTCTGCAGTCGACTTGGACAGACTCCTACTT 





















GAPDH F CTGTTGCTGTAGCCAAATTCGT 
GAPDH R ACCCACTCCTCCACCTTTGAC 
RLUC F TCGGTTGGCAGAAGCTATGA 
RLUC R CCGATAAATAACGCGCCCAA 
FLUC F ACAAAGGCTATCAGGTGGCT 
FLUC R CGTGCTCCAAAACAACAACG 
qcircGFP F GCAGTGCTTCAGCCGCTAC  
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Human cytomegalovirus (HCMV) is a ubiquitous pathogen that infects a majority 
of the world’s population. Lytic HCMV replication in immunocompromised individuals or 
neonates can lead to disease in multiple organ systems, morbidity, and even and 
mortality. The HCMV protein TRS1 (pTRS1) and its functional homologue (pIRS1) are 
necessary for lytic replication. Both proteins antagonize the antiviral protein kinase R 
(PKR) to inhibit the host antiviral respsone and ensure efficient HCMV replication. 
pTRS1 has additional PKR-independent functions, including the ability to stimulate cap-
dependent and cap-independent translation. However the mechanism behind these 
functions remains unknown. To determine how pTRS1 promotes translation in a PKR-
independent manner we identified ribosome-associated cellular proteins that interact 
with pTRS1. We found that pTRS1 interacts with protein phosphatase 1 (PP1) catalytic 
subunits both in vitro and during HCMV infection. pTRS1-specific immune complexes 
were significantly associated with phosphatase activity, but pTRS1 expression had no 
effect on PP1 catalytic activity. Rather, pTRS1 expression changed the complement of 
proteins that interact with the PP1 alpha catalytic subunit. These data suggest that 
rather than affecting PP1 catalytic activity, pTRS1 changes the substrate specificity of 
the PP1 holoenzyme. Thus the interaction of pTRS1 with PP1 could affect the 
regulation of multiple signaling pathways during HCMV infection. 
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INTRODUCTION 
Human cytomegalovirus (HCMV) is a significant human pathogen. Reactivation 
of a latent infection or primary infection in immunocompromised individuals can lead to 
significant morbidity and mortality (1). In addition, primary HCMV infection during 
pregnancy is a leading cause of congenital birth defects (2). HCMV infection is 
characterized by a prolonged replication cycle and substantial manipulation of cellular 
signaling processes (1). HCMV regulates cellular metabolism, cell cycle progression, 
and protein synthesis pathways to ensure that viral proteins are expressed and progeny 
virions are produced (3-6). Viral infection is an inherently stressful event, thus HCMV 
must also blunt cellular stress responses to ensure efficient replication (7).  
HCMV expresses several viral proteins that regulate cellular stress response 
pathways, including the viral proteins pTRS1 and pIRS1, which inhibit activation of the 
antiviral kinase PKR (8-11). PKR is activated upon binding to viral double-stranded RNA 
(dsRNA) (12, 13). Once activated, PKR phosphorylates the alpha subunit of the eIF2 
translation initiation factor (eIF2α) (13). Phosphorylation of eIF2α prevents the formation 
of ternary complexes, which are essential for translation initiation (14, 15). Therefore, 
activation of PKR in response to viral infection leads to an overall inhibition of 
translation, which prevents the synthesis of viral proteins. pTRS1 blocks PKR activation 
by binding PKR and inhibiting PKR kinase activity (8). As a result, loss of pTRS1 
expression, and expression of its functional homologue pIRS1, leads to robust PKR 
activation and eIF2α phosphorylation early in infection (9). The resulting inhibition of 
protein synthesis severely attenuates viral protein expression, and therefore virus 
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replication (8, 10). Thus pTRS1 and pIRS1 block the activation of the PKR-eIF2α stress 
response pathway to ensure the synthesis of viral proteins during infection.   
Viruses use multiple strategies to prevent eIF2α phosphorylation during infection 
(16). The vaccinia virus proteins E3L and K3L both antagonize PKR. E3L binds and 
sequesters viral dsRNA, preventing detection by PKR, while K3L acts as a PKR 
pseudosubstrate and prevents its interaction with eIF2α (17-19). Herpes simplex virus-1 
(HSV-1) also encodes two viral proteins that block the PKR-eIF2α signaling pathway. 
The HSV-1 US11 protein binds both dsRNA and PKR, and prevents PKR activation (20-
22). Further, the HSV-1 protein ICP34.5 recruits the cellular phosphatase PP1 to de-
phosphorylate eIF2α (16, 23). A similar function is used by the papilloma virus (HPV) 
protein E6 and the African Swine Fever Virus protein DP71L, which both recruit PP1 to 
dephosphorylate eIF2α (24, 25). While targeting PP1 to phosphorylated eIF2α is a 
common viral strategy to maintain protein synthesis, the role of PP1 in HCMV infection 
has not been studied in detail. Both PP1 levels and overall levels of phosphatase 
activity increase during HCMV infection. Also, phosphorylation of eIF2α is regulated by 
phosphatase activity during infection, and treatment with phosphatase inhibitors at the 
start of infection inhibits overall levels of protein synthesis. These data suggest that PP1 
may play an important role in HCMV replication (26). 
Although PKR antagonism is a primary pTRS1 function, pTRS1 has multiple 
functions independent of its ability to inhibit PKR activation. pTRS1 increases overall 
levels of protein synthesis and stimulates the translation of reporter mRNAs in cells 
lacking PKR expression (chapter 3)(27). In addition, pTRS1 limits eIF2α 
phosphorylation in response to activation of another eIF2α kinase, HRI, in PKR KO cells 
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(8). These data suggest that pTRS1 regulates multiple stress response pathways to 
prevent eIF2α phosphorylation. However, the mechanism behind these additional 
pTRS1 functions remains unknown. 
Here we show that pTRS1 interacts with multiple PP1 catalytic subunits and 
changes the complement of proteins that interact with the PP1 alpha catalytic subunit. A 
screen of pTRS1-interacting proteins revealed that pTRS1 interacts with all three PP1 
catalytic subunits. We confirmed the interaction of pTRS1 with the PP1Cα, PP1Cβ, and 
PP1Cγ catalytic subunits in vitro, and showed that pTRS1 interacts with the PP1Cβ 
catalytic subunit during HCMV infection. Phosphatase activity is associated with pTRS1-
specific immune complexes, however pTRS1 expression does not affect PP1Cα 
catalytic activity. Rather we found that pTRS1 changes the complement of proteins that 
interact with PP1Cα, suggesting that pTRS1 may change PP1 substrate specificity. 
Together, these data suggest that the interaction of pTRS1 with PP1 may regulate 
multiple signaling pathways during HCMV replication.  
 
MATERIALS AND METHODS 
Cell culture, viral infections, and drug treatments. HeLa cells, HEK293T cells, 
and MRC-5 primary human fibroblasts were maintained in Dulbecco’s Modified Eagle’s 
Medium (DMEM, Sigma) supplemented with 1% penicillin/streptomycin (Sigma) and 
10% fetal bovine serum (FBS, Gibco). HeLa cells in which PKR expression was ablated 
using CRISPR/Cas9 (9) were maintained in DMEM containing 1% penicillin/ 
streptomycin, 10% FBS, and 1 µg/ml puromycin.  
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MRC-5 cells were infected with HCMV AD169inGFP at a multiplicity of infection 
(MOI) of 3 for all experiments. This virus contains a GFP open reading frame (ORF) 
under the control of an SV40 promoter that is expressed throughout infection (9). 
Where indicated, cells were treated with 0.5 mM arsenite (Sigma) for 1 hour to 
induce eIF2α phosphorylation. For BioID experiments, cells were treated with 50 µM 
biotin (Sigma) diluted in serum-free DMEM for 18 hours before harvest.  
Generation of recombinant plasmids. The full-length TRS1 plasmid was a kind 
gift from Adam Geballe (28). For the construction of pTRS1 BioID: the BirA open 
reading frame (ORF) was amplified using TRS1 BirA F and BirA R (Table 1) from the 
pcDNA3.1 mycBioID plasmid (Addgene #35700). The TRS1 ORF was amplified using 
TRS1 F and TRS1 BirA R (Table 1). TRS1 in pcDNA3.1 was digested with BamHI and 
XhoI to remove the TRS1 ORF and linearize the backbone plasmid. The BirA ORF and 
TRS1 ORF were then cloned into linear pcDNA3.1 using a Gibson cloning strategy 
(NEB). For the construction of TRS1 ΔRVTF: The TRS1 pcDNA3.1 plasmid was 
amplified using RVTF F and RVTF R (Table 1). The PCR product was ligated using 
Gibson (NEB). These mutations lead to a 780RVTF783 to 780AAAA783 mutation in TRS1.  
Plasmids containing the PPP1CA, PPP1CB, and PPP1CC ORFs were obtained 
from the ORFeome collection at the Tissue Culture Facility at University of North 
Carolina at Chapel Hill. For the construction of carboxyl-terminal myc-tagged PP1 
catalytic subunits: The PPP1CA ORF was amplified using PPP1CA mycF and PPP1CA 
mycR. The PPP1CB ORF was amplified using PPP1CB mycF and PPP1CB mycR. The 
PPP1CC ORF was amplified using PPP1CC mycF and PPP1CC mycR. All primers are 
listed in Table 1. pcDNA3.1 was linearized following digestion with BamHI and XhoI and 
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the PPP1 catalytic subunits were cloned into the plasmid backbone using Gibson 
cloning (NEB). For the PPP1CA F293A mutant: PPP1CA in pcDNA3.1 was amplified 
using the primers PP1 F293A F and PP1 F293A R (Table 1). The PCR product was 
then cirularized using Gibson (NEB). For the amino-terminal BirA tag on PPP1CA: The 
BirA ORF was amplified using BirA pcD F and BirA R2 and the PPP1CA ORF was 
amplified using PPP1CA BioIDF and PPP1CA BioIDR (Table 1). pcDNA3.1 was 
linearized following digestion with BamHI and XhoI and the BirA and PPP1CA ORFs 
were cloned into the plasmid backbone using Gibson cloning (NEB). The sequence of 
all clones was confirmed using Sanger sequencing. 
PKR activation. HEK293T cells were transfected with either TRS1 BioID or a 
GFP control for forty-eight hours. Cells were then lysed in 120 µl of PKR lysis buffer (50 
mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.5% NP-40, 10% glycerol, and 1 mM EDTA with 
protease and phosphatase inhibitors (Roche)). Cell debris was removed following a 10 
min, 10,000 x g spin at 4°C. 1 mg/ml poly(I:C) (LMW, Invivogen) was added to 100 µl of 
lysate and incubated at 30°C for 30 min to induce PKR activation. Levels of PKR 
activation, measured by phosphorylation at PKR Thr446, were then determined by 
Western blot analysis (see below). 
Metabolic labeling. HeLa cells were transfected with either TRS1 BioID or an 
empty vector control for 24 hours. Cells were then starved in methionine/cysteine-free 
media (Sigma) for 15 min and subsequently treated with 125 µCi of 35S-labeled 
methionine and cysteine (PerkinElmer EasyTag Express Labeling Mix) for 30 min. Cells 
were then washed twice in ice-cold 1X PBS and scraped. Cell pellets were lysed in 
RIPA buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% NP-40, 0.25% deoxycholate, 
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1 mM EDTA, containing protease and phosphatase inhibitors (Roche)). Protein was 
then precipitated by adding trichloroacetic acid (TCA) to a final concentration of 20%. 
Precipitated proteins were transferred to a glass microfiber filter, washed twice with 20% 
TCA, washed once with 100% ethanol and then allowed to air dry. Filters were 
transferred to vials containing scintillation fluid and levels of radioactivity were 
determined using a scintillation counter. Levels of radioactivity were normalized to the 
levels of protein within the lysate as determined by Bradford assay (Amresco). 
Ribosome Isolation. Cells were transfected with TRS1, BioID, or TRS1 BioID 
for 24 hours and then treated with 50 µM biotin for 18 hours. Cells were then treated 
with 0.1 mg/ml cyclohexamide (CHX) for 10 min. Cells were washed twice in ice-cold 
PBS containing 0.1 mg/ml CHX, scraped, and pelleted at 4°C. Cell pellets were lysed in 
polysome lysis buffer (20 mM Tris-HCl (pH 7.4), 140 mM KCl, 5 mM MgCl2, 0.1% 
TritonX-100, 10 mM DTT, 0.1 mg/ml CHX), allowed to swell on ice for 10 min, and then 
passed through a 27-gauge needle five times. Lysates were spun for 5 min at 3,000 x g 
at 4°C to pellet nuclei. Supernatant was then moved to a new tube and spun for 10 min 
at 10,000 x g at 4°C to remove mitochondria. 0.5 ml of supernatant was then layered 
onto a 1 ml sucrose cushion (1M sucrose, 0.5M KCl, 5 mM MgCl2, 50 mM Tris-HCl (pH 
7.4)) and spun for 2h at 245,000 x g. Supernatant was decanted and ribosomal pellets 
washed once with ice-cold water before being stored at -80°C. 
Immunoprecipitations. For the TRS1 BioID streptavidin affinity 
chromatography, ribosome pellets from cells transfected with TRS1, BioID, or TRS1 
BioID were lysed in RIPA buffer supplemented with 2M Urea (50 mM Tris-HCl (pH 7.4), 
150 mM NaCl, 1% NP-40, 0.25% deoxycholate, 1 mM EDTA, 2M Urea, containing 
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protease and phosphatase inhibitors (Roche)) for 10 min on ice. Lysates were sonicated 
(3 pulses, 30% output) and cell debris removed following a 10 min spin at 10,000 x g at 
4°C. 20 µl of Dynabeads MyOne Streptavidin T1 beads (Thermo Scientific) were 
washed three times and re-suspended in 100 µl of RIPA + Urea buffer. Re-suspended 
beads were added to cleared lysates and nutated at 4°C for 3 hours. Beads were then 
washed three times with RIPA + Urea buffer and washed an additional three times in 50 
mM ammonium bicarbonate (ABC). Beads were re-suspended in 100 µl ABC and 
submitted to the mass spectrometry facility for analysis.  
To confirm the pTRS1 interactions during infection, MRC-5 fibroblasts were 
infected with HCMV (MOI of 3) for 48 or 72 hours. Cells were washed once with 1X 
PBS, pelleted, and lysed in RIPA light buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 
1% NP-40, 1 mM EDTA, containing protease and phosphatase inhibitors (Roche)) for 
10 min on ice. Cell debris was removed following a 10,000 x g spin at 4°C. 20 µl of 
Protein A/G bead slurry (Santa Cruz Biotechnology) were then washed three times and 
re-suspended in 100 µl of RIPA light buffer. Re-suspended beads were added to 
cleared lysates and nutated at 4°C for 30 min in a pre-clear step. Beads were then spun 
out and the pTRS1 antibody (29) or mouse igG control (Bethyl) or anti-IE1 antibody 
control (30) were added to the lysates and nutated at 4°C for 1 hour. 100 µl of re-
suspended protein A/G beads were then added to each lysate and nutated for an 
additional 1.5 hours at 4°C. Beads were then washed three times with RIPA light buffer 
and re-suspended in 1X sample buffer before Western blot analysis (see below).  
For the PP1 catalytic subunit immunoprecipitations, both transfected HeLa cells 
and infected MRC-5 fibroblasts were washed once with 1X PBS, pelleted, and lysed in 
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Strang buffer (31) (50 mM Hepes (pH 7.4), 150 mM NaCl, 1% TritonX-100, 10% 
glycerol, 2 mM EDTA, 0.1 mM DTT, containing protease and phosphatase inhibitors 
(Roche)) for 10 min on ice. Cell debris was removed following a 10,000 x g spin at 4°C. 
20 µl of Protein A/G bead slurry (Santa Cruz Biotechnology) were then washed three 
times and re-suspended in 100 µl of Strang buffer. Re-suspended beads were added to 
cleared lysates and nutated at 4°C for 30 min in a pre-clear step. Beads were then spun 
out and the appropriate antibody or mouse IgG control (Bethyl) was added to the 
lysates and nutated at 4°C for 1 hour. 100 µl of re-suspended protein A/G beads were 
then added to each lysate and nutated for an additional 1.5 hours at 4°C. Beads were 
then washed three times with Strang buffer and re-suspended in 1X sample buffer 
before Western blot analysis (see below). 
Western blot analysis. Unless otherwise stated, cell pellets were lysed in RIPA 
buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% NP-40, 0.25% deoxycholate, 1 mM 
EDTA, containing protease and phosphatase inhibitors (Roche)) for 10 min on ice. Cell 
debris was then removed by a 10,000 x g spin at 4°C, and the lysate protein 
concentration was determined by Bradford assay. Lysates were brought to a final 
concentration of 1X sample buffer (0.1 M Tris-HCl (pH 6.8), 6% glycerol, 2% SDS, 0.1 
mM DTT, 0.002% bromophenol blue), boiled for 10 min and spun at 10,000 x g for 2 
min before loading onto SDS-PAGE gels. Equal amounts of protein were then resolved 
on 10% SDS-PAGE gels and transferred to 0.45 µM nitrocellulose membrane (GE 
healthcare). Membranes were blocked in 5% non-fat milk in TBS-T (20 mM Tris-HCl (pH 
7.6), 150 mM NaCl, 0.1% Tween 20) for one hour at room temperature. All mouse 
primary antibodies were diluted in 1% bovine serum albumin (BSA, VWR) in TBS-T. 
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Membranes were incubated in mouse primary antibody for either one hour at room 
temperature or overnight at 4°C. Rabbit antibodies were diluted in 5% BSA in TBS-T, 
with the exception of anti-His which was diluted in 1% BSA in TBS-T. Membranes were 
incubated in rabbit primary antibody overnight at 4°C. Both anti-mouse and anti-rabbit 
secondary antibodies (KPL) were diluted 1:10,000 in 1% BSA in TBS-T. Membranes 
were incubated in secondary antibody for one hour at room temperature before being 
developed with WesternBlot ECL and peroxide (Advansta). Membranes probed with 
streptavidin-HRP (Pierce, diluted 1:500 in 1% BSA in TBS-T) were incubated with 
antibody for one hour at room temperature before being developed. Membranes probed 
for eIF2α phosphorylation were blocked overnight with 5% BSA in TBS-T followed by an 
overnight incubation in primary antibody. The following primary antibodies were used: 
Tubulin (1:20,000; Thermo Scientific), TRS1 (1:100; (29)), Total PKR (1:1,000; Santa 
Cruz Biotechnologies), Phospho-PKR (Thr446) (1:1,000; Abcam), Streptavidin-HRP 
(1:500; Pierce), PAN3 (1:1,000; Bethyl), PABP (1:1,000; CST), CPEB4 (1:1,000; 
Genetex), myc (1:1,000; CST), PP1Cα (1:1,000; CST), PP1Cβ (1:1,000; CST), PP1Cγ 
(1:1,000; CST), Total eIF2α (1:1,000; CST), Phospho-eIF2α (1:1,000; CST). 
Phosphatase assay. TRS1 and PP1 immune complexes were isolated as above 
and associated phosphatase activity was determined using the Millipore Ser/Thr 
Phosphatase Assay Kit 1 (#17-127). Briefly, beads were washed once with Ser/Thr 
buffer following three washes with Strang buffer. Beads were then re-suspended in a 
final volume of 80 µl of Ser/Thr buffer and 750 µM phosphopeptide. The phosphatase 
assay was ran for 10 min at 30°C with shaking, whereupon free phosphate levels were 
determined using Malachite green according to manufacturer instructions. For the rate 
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of phosphatase activity experiments: PP1 immune complexes were isolated as above 
and washed once with Ser/Thr buffer. Phosphatase assays were ran with 
phosphopeptide concentrations of 750 µM, 500 µM, 350 µM, 175 µM, or 100 µM. All 




pTRS1 BioID to identify cellular pTRS1 binding partners. pTRS1 has multiple 
PKR-independent functions, including promotion of both cap-dependent and cap-
independent translation and inhibition of eIF2α phosphorylation following HRI activation 
(chapter 3)(8, 27). However, the mechanism behind these functions remains unclear. To 
elucidate the mechanism of PKR-independent pTRS1 functions, we used the BioID 
approach to identify cellular proteins that interact with pTRS1 (32). We fused a 
promiscuous biotin ligase (BioID) to the carboxyl-terminus of pTRS1 (pTRS1 BioID). 
When expressed in the presence of excess biotin, proteins that interact with pTRS1 
BioID, even transiently, will be covalently biotinylated. pTRS1-interacting proteins can 
then be isolated using streptavidin affinity chromatography, and identified by mass 
spectrometry (Fig 1A). We confirmed that the pTRS1 BioID fusion protein maintained 
wild-type function by assessing the ability of pTRS1 BioID to antagonize PKR and 
stimulate translation. We found that pTRS1 BioID prevented PKR autophosphorylaton in 
response to poly(I:C) treatment (Fig 1B), and increased overall levels of protein 
synthesis by 50% compared to cells expressing GFP, similar to untagged pTRS1 (Fig 
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1C)(27). Thus pTRS1 BioID retains the known functions of pTRS1, suggesting the 
fusion protein functions similarly to wild type pTRS1. 
To visualize proteins that interact with pTRS1 we transfected cells with TRS1, 
BioID, or TRS1 BioID and treated them with exogenous biotin. Biotinylated proteins in 
whole cell lysates were analyzed by Western blot (Fig 1D). No biotinylated proteins 
were observed in cells transfected with untagged pTRS1, as expected. Many proteins 
were labeled in cells transfected with BioID. However, cell expressing pTRS1 BioID 
showed a different banding pattern compared to the BioID control. pTRS1 binds the 
mRNA cap, associates with 40S ribosomal subunits, and enhances translation in PKR 
deficient cells (27). These data highlight a role for pTRS1 in translation regulation. Thus, 
to identify pTRS1-associated proteins likely involved in translation regulation, we 
identified ribosome-associated proteins that interact with pTRS1. We pelleted 
ribosomes from cells transfected with untagged TRS1, free BioID, or TRS1 BioID, 
isolated biotinylated proteins from ribosome pellets using streptavidin affinity 
chromatography, and examined the recovered proteins by Western blot (Fig 1E). No 
biotinylated proteins were observed in control cells expressing untagged pTRS1, and a 
unique banding pattern of biotinylated proteins was found in cells expressing pTRS1 
BioID compared to cells expressing free BioID. These data suggest that pTRS1 
interacts with a specific subset of ribosome-associated proteins. 
pTRS1 interacts with proteins that regulate RNA metabolism and post-
transcriptional control of gene expression We next identified ribosome-associated, 
pTRS1 interactors. Ribosome-associated, biotinylated proteins from cells transfected 
with untagged TRS1, free BioID, or TRS1 BioID were identified by mass spectrometry. 
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The identified proteins were considered to specifically interact with pTRS1 if they were 
only observed in the pTRS1 BioID sample. We consistently identified 114 cellular 
proteins that specifically interact with pTRS1 (Fig 2A). As expected, PKR was amongst 
the top hits in our screen, validating that the BioID approach identifies known pTRS1 
binding partners. Gene ontogeny analysis (GO analysis) revealed the molecular 
functions most associated with pTRS1 interacting partners were double-stranded and 
single-stranded RNA binding, 3’ untranslated region (UTR) binding, and 3’-5’ 
exoribonuclease activity (Fig 2B). GO analysis of biological processes showed that 
proteins that interact with pTRS1 are significantly enriched for nuclear mRNA 
surveillance, RNA helicase activity, and stress granule assembly (Fig 2C). 
We validated the interaction of pTRS1 with several proteins identified in our mass 
spectrometry analysis: PABP, PAN3 and CPEB4. Poly(A) binding protein (PABP) binds 
the poly(A) tail of mRNAs and regulates translation initiation and mRNA stability (33). 
PAN3 is a poly(A)-specific ribonuclease involved in mRNA decay (34), while the 
cytoplasmic polyadenylation element binding protein 4 (CPEB4) regulates poly(A) tail 
length and stability of target mRNAs (35). The interaction of pTRS1 with PABP and 
PAN3 was confirmed in HCMV infected cells, demonstrating the relevance of these 
results to pTRS1 function during infection (Fig 3A,B). We also confirmed the interaction 
of CPEB4 and pTRS1 in transfected cells (Fig 3C). These data show that BioID is a 
valid approach to identify novel interactions between pTRS1 and cellular proteins. 
pTRS1 interacts with PP1 catalytic subunits. Our mass spectrometry analysis 
showed that pTRS1 specifically interacts with the alpha, beta and gamma catalytic 
subunits of protein phosphatase 1 (PP1Cα, β, γ, respectively). We confirmed the 
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interaction of pTRS1 with each PP1 catalytic subunit in transfected cells (Fig 4A-C) and 
also found that pTRS1 interacts with PP1Cβ during HCMV infection (Fig 4D). PP1 is a 
serine/threonine phosphatase that regulates a majority of cellular signaling pathways. 
PP1 catalytic subunits have no substrate specificity themselves, but are recruited to 
specific substrates through interactions with PP1 regulatory proteins. The majority of 
PP1 regulatory proteins contain an ‘RVxF’ motif that mediates their binding to PP1 (36, 
37). pTRS1 contains an ‘RVTF’ motif in its carboxyl-terminus. To determine if this motif 
mediated pTRS1 binding to PP1 catalytic subunits, we mutated TRS1 780RVTF783 to 
780AAAA783 (TRS1 ΔRVTF) and determined if pTRS1 still interacted with PP1Cα. We 
found that the pTRS1 RVTF motif was dispensable for this interaction. These data 
suggest that another pTRS1 motif mediates the interaction of pTRS1 with PP1. 
A single amino acid (Phe293) in PP1 catalytic subunits mediates the binding of 
PP1 to regulatory subunits containing an RVxF motif (36). As most PP1 regulatory 
subunits bind Phe293, we tested the effect of mutating Phe293 to an alanine residue 
(PP1Cα F293A) on the ability of pTRS1 to interact with PP1Cα (Fig 4F). The PP1Cα 
F293A mutation completely ablated pTRS1 binding, suggesting that pTRS1 either binds 
PP1 through an indirect interaction, or a non-RVxF pTRS1 motif interacts with the PP1 
F293 residue. 
pTRS1 expression does not affect PP1Cα phosphatase activity. We next 
determined if pTRS1 interacts with active PP1 catalytic subunits by measuring 
phosphatase activity in pTRS1 immune complexes from transfected cells (Fig 5A). 
There was a significant increase in phosphatase activity associated with pTRS1-specific 
immune complexes compared to the antibody control, suggesting that active 
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phosphatases are associated with pTRS1. To determine if pTRS1 changes the activity 
of the PP1Cα catalytic subunit, we measured the rate of PP1Cα phosphatase activity in 
cells expressing pTRS1 or a control protein (GFP) (Fig 5B). There was no significant 
difference in the rate of PP1Cα phosphatase activity in cells expressing pTRS1 
compared to control cells. We conclude that pTRS1 associates with active PP1 catalytic 
subunits, and that pTRS1 does not affect PP1 phosphatase activity. 
pTRS1 changes PP1Cα  binding partners. The majority of PP1 regulatory 
binding proteins do not affect PP1 catalytic activity, but rather change the substrate 
specificity of the bound catalytic subunit (36). Since pTRS1 does not change PP1 
catalytic activity, we hypothesized that pTRS1 may change PP1 substrate specificity by 
altering the complement of regulatory proteins bound to PP1 catalytic subunits. To test 
this hypothesis we examined the effect of pTRS1 expression on PP1 catalytic subunit 
binding partners in transfected cells. We fused BioID to the amino-terminus of PP1Cα to 
create PP1Cα BioID. Importantly, PP1Cα BioID maintained wild-type levels of 
phosphatase activity (Fig 6A). We then co-transfected WT or PKR KO cells with 
PPP1CA BioID and GFP or TRS1, treated cells with exogenous biotin, and isolated 
biotinylated proteins. When PP1Cα-interacting proteins were analyzed by Western blot 
we found that there was a difference in the complement of proteins in the presence of 
pTRS1 (Fig 6B), which was independent of PKR expression. These data suggest that 






 In this study we identified ribosome-associated cellular proteins that interact with 
pTRS1, with the goal of understanding how pTRS1 stimulates translation in a PKR-
independent manner. pTRS1 specifically interacted with multiple ribosome-associated 
cellular proteins, which were significantly enriched in functions associated with 
translation initiation, 3’UTR binding, and RNA metabolism (Fig 2A,2B). We confirmed 
multiple novel pTRS1 interactions in transfected and HCMV-infected cells, including 
interactions with all three PP1 catalytic subunits (Fig 3,4). Phosphatase activity was 
found in pTRS1-specific immune complexes (Fig 5A), demonstrating that pTRS1 
associates with active PP1. However pTRS1 did not affect the rate of PP1 catalytic 
activity (Fig 5B). Rather, pTRS1 appears to change the complement of proteins that 
interact with PP1 catalytic subunits (Fig 6B), potentially altering the complement of PP1 
regulatory subunits or changing the substrate specificity of PP1 catalytic subunits. 
 We found that ribosome-associated proteins that interact with pTRS1 shared 
similar functions (Fig 2A). GO analysis of molecular functions revealed that pTRS1-
interactors were significantly enriched for both double-stranded and single-stranded 
RNA binding, and RNA helicase activity (Fig 2B). pTRS1 stimulates mRNA translation, 
independent of its ability to inhibit PKR activation (27). We found pTRS1 interacts with 
multiple RNA helicases, including DDX3X, DDX6, and DHX29 (Fig 2A). Each of these 
helicases associates with translation initiation complexes, and regulates the translation 
of a subset of cellular mRNAs (38). In addition, we confirmed that pTRS1 interacts with 
the poly(A) binding protein (PABP). These data, together with the fact that pTRS1 binds 
the m7G cap, dsRNA, and associates with 40S ribosomal subunits (27, 38-40), suggest 
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that pTRS1 may stimulate translation by recruiting translation initiation factors and 
ribosomal subunits to mRNAs. While additional studies are needed to test this 
hypothesis, our data have identified novel pTRS1-interactors that are likely important for 
the ability of pTRS1 to stimulate translation, independent of its ability to inhibit PKR.  
 GO analysis also revealed potential new pTRS1 functions. In addition to the 
functions described above, pTRS1-interacting proteins were also significantly enriched 
for 3’-5’ exoribonuclease activity (Fig 3C). pTRS1 specifically interacted with multiple 
RNA exosome components (Fig 2A). In addition, we confirmed that pTRS1 associates 
with PAN3 in HCMV-infected cells (Fig 3B). PAN3 is part of the PAN2/3 
exoribonuclease complex, which mediates deadenylation of mRNAs targeted for 
degradation. pTRS1 also interacted with several 3’UTR binding proteins that regulate 
mRNA stability and translation efficiency, such as STAU1, FUBP3, and SYNCRIP (34, 
35). Thus regulation of mRNA stability may be an additional mechanism used by pTRS1 
to facilitate translation. Promotion of mRNA stability, or inhibition of mRNA degradation, 
could enhance the translation of pTRS1 target mRNAs.  
  We showed that pTRS1 interacts with all three PP1 catalytic subunits, and that 
pTRS1 is associated with active phosphatase(s) (Fig 4,5A). More than 80% of proteins 
that bind PP1 do so through an ‘RVxF’ consensus motif (36). pTRS1 contains an ‘RVTF’ 
motif in its carboxyl-terminus, however this motif was dispensable for pTRS1 
association with PP1Cα (Fig 4E). In contrast, mutating the PP1 residue necessary for 
binding of RVxF motif-containing PP1 regulatory subunits led to a loss of pTRS1 
association with PP1Cα (Fig 4F). These data suggest that either another motif within 
pTRS1 interacts with the PP1 RVxF binding pocket, or the interaction between pTRS1 
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and PP1 is not direct. As no other motif within pTRS1 matches even the least stringent 
RVxF motif ‘rules’, we hypothesize that pTRS1 associates with PP1Cα through an 
indirect interaction, possibly through an interaction with a PP1 regulatory subunit. This is 
consistent with our result showing that disrupting the residue in the PP1 catalytic 
subunit recognized by most PP1 regulatory subunits ablated the interaction of pTRS1 
with PP1Cα. We also show that pTRS1 expression changes the complement of proteins 
that interact with PP1Cα (Fig 6B), suggesting that pTRS1 interacts with PP1 regulatory 
subunits to either change PP1 holoenzyme structure and/or PP1 substrate specificity. 
 PP1 regulates dozens of cellular processes by dephosphorylating its target 
substrates (41). PP1 levels and overall levels of phosphatase activity increase during 
HCMV infection, and phosphatase activity is required for HCMV protein synthesis. Hakki 
et al. also showed that phosphatase activity is required to limit eIF2α phosphorylation 
during infection, but is dispensable for preventing PKR activation (26). This is consistent 
with our data showing that pTRS1 binds PKR and prevents its autophosphorylation and 
activation (8). If PKR is never phosphorylated, then phosphatase activity is irrelevant for 
its control. However these data raise the possibility that pTRS1 may also regulate the 
PKR-eIF2α pathway by recruiting PP1 to reverse eIF2α phosphorylation. We previously 
found that pTRS1 limits eIF2α phosphorylation in response to activation of an additional 
eIF2α kinase, HRI, in PKR deficient cells (8). Here we show that pTRS1 interacts with 
active PP1 catalytic subunits and may change PP1 substrate specificity (Fig 5A,6B). 
Perhaps pTRS1 recruits PP1 to eIF2α that has been phosphorylated by other eIF2α 
kinases (16). If so, this would suggest a more general role for pTRS1 in mitigating virus-
induced stress by limiting eIF2α phosphorylation through an interaction with PP1. 
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 It is also possible that the interaction of pTRS1 with PP1 catalytic subunits 
impacts additional signaling pathways during HCMV infection. We recently found that 
HCMV changes the activity of a large number of cellular kinases (4). Many kinases are 
regulated by phosphorylation, thus pTRS1 could recruit PP1 to phosphorylated kinases 
to alter their activity. Or pTRS1 could recruit PP1 to dephosphorylate kinase substrates 
and inhibit signaling. Future studies to determine how the association of pTRS1 with 
PP1 globally impacts kinase activity and substrate phosphorylation are in order to 



















Figure 4.1. pTRS1 interacts with specific ribosome-associated proteins. (A) 
Schematic of BioID approach to identifying pTRS1-interacting proteins. Cellular proteins 
that interact with pTRS1 BioID, in the presence of excess biotin, will be biotinylated. (B) 
Lysates of cells transfected with either GFP or TRS1 BioID were spiked with poly(I:C) to 
activate PKR. Levels of PKR activation, measured by phosphorylation at PKR Thr446, 
were determined by Western blot analysis. (C) Overall levels of protein synthesis of 
cells transfected with an empty vector control or pTRS1 were determined through 
metabolic labeling of nascent peptides. (D) Cells were transfected with TRS1, BioID, or 
TRS1 BioID and treated with excess biotin. Biotinylated proteins from whole cell lysates 
were isolated by streptavidin affinity chromatography and examined by Western blot 
analysis. (E) As in (D), but ribosomes were extracted from lysates of cells transfected 
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with TRS1, BioID, or TRS1 BioID before ribosome-associated, biotinylated proteins 
were isolated. 
 
Figure 4.2. Ribosome-associated proteins that specifically interact with pTRS1. 
(A) STRING analysis of 114 cellular proteins that were identified as hits by mass 
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spectrometry data only in cells transfected with TRS1 BioID. Gene ontology (GO) 
analysis of the molecular function (B) and biological processes (C) associated with 




Figure 4.3. Validation of pTRS1-interacting proteins. Fibroblasts were infected with 
HCMV at an MOI of 3 for 72 hours. The presence of PABP (A) and PAN3 (B) in pTRS1-
specific immune complexes was determined by Western blot analysis. (C) HeLa cells 
were co-transfected with CPEB4 and TRS1 and the presence of pTRS1 in CPEB4-





Figure 4.4. pTRS1 interacts with all three PP1 catalytic subunits. HeLa cells were 
co-transfected with TRS1 and PPP1CA (A), PPP1CB (B), or PPP1CC (C). The 
presence of pTRS1 in PP1-specific immune complexes was determined by Western 
blot. (D) Fibroblasts were infected with HCMV at an MOI of 3 for 48 hours. The 
presence of PP1Cβ in pTRS1-specific immune complexes was then determined by 
Western blot. (E) HeLa cells were co-transfected with PPP1CA and a pTRS1 mutant 
lacking its RVTF motif (ΔRVTF). The presence of WT pTRS1 or ΔRVTF in PP1Cα-
specific immune complexes was then determined by Western blot. (F) HeLa cells were 
co-transfected with TRS1 and either WT PPP1CA or PPP1CA F293A and the presence 




Figure 4.5. pTRS1 does not affect PP1Cα phosphatase activity. (A) HeLa cells were 
transfected with pTRS1 and a phosphatase reaction was ran on pTRS1-specific or 
control immune complexes. Free phosphate was detected using a malachite green 
assay. (B) HeLa cells were co-transfected with PPP1CA and either GFP or TRS1. 
Phosphatase assays were run on PP1Cα-specific immune complexes with increasing 
concentrations of phosphopeptide. Free phosphate concentrations were determined 






Figure 4.6. pTRS1 changes the complement of proteins that interact with PP1Cα. 
(A) HeLa cells were transfected with PPP1CA or PPP1CA BioID. PP1 was 
immunoprecipitated and the level of phosphatase activity associated with PP1-specific 
immune complexes was determined. (B) WT or PKR KO HeLa cells were co-transfected 
with PPP1CA BioID and GFP or TRS1. Cells were treated with biotin, lysed and 
biotinylated proteins isolated by streptavidin affinity chromatography. Biotinylated 











Table 4.1. Primer Sequences 
Primer Name Sequence (5'à3') 
TRS1BirA F CACTACCATTACAATGCTCAAGAACAAAAACTCATCTCAGAAGAGG 
BirA R CGCGGGCCCTCTAGACTCGATCACTTCTCTGCGCTTCTCAGGGAG 
TRS1 F TAAGCTTGGTACCGAGCTCGATGGCCCAGCGCAACGGCATG 
TRS1BirA R CTTCTGAGATGAGTTTTTGTTCTTGAGCATTGTAATGGTAGTG 
RVTF F GACATGCGAGCAGCTGCAGCTTCTAATGTCTAATGTAGCCACACACTACC 
RVTF R CATTAGAAGCTGCAGCTGCTCGCATGTCGCGGCACAATCTGGCAGC 
PPP1CA mycF TAAGCTTGGTACCGAGCTCGGCCGCCACCATGTCCGACAGCGAGAAGCTC 
PPP1CA mycR CGCGGGCCCTCTAGACTCGACTACAGATCCTCTTCTGAGATGAGTTTTTGTTCTTTCTTGGCTTTGGCGGAATTGC 
PPP1CB mycF TAAGCTTGGTACCGAGCTCGGCCGCCACCATGGCGGACGGGGAGCTGAACG 
PPP1CB mycR CGCGGGCCCTCTAGACTCGATCACAGATCCTCTTCTGAGATGAGTTTTTGTTCCCTTTTCTTCGGCGGATTAGC 
PPP1CB mycF TAAGCTTGGTACCGAGCTCGGCCGCCACCATGGCGGATTTAGATAAACTC 
PPP1CB mycR CGCGGGCCCTCTAGACTCGACTACAGATCCTCTTCTGAGATGAGTTTTTGTTCTTTCTTTGCTTGCTTTGTGATC 
PP1 F293A F CATGTGCTCTGCTCAGATCCTCAAGCCCGCCGACAAGAAC 
PP1 F293A R GAGGATCTGAGCAGAGCACATGAGGGTCTCGTCCACACTC 
BiRA pcD F TAAGCTTGGTACCGAGCTCGGCCGCCACCATGGAACAAAAACTCATCTCAG 
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CHAPTER 5: DISCUSSION 
In this chapter I summarize the work presented in my thesis, and discuss how my 
findings have advanced our knowledge of the role of pTRS1 in mRNA translation 
regulation. In addition I discuss several outstanding questions raised by my work, and 
the future studies needed to answer those questions, to further our understanding of 
translation regulation in the control of HCMV protein synthesis.  
 
Summary of my findings  
 The HCMV protein TRS1 (pTRS1) is packaged in the tegument of the HCMV 
virion (1). pTRS1 is first expressed at immediate early times during infection, and 
pTRS1 abundance increases as infection progresses (2). Thus pTRS1 is present 
throughout the entire HCMV replication cycle. Both pTRS1 and its functional homologue 
pIRS1 are necessary for virus replication in primary human fibroblasts, as a virus 
lacking both pTRS1 and pIRS1 (ΔTRS1/ΔIRS1) does not replicate. Infection with 
ΔTRS1/ΔIRS1 results in robust PKR activation and eIF2α phosphorylation, leading to a 
significant inhibition of overall levels of protein synthesis, and decreased expression of 
viral proteins (3, 4). Our group and others have shown that pTRS1 binding to PKR is 
necessary for PKR antagonism during infection (4, 5), however the molecular 
mechanism behind PKR inhibition was unknown. In chapter 2 I showed that the ability of 
pTRS1 to bind PKR is necessary for inhibition of PKR activation in vitro (Figure 2.2)(6). I 
found that pTRS1 does not sequester RNA ligands from PKR or prevent PKR 
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dimerization (Figure 2.3, 2.4). Rather, pTRS1 interacts with conserved residues in the 
PKR kinase domain that are necessary for PKR to bind its substrate eIF2α (Figure 2.5). 
I also showed that pTRS1 binding to PKR was necessary for pTRS1 to inhibit PKR 
kinase activity (Figure 2.6). Lastly, I found that pTRS1 limits eIF2α phosphorylation in 
response to activation of an additional eIF2α kinase, in cells lacking PKR (Figure 2.7), 
suggesting that pTRS1 may antagonize multiple eIF2α kinases during infection. 
 pTRS1 also promotes cap-dependent translation, independent of its ability to 
inhibit PKR. pTRS1 binds the m7G mRNA cap, stimulates the translation of reporter 
mRNAs containing viral or cellular 5’UTRs, and increases overall levels of protein 
synthesis (7). In chapter 3 I found that pTRS1 also stimulates cap-independent 
translation. pTRS1 enhanced the activity of multiple IRESs in a bicistronic reporter 
assay (Figure 3.1, 3.2), however, bicistronic reporter assays are prone to false 
positives. I therefore developed a new assay for IRES activity that circumvents several 
of the caveats of bicistronic reporters. Namely, this assay tests the ability of a purported 
IRES to drive the translation of a circular mRNA lacking both an m7G mRNA cap and a 
poly(A) tail. Using this assay, I found that pTRS1 enhances the translation of circular 
RNA (circRNA) reporters containing either viral or cellular IRESs (Figure 3.3, 3.4). 
Importantly, the increase in translation was not solely due to PKR antagonism, as 
pTRS1 enhanced circular RNA translation in cells lacking PKR (Figure 3.5). Rather the 
ability of pTRS1 to enhance circRNA translation was dependent on the ability of pTRS1 
to bind dsRNA (Figure 3.6). Together these data show that pTRS1 enhances both cap-
dependent and cap-independent translation through a PKR-independent mechanism. 
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 To begin to define the mechanism by which pTRS1 stimulates translation 
independent of PKR antagonism, in chapter 4 I identified pTRS1 cellular binding 
partners using the BioID approach (8). I fused a promiscuous biotin ligase domain (BirA) 
to the carboxyl-terminus of pTRS1 (pTRS1 BioID), and expressed pTRS1 BioID in the 
presence of exogenous biotin. Cellular proteins that interact with pTRS1 BioID, even 
transiently, are covalently biotinylated, and can be isolated with streptavidin affinity 
chromatography and identified by mass spectrometry (Figure 4.1). To identify pTRS1 
interactors likely involved in translation, we isolated biotinylated proteins associated with 
ribosomes in cells expressing pTRS1 BioID. We identified 114 pTRS1-interacting 
partners, including the alpha, beta and gamma catalytic subunits of protein phosphatase 
1 (PP1) (Figure 4.2). I confirmed that pTRS1 interacts each PP1 catalytic subunit in 
vitro, and interacts with the PP1Cβ subunit during HCMV infection (Figure 4.4). I found 
that phosphatase activity is associated with pTRS1-specific immune complexes, but that 
pTRS1 does not change the rate of PP1Cα catalytic activity (Figure 4.5). Rather, my 
data show that pTRS1 changes the complement of proteins that interact with 
PP1Cα (Figure 4.6), suggesting that pTRS1 alters the structure of the PP1 holoenzyme, 
and potentially PP1 substrate specificity. 
 In summary, I have defined the molecular mechanism by which pTRS1 
antagonizes PKR, identified an additional pTRS1 function (PKR-independent stimulation 
of cap-independent mRNA translation), and identified pTRS1-interacting proteins that 
are potentially important for HCMV replication. Below I discuss the outstanding 
questions that my data has raised, and how these questions might be addressed. 
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Outstanding questions related to pTRS1 and PKR 
What are the dsRNA ligands that activate PKR during HCMV infection? In the 
absence of both pTRS1 and pIRS1, PKR is activated within 24 hours of infection (4). 
However, the ligands responsible for PKR activation in HCMV-infected cells have not 
been identified. Binding to viral dsRNA activates PKR (9), and viral dsRNA accumulates 
during HCMV infection, presumably due to the presence of overlapping transcriptional 
units on opposite strands of the HCMV genome (3). These viral dsRNAs could act as 
PKR ligands in the absence pTRS1/pIRS1. In addition, viral RNA packaged within the 
tegument of the virus could also activate PKR upon infection, although the complement 
of RNAs packaged within the virion is unknown (10). Thus, it is possible that RNAs 
packaged within the virion, newly transcribed viral RNA, or a combination of both, act as 
PKR ligands in the absence of pTRS1 and pIRS1.  
 To determine which ligands activate PKR during HCMV infection we could 
examine PKR activation immediately after infection with a ΔTRS1/ΔIRS1 virus, before 
viral transcription begins (<3 hpi). If PKR were activated this early, it would suggest that 
viral RNAs packaged within the tegument are the PKR activating ligands. We could 
confirm this by examining PKR activation in the presence of the transcription inhibitor 
actinomycin D (ActD). If PKR is not active at very early times post infection with 
ΔTRS1/ΔIRS1, or in the presence of ActD, it would suggest that newly synthesized viral 
RNA activates PKR. RIP-seq or HITS-CLIP could be used to identify the RNAs bound 
by PKR in HCMV-infected cells. The RNAs that activate PKR have not been identified in 
any viral infection. Thus identifying HCMV RNAs bound by PKR would provide insight 
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into structural or sequence similarities that PKR uses to discriminate between host and 
viral RNAs.  
Does pTRS1 prevent PKR binding to eIF2α? My data show that pTRS1 inhibits 
PKR kinase activity to prevent PKR activation (Figure 2.6), and also suggest that 
pTRS1 blocks the interaction of PKR with its substrate eIF2α. Both pTRS1 and 
eIF2α bind the Thr487 residue in the PKR kinase domain. When Thr487 is mutated to 
an alanine residue, PKR undergoes activating autophosphorylation, but cannot bind or 
phosphorylate eIF2α (Figure 2.5)(6, 11). pTRS1 binds PKR Thr487, suggesting it 
prevents PKR binding to eIF2α. The vaccinia virus K3L protein uses a similar 
mechanism; K3L acts as a PKR pseudosubstrate and prevents the interaction of PKR 
with eIF2α (12). However, since pTRS1 inhibits PKR kinase activity, it seems unlikely 
that pTRS1 functions as an eIF2α pseudosubstrate. Rather I hypothesize that pTRS1 
serves two roles, both blocking PKR autophosphorylation and acting as a physical 
barrier to PKR binding to eIF2α. To test this hypothesis we could conduct in vitro 
binding assays using purified proteins to determine if pTRS1 blocks an interaction 
between activated PKR and eIF2α. This would allow us to fully understand how pTRS1 
prevents eIF2α phosphorylation by binding to PKR. 
 Does pTRS1 antagonize multiple eIF2α kinases during HCMV infection? The 
mechanism by which pTRS1 inhibits PKR suggests that pTRS1 may also inhibit 
additional eIF2α kinases. My data shows that pTRS1 binds HRI and limits eIF2α 
phosphorylation in response to an HRI agonist (Figure 2.7)(6). Thus in addition to 
inhibiting PKR, pTRS1 may also limit HRI activation. pTRS1 interacts with amino acids 
in the αG helix of the PKR kinase domain that are conserved in all four eIF2α kinases 
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(Figure 2.5). This suggests that pTRS1 can bind and inhibit multiple eIF2α kinases. 
While I found that pTRS1 binds both PKR and HRI during HCMV infection (Figure 2.2, 
2.7), it remains to be determined if pTRS1 also interacts with PERK and GCN2. We 
could test this by looking for the presence of PERK and GCN2 in pTRS1-specific 
immune complexes isolated from infected cells. If pTRS1 does interact with multiple 
eIF2α kinases we could then introduce the synonymous PKR Thr487 mutation into the 
other eIF2α kinases and see if this disrupts pTRS1 binding in vitro. If this mutation 
disrupts binding it would suggest that pTRS1 binds all eIF2α kinases through a 
conserved mechanism. Experiments measuring the activation of HRI, PERK, and GCN2 
in the presence of pTRS1 would then be needed to determine if pTRS1 binding inhibits 
activation of the other eIF2α kinases, and potentially prevents their interaction with 
eIF2α. These experiments would further our understanding of how pTRS1 regulates 
stress response pathways that could inhibit translation during HCMV infection.  
 What drives eIF2α phosphorylation during the late stage of HCMV replication? 
Whether or not pTRS1 inhibits multiple eIF2α kinases, eIF2α becomes phosphorylated 
during the late stage of HCMV replication (13-15). Thus an outstanding question is what 
causes eIF2α phosphorylation late in infection? PKR remains inactive throughout 
infection, showing that pTRS1/pIRS1 effectively antagonize PKR (14). In addition, 
PERK depletion does not prevent the increase in eIF2α phosphorylation (13). Thus 
presumably either HRI or GCN2 are activated during infection and phosphorylate eIF2α. 
However the activation state of HRI and GCN2 throughout infection has not been 
examined. To determine which kinase is responsible for eIF2α phosphorylation, we 
could measure the activation of HRI and GCN2 across a time course of infection. We 
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could then measure the ability of HCMV to induce eIF2α phosphorylation at late times 
after infection in cells where HRI or GCN2 expression has been ablated using 
CRISPR/Cas9 mutagenesis. It is also possible that multiple eIF2α kinases contribute to 
eIF2α phosphorylation. In this case, the combined disruption/depletion of both HRI and 
GCN2 would be needed to limit eIF2α phosphorylation. This will allow us to determine 
which eIF2α kinase phosphorylates eIF2α, and what kind of cellular stress leads to 
eIF2α phosphorylation during HCMV replication.  
 These data also suggest that HRI and/or GCN2 escape inhibition by pTRS1. 
Because pTRS1 binds HRI and limits eIF2α phosphorylation in response to an HRI 
agonist (Figure 2.7), it is probable that pTRS1 binds HRI and inhibits its activation 
and/or binding to eIF2α during infection (6). Unlike the other three eIF2α kinases, GCN2 
contains a pseudokinase domain in its amino terminus that binds the GCN2 protein 
kinase domain and prevents its activation. The GCN2 pseudokinase domain is 
homologous in structure to eIF2α protein kinase domains (16), suggesting it could be 
bound by pTRS1. Perhaps pTRS1 binds the pseudokinase domain rather than the 
active kinase domain. To test this hypothesis we could remove the GCN2 pseudokinase 
domain and see if the deletion disrupts pTRS1 binding to GCN2. If pTRS1 interacts with 
the GCN2 pseudokinase domain it could allow GCN2 to become activated in the 
presence of pTRS1 and phosphorylate eIF2α. Understanding how pTRS1 interacts with 
eIF2α kinases will allow us to determine the role of pTRS1 in regulating stress response 
pathways during HCMV replication. 
 What is the role of pIRS1 during infection? pTRS1 and pIRS1 are partially 
encoded by the repeat regions flanking the US region of the HCMV genome. As a result, 
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the amino terminal 550 amino acids of the two proteins are identical (17). While the 
carboxyl terminus of pTRS1 and pIRS1 differ, this region of both proteins binds PKR (2). 
However the contribution of the pIRS1 PKR binding domain during infection has not 
been examined, nor has the mechanism by which pIRS1 prevents PKR activation. 
Since the majority of pIRS1 and pTRS1 are homologous, and pIRS1 contains the 
residues necessary for PKR binding, it is probable that pIRS1 inhibits PKR through the 
same mechanism as pTRS1. Therefore, why does HCMV encode two proteins with 
seemingly identical functions? Expression of either pTRS1 or pIRS1 alone is sufficient 
to inhibit PKR activation (4). In addition, recombinant viruses lacking either TRS1 or 
IRS1 replicate nearly as efficiently as wild type HCMV; however, the replication of 
ΔTRS1 and ΔIRS1 viruses has only been characterized in unstressed cells (18). HCMV 
induces the expression of type I interferons (IFNs), which upregulate the expression of 
antiviral interferon stimulated genes (ISGs), including PKR, in neighboring uninfected 
cells (19-21). Perhaps the presence of both pIRS1 and pTRS1 is necessary when 
infecting a cell with a higher baseline level of PKR expression. To test this we could pre-
treat cells with type I IFNs before infection with a ΔTRS1, ΔIRS1, or wild type virus. If 
the presence of both pIRS1 and pTRS1 is necessary to establish infection in cells 
previously primed to express ISGs, we would expect a defect in ΔTRS1 and ΔIRS1 
replication compared to a wild type infection. We could also examine PKR activation 
during these infections. If PKR activation is observed after infection with ΔTRS1 or 
ΔIRS1, it would suggest that the presence of both pTRS1 and pIRS1 is necessary to 
inhibit PKR activation in cells primed to express ISGs. Thus the redundant functions of 
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pTRS1 and pIRS1 may provide a fail safe for the virus when spreading to uninfected, 
IFN-primed cells in vivo.  
 In addition to PKR, type I IFNs induce the expression of multiple innate immune 
sensors that recognize viral RNA and contribute to the antiviral response (21). Both 
pTRS1 and pIRS1 have non-canonical RNA binding domains in their amino terminus, 
and are packaged in the tegument of the virion (1, 22, 23). Thus pTRS1 and pIRS1 
together could be necessary to sequester RNA ligands from innate immune sensors in 
cells previously exposed to type I IFNs. Such a scenario is probable in vivo, as HCMV-
infected cells produce significant levels of type I IFNs (19). Comparing HCMV 
replication in cells pre-treated with type I IFNs and infected with wild type virus or a 
recombinant virus containing mutations in pTRS1/pIRS1 that disrupt dsRNA binding 
would shed light on the function of pTRS1/pIRS1 dsRNA binding during infection. 
Sequestration of RNA ligands by pTRS1 and pIRS1 could be an additional HCMV 
strategy to block innate immune activation early in infection. 
 How does pTRS1 stimulate translation in a PKR-independent manner? pTRS1 
promotes translation through both PKR-dependent and PKR-independent mechanisms 
(Figure 3.5)(7). While the ability of pTRS1 to enhance translation is dampened in cells 
lacking PKR, pTRS1 increases overall levels of protein synthesis and the translation of 
reporter genes in PKR deficient cells. Thus inhibition of PKR alone cannot fully account 
for the ability of pTRS1 to enhance translation. The mechanism by which pTRS1 
stimulates translation in a PKR-independent manner remains unknown. To begin to 
understand how pTRS1 promotes translation, in chapter 4 I identified ribosome-
associated cellular proteins that interact with pTRS1. Based on these data I have two 
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hypotheses for how pTRS1 enhances translation: (1) pTRS1 antagonizes additional 
signaling pathways that inhibit translation or (2) pTRS1 facilitates the recruitment of 
ribosomes to specific mRNAs.  
 Hypothesis 1: pTRS1 antagonizes additional signaling pathways that inhibit 
translation. In support of my first hypothesis, I found that pTRS1 interacts with all three 
catalytic subunits of protein phosphatase 1 (PP1) (Figure 4.2). PP1 is a serine/threonine 
phosphatase that regulates many cellular signaling pathways, including the eIF2α 
pathway (24). The heterotrimeric PP1 holoenzyme consists of a catalytic subunit bound 
by two regulatory subunits that control the activity and/or specificity of the catalytic 
subunit (25, 26). I confirmed that pTRS1 interacts with all three PP1 catalytic subunits in 
transfected cells, and PP1Cβ during HCMV infection (Figure 4.4). pTRS1 did not 
change PP1Cα catalytic activity (Figure 4.5), but appeared to change the complement 
of proteins that interact with PP1Cα (Figure 4.6). PP1 is recruited to dephosphorylate 
eIF2α by GADD34 (24). Recruitment of GADD34 to eIF2α by viral proteins is a common 
strategy used by several viruses to dephosphorylate eIF2α during infection (27-29). 
However pTRS1 does not seem to use this strategy, as we did not identify GADD34 as 
a pTRS1-associated protein in our proteomics screen. Rather, we hypothesize that the 
interaction of pTRS1 with PP1 changes the substrate specificity of the PP1 holoenzyme 
to enhance recruitment to eIF2α. Mass spectrometry analysis of proteins that interact 
with PP1Cα in the presence or absence of pTRS1 is currently ongoing to identify how 
pTRS1 may affect PP1 substrate specificity.  
Another possibility is that pTRS1 nucleates the formation of a unique PP1 
complex in infected cells. Perhaps pTRS1 recruits additional cellular or viral proteins to 
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the PP1 holoenzyme. To test this, we could use a tandem immunoaffinity approach to 
identify proteins associated with both PP1 catalytic subunits and pTRS1. We would 
construct a TRS1 BioID virus, and then infect cells with the pTRS1 BioID virus in the 
presence of exogenous biotin. Following immunoprecipitation of PP1 from HCMV TRS1 
BioID-infected cells, we would then isolate biotinylated proteins from PP1 immune 
complexes. The recovered proteins would thus interact with both PP1 and pTRS1, and 
could potentially form a novel PP1 holoenzyme found only in infected cells. While PP1 
dephosphorylates eIF2α, it also regulates many other cellular signaling pathways, which 
could be impacted by its association with pTRS1. Phosphoproteomics analyses of cells 
infected with HCMV ΔTRS1/ΔIRS1 could allow us to correlate changes in PP1 binding 
partners with changes to cellular signaling pathways observed during HCMV replication.  
 Hypothesis 2: pTRS1 facilitates the recruitment of ribosomes to specific mRNAs. 
My analysis of pTRS1 interacting partners also supports my second hypothesis that 
pTRS1 facilitates the recruitment of ribosomes to specific mRNAs. Myself and others 
have shown that pTRS1 binds dsRNA, the m7G mRNA cap, multiple RNA helicases, 
translation initiation factors, and the poly(A) binding protein (PABP) (Figure 4.2, 4.3)(7, 
22, 23). These interactions suggest that pTRS1 promotes mRNA translation initiation as 
a mechanism to stimulate translation. We could test this hypothesis by measuring the 
effect of pTRS1 on the formation of 48S translation initiation complexes. The 48S 
complex consists of multiple translation initiation factors, the 40S ribosomal subunit, and 
the ternary complex, which consists of eIF2-GTP and tRNAiMet. The 48S scans an 
mRNA 5’UTR until recognizing the translation start codon, whereupon hydrolysis of the 
eIF2-bound GTP promotes 60S binding and the release of translation initiation factors 
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(30). Treating translation competent lysates with GMP-PNP prevents 60S binding and 
allows for the isolation of 48S complexes by sucrose density centrifugation. To 
determine if pTRS1 promotes translation initiation, we could see if translation competent 
cell lysates from cells expressing pTRS1 support increased levels of 48S formation on a 
reporter mRNA. If pTRS1 increases 48S formation, it would suggest that pTRS1 recruits 
translation initiation factors and ribosomal subunits to that mRNA to stimulate 
translation. This could be a mechanism used by pTRS1 to enhance the translation of 
target mRNAs during HCMV infection. 
To determine if pTRS1 binds mRNAs and enhances their translation during 
infection we need to first identify which RNAs are bound by pTRS1 using a RIP-seq 
experiment. Once the pTRS1-bound mRNAs have been identified we could infect cells 
with a ΔTRS1 virus and see if we observe a change in the translation efficiency of 
pTRS1-bound mRNAs in the absence of pTRS1 expression using ribosome profiling. If 
there is a decrease in the translation efficiency of pTRS1-bound mRNAs it suggests that 
pTRS1 enhances the translation of target mRNAs during HCMV replication. If we 
observe no change in the translation efficiency of pTRS1-target mRNAs it would 
suggest that stimulation of translation is a redundant function between pTRS1 and 
pIRS1. If this were the case, we would repeat the experiment with a ΔTRS1/ΔIRS1 virus 
in PKR KO cells. We could then repeat the 48S accumulation experiment described 
above, but spike a labeled pTRS1-target mRNA into translation competent lysates from 
cells infected with wild type, ΔTRS1, or a ΔTRS1/ΔIRS1 virus. If we only see an 
accumulation of 48S complexes in lysates from cells infected with wild type virus it 
would suggest that pTRS1, and possibly pIRS1, promote translation initiation on specific 
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mRNAs. This mechanism could ensure that pTRS1-bound mRNAs are efficiently 
translated during HCMV infection when the availability of translation initiation factors 
and ribosomal subunits is limiting.  
 I also found that pTRS1 promotes the activity of both cellular and viral IRESs 
(chapter 3). Importantly, pTRS1 enhances IRES activity in the absence of PKR 
expression (Figure 3.5), thus the enhancement of IRES activity is not solely due to PKR 
inhibition. HCMV enhances the expression of several cellular proteins required for 
efficient virus replication that are encoded on IRES-containing mRNAs (31-33). For 
example, the BiP mRNA contains an IRES whose activity increases during HCMV 
infection. BiP is necessary for efficient virus replication, and we found that pTRS1 
enhances BiP IRES activity (Figure 3.4)(34-36). Therefore, pTRS1 expression may be 
necessary for the increased translation of cellular mRNAs containing IRESs during 
HCMV infection. pTRS1 could also facilitate the translation of IRES-containing HCMV 
mRNAs. While only a single HCMV IRES has been identified to date, ~100 HCMV 
5’UTRs were recently shown to possess IRES activity in an in vitro screen (37, 38). This 
suggests that the role of cap-independent translation in HCMV protein synthesis may be 
more extensive than currently appreciated, and that the ability of pTRS1 to stimulate 
cap-independent translation could affect the expression of multiple viral proteins.  
The pTRS1 RIP-Seq data (described above) will determine if pTRS1 enhances 
the translation of mRNAs containing IRES elements during infection. However, it will not 
reveal the RNA sequences and/or structures needed for pTRS1 to bind IRES elements. 
Because pTRS1 stimulates the activity of multiple IRESs that share little sequence 
homology (chapter 3), and the stimulation of IRES activity is dependent on pTRS1 
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dsRNA binding (Figure 3.6), I hypothesize that pTRS1 binds common structural 
elements within these IRESs. We could test this hypothesis using HITS-CLIP to 
determine where pTRS1 binds IRES-containing mRNAs. We could then determine if 
pTRS1-binding sites share similar RNA secondary structure using mFold or SHAPE-
MaP analysis. This experiment would also allow us to determine if pTRS1 binding to all 
mRNAs is mediated through an interaction with a specific RNA secondary structure or 
specific RNA sequences. Thus pTRS1 could promote the translation of target mRNAs 
during HCMV replication by binding a common RNA secondary structure and/or 
sequence and recruiting translation initiation factors and ribosomal subunits to facilitate 
translation initiation.  
 The ability of pTRS1 to stimulate translation on RNAs that lack a m7G mRNA cap 
suggests that pTRS1 could play a role in the eIF4F-independent translation of viral 
mRNAs (chapter 3). The eIF4F complex binds the m7G mRNA cap and recruits 43S 
translation initiation complexes to the 5’ end of the mRNA to begin 5’UTR scanning (30). 
eIF4F formation is heavily regulated, and the eIF4F complex is required for the 
translation of many cellular mRNAs (39-41). eIF4F component expression and the 
abundance of assembled eIF4F complexes increase during HCMV infection (42, 43). In 
fact, the eIF4F complex is necessary for virus replication early in infection (43, 44). 
However, we previously showed that the translation of HCMV mRNAs becomes 
resistant to eIF4F complex disruption or depletion late in infection (44). Thus HCMV 
mRNAs can recruit ribosomes and translation initiation factors through an eIF4F-
independent mechanism. Based on my data showing that pTRS1 stimulates translation 
independent of an m7G cap, I hypothesize that pTRS1 also stimulates translation 
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independently of eIF4F. We could test this by determining if translation of viral mRNAs 
remains resistant to eIF4F disruption following infection with a ΔTRS1/ΔIRS1 virus. We 
would perform this experiment in PKR KO cells to control for the effect of pTRS1 
inhibition of PKR activation. The ability of pTRS1 to promote translation of HCMV 
mRNAs in the absence of the eIF4F complex could allow viral protein synthesis to 
escape regulation by the cell, and limit competition between host and viral mRNAs for 
translation initiation factors. Thus if pTRS1 facilitates the eIF4F-independent translation 
of HCMV mRNAs, this likely plays a significant role in HCMV spread and pathogenesis 
within a host.  
 
Outstanding questions pertaining to translation regulation during HCMV infection 
 What is the complement of full-length transcripts produced during HCMV 
replication? We have shown that pTRS1 stimulates the translation of mRNAs containing 
both cellular and viral 5’UTRs, with a greater effect on mRNAs containing viral 5’UTRs 
(chapter 3)(7). This data suggests that pTRS1 binds a specific RNA secondary structure 
and/or sequence within mRNA 5’UTRs that mediates the enhancement of their 
translation. Above I proposed to use HITS-CLIP to identify the structure and/or 
sequence that give pTRS1 specificity to target mRNAs. A caveat of this approach is that 
the full-length HCMV transcriptome has not been defined. While RNA-Seq has revealed 
that the majority of the HCMV genome on both strands is transcribed, the presence of 
overlapping and antisense transcription units complicates the identification of the ends 
of HCMV mRNAs (45). As a result we have limited knowledge of the 5’ and 3’UTRs of 
HCMV mRNAs, which play important roles in regulating translation (46, 47). Therefore I 
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could define the viral sequences bound by pTRS1, but might not be able to identify the 
full complement of viral mRNAs that contain that sequence. Thus we need to define the 
full-length HCMV transcriptome to understand how pTRS1 regulates mRNA translation.  
 We also need define the full-length HCMV transcriptome in order to understand 
how HCMV mRNA translation is regulated during infection. Ribosome profiling data 
from Stern-Ginossaur et al. redefined the number of HCMV ORFs, increasing the 
number of peptide coding regions from a previous estimate of ~200 to more than 750 
(48). Thus, the HCMV proteome was shown to be much more complex than previously 
thought. Translation is largely regulated at the 5’ and 3’UTR of an mRNA. 5’UTRs serve 
as binding sites for factors that regulate translation initiation, while sequences in the 
3’UTR play important roles in mRNA stability and localization (46, 47). Thus, to fully 
understand how the translation of an HCMV transcript is controlled during replication, 
and the potential affect(s) of pTRS1 on that transcript, we must define the full sequence 
of that transcript, from m7G cap to poly(A) tail. 
 As mentioned above, standard RNA-Seq approaches are not sufficient to define 
the full-length HCMV transcriptome. Gatherer et al. used short (2X75 bp) sequencing 
reads to show that nearly the entirety of both stands of the HCMV genome is 
transcribed during infection (45). However the short sequencing reads in this dataset 
were not capable of detecting full-length transcripts. Current high throughput 
sequencing reads (2x300 bp) are also not long enough to capture the full length of all 
HCMV transcripts, which in some cases exceed 5,000 bp in length (49). In addition, 
long-read sequencing platforms, such as PacBio, provide many fewer reads and have 
very high error rates compared to high throughput approaches. Thus neither approach 
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alone is sufficient to define the full-length HCMV transcriptome. To overcome these 
problems, we have used a hybrid-sequencing approach that combines these two 
technologies. This approach uses long-read sequencing data to define full-length 
transcripts. High throughput ‘short reads’, which have very low error rates, are then 
mapped to full-length transcripts to define the exact sequence of the transcript. 
Together, long-read and short-read datasets allow us to define full-length transcripts 
with certainty.  
Once full-length transcripts are identified, the published ribosome profiling 
dataset will allow us to define how the 5’ and 3’UTRs of specific viral mRNAs affect their 
translation efficiency during infection. The transcription start sites of many HCMV genes 
change over the course of infection. Using this approach we could determine if changes 
in 5’UTR length and sequence affect the translation of those mRNAs. Additionally, we 
could identify which mRNAs contain pTRS1-binding sites and determine how their 
translation efficiency is regulated throughout infection. We could also identify viral 
mRNAs whose translation is coordinately regulated. Identifying sequence and/or 
structural similarities in coordinately regulated HCMV 5’ and 3’UTRs could reveal new 
mechanisms controlling the regulation of viral protein synthesis.  
 What are the RNAs packaged within the HCMV virion, and are they functional? 
Both cellular and viral mRNAs are packaged alongside pTRS1 and pIRS1 in the 
tegument of the HCMV virion (1, 10). This suggests that pTRS1/pIRS1 recruit mRNAs 
to the tegument. However the role of pTRS1 and pIRS1 in packaging RNAs in the 
virion, or their role in the regulation of tegument mRNAs after infection, is unknown. 
Conflicting reports suggest that either specific mRNAs are incorporated in the tegument, 
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or that tegument RNAs are packaged according to their abundance within the infected 
cell (10, 50-52). To date a comprehensive analysis of HCMV virion RNAs has not been 
performed. This could easily be accomplished using high throughout sequencing of 
RNA isolated from purified HCMV virions. Defining the complement of HCMV RNAs 
packaged within the tegument could identify RNA features that dictate their packaging. 
Comparing these data to the complement of RNAs bound by pTRS1 (see above) could 
identify which RNAs are specifically incorporated into the virion by pTRS1/pIRS1. 
If pTRS1 and pIRS1 bind mRNAs in the tegument, they could promote the 
translation of their associated virion mRNAs immediately after HCMV entry. While it is 
currently unknown if virion mRNAs are translated, it is tempting to speculate that HCMV 
incorporates mRNAs encoding viral antagonists of the innate antiviral response. These 
mRNAs could then be immediately translated into proteins that inactivate cellular 
defenses. Alternatively, virion mRNAs could encode for host or viral proteins that 
remodel cell signaling pathways to support virus replication even before the incoming 
virion has reached the nucleus. The hypothesis that virion mRNAs are translated could 
be tested by determining the fate of virion RNA in newly infected cells. Virion RNA could 
be labeled by treating infected cells with 4-thiouridine (4SU) late in infection when 
virions are being produced. If labeled virion mRNAs associate with polyribosomes early 
in infection, it would show that mRNAs packaged within the tegument are translated. 
We could also determine which, if any, virion mRNAs are translated using RNA-Seq of 
4SU-labeled mRNAs associated with polyribosome fractions in newly infected cells 
treated with ActD. We could also examine the role of pTRS1 and pIRS1 in virion mRNA 
translation by repeating the experiment above with wild type and ΔTRS1/ΔIRS1 virus 
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grown in PKR KO cells (ΔTRS1/ΔIRS1 must be grown in PKR KO cells to achieve viral 
replication and virion production). We would then determine if the translation efficiency 
of virion mRNAs changes in the absence of pTRS1/pIRS1. Characterizing the function 
of tegument mRNAs immediately upon infection will be crucial for understanding if these 
very early events are required to prepare the infected cell for efficient virus replication. 
 It would also be interesting to determine if the complement of RNAs packaged in 
the virion is consistent across cell types. Do virions produced from infected fibroblasts 
contain the same RNAs as virions produced from infected epithelial cells? If they differ, 
is there a change in the fitness of virions produced in one cell type or another? These 
differences could affect the efficiency of lytic replication in different tissues in vivo, and 
ultimately affect pathogenesis. 
 Does mRNA stability regulate mRNA translation during HCMV infection? Our 
pTRS1 BioID screen revealed that pTRS1-associated proteins are significantly enriched 
for functions involved in mRNA degradation. For example, both PAN3 and PABP were 
identified as pTRS1-interactors in our proteomics screen, and we confirmed both 
interactions during HCMV infection (Figure 4.3). The PAN2/3 exoribonuclease complex 
is recruited to mRNAs marked for degradation. PAN3 displaces PABP from the poly(A) 
tail to allow for progressive deadenylation by PAN2. Once the poly(A) tail is <15 nt in 
length, the CCR4/NOT complex completely removes the poly(A) tail and recruits the 
RNA exosome to mediate 3’à5’ degradation of the mRNA (47). We also found that 
pTRS1 specifically interacted with multiple components of the RNA exosome 
machinery, suggesting that pTRS1 may affect mRNA degradation. One possibility is 
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that pTRS1 blocks mRNA degradation, which would stabilize mRNAs and thus enhance 
their translation. 
mRNA degradation is partially governed by the length of the mRNA poly(A) tail. 
Increased poly(A) length increases the amount of bound PABP, which promotes mRNA 
circularization and translation, and thus mRNA stability (53, 54). While mRNAs are 
polyadenylated in the nucleus, cytoplasmic polyadenylation element binding proteins 
(CPEBs) bind mRNA 3’UTRs and mediate the recruitment of deadenylases or poly(A) 
polymerases in the cytoplasm. Four CPEBs (CPEB 1-4) are expressed in mammalian 
cells, and their activation state determines if they promote deadenylation or 
polyadenylation of their bound mRNAs (55). A recent study showed that CPEB1 
expression is necessary for efficient polyadenylation of HCMV mRNAs, expression of 
viral proteins, and efficient HCMV replication (56). These data suggest that viral mRNAs 
with shorter poly(A) tails are translated less efficiently, or are more prone to mRNA 
degradation, leading to decreased levels of viral proteins. We identified CPEB4 as a 
pTRS1-interacting protein and confirmed this interaction in transfected cells. Thus I 
hypothesize that pTRS1 may also play a role in the regulation of viral mRNA poly(A) tail 
length. We could test this by determining the poly(A) tail length of viral mRNAs using 
TAIL-Seq following infection with a wild-type virus or ΔTRS1 virus. If we see no 
difference in poly(A) tail length we would repeat the experiment using a ΔTRS1/ΔIRS1 
virus in PKR KO cells to control for a possibly redundant function of pTRS1 and pIRS1. 
We could then determine if there is a change in translation efficiency (using ribosome 
profiling experiments proposed above) or mRNA stability (see below) for the mRNAs 
that show a change in poly(A) tail length in the absence of pTRS1 and/or pIRS1 
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expression. Stabilization of poly(A) tail-length by pTRS1, possibly through an 
interactions with PABP or CPEB4, could promote mRNA stability and translation of 
pTRS1-target mRNAs. 
These data highlight an aspect of post-transcriptional regulation that has not 
been characterized during HCMV infection. Does the stability of viral mRNAs change 
during infection? And if so, does that change regulate the translation efficiency of viral 
mRNAs? Regulation of mRNA stability and/or poly(A) tail length would add yet another 
level of control that could allow the virus to rapidly change the translation efficiency of 
an mRNA, and therefore regulate the levels of viral and/or cellular proteins. To identify 
changes in mRNA stability caused by infection, we could label newly transcribed RNAs 
with 4SU for a defined period of time during infection, and then add ActD to prevent 
further transcription. 4SU-labeled RNA could be captured at progressive times after 
ActD addition, and the amount of each labeled RNA remaining determined by RNA-Seq. 
Performing this analysis at different times after infection would allow us to determine if 
there are changes in the stability of specific host and viral mRNAs during different 
stages of infection. By combining this data with previously published ribosome profiling 
datasets, we could determine if changes in the abundance or translation efficiency of 
cellular and viral mRNAs during infection results from changes in mRNA stability. We 
could then repeat this experiment in cells infected with a ΔTRS1 (or ΔTRS1/ΔIRS1, in 
case of a redundant pIRS1 function) virus to see if pTRS1 and/or pIRS1 expression has 
an effect on mRNA stability during infection. If we find that pTRS1 affects mRNA 
translation efficiency by regulating mRNA stability, it would suggest that pTRS1-
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dependent regulation of mRNA stability is another layer of regulation utilized by the 
virus to ensure the efficient translation of mRNAs necessary for infection. 
 What is the role of 3’UTR binding proteins in HCMV mRNA translation 
regulation? One of the striking, and surprising, results from our pTRS1 BioID screen 
was the significant association of pTRS1 with 3’UTR binding proteins. Interestingly, a 
majority of the 3’UTR binding proteins identified as pTRS1 interactors have roles in 
regulating target mRNA stability, and therefore potentially translation efficiency, as 
discussed above (47). We have found that pTRS1 lacking its previously identified 
dsRNA binding domain (pTRS1 ΔRBD) still associates with poly(A) mRNA. Thus pTRS1 
may interact with poly(A) mRNA through an interaction with PABP, a 3’UTR binding 
protein, or through an unindentified additional RNA binding domain. These data suggest 
that pTRS1 could regulate the stability and translation efficiency of mRNAs through 
interactions with cellular 3’UTR binding proteins.  
 The role of 3’UTR binding proteins in HCMV replication has not been thoroughly 
examined. This is surprising as the number of transcription start sites far outnumbers 
the number of polyadenylation signals in the HCMV genome (manuscript in 
preparation), suggesting that multiple HCMV transcripts share a common 3’UTR or 
polyadenylation site. Perhaps the most extreme example is the HCMV UL74A locus, 
where 34 splice donor sites scattered across 30 kB of the HCMV genome splice into a 
single acceptor site within UL74A (unpublished data). Thus, there are at least 34 HCMV 
transcripts that share a common 3’UTR. A similar splicing pattern is observed for 
several other HCMV mRNAs, although not to the extent observed in the UL74A locus. 
Shared 3’UTRs have the potential to commonly regulate the stability, localization, and 
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translation of many HCMV mRNAs. It is therefore likely that 3’UTR binding proteins play 
a major role in the regulation of HCMV mRNA stability and translation. pTRS1 binding to 
a specific 3’UTR binding protein could allow pTRS1 to regulate the translation or 
stability of groups of HCMV mRNAs through a single interaction. pTRS1 binding to 
3’UTR binding proteins could allow pTRS1 to have a broader effect on translation than if 
its interaction with mRNA was solely mediated through its ability to bind dsRNA. Thus it 
is likely that the translation of many mRNAs, in addition to those directly bound by 
pTRS1, is regulated by pTRS1 expression during HCMV infection.  
Do mRNA modifications affect translation regulation during HCMV infection? We 
also found that pTRS1 interacted with the cellular proteins YTHDC2, YTHDF2, and 
YTHDF3, which bind RNA marked with an N6-methyladenosine (m6A) modification. m6A 
is the most abundant RNA modification, and was recently shown to play a critical role in 
stress-resistant translation (57, 58). As pTRS1 is involved in translation regulation 
following cellular stress and interacts with multiple m6A readers, I hypothesize that m6A 
modifications play a role in the ability of pTRS1 to stimulate translation. Determining the 
effect of depleting m6A readers or m6A methyltransferases on the ability of pTRS1 to 
enhance reporter mRNA translation would allow us to determine if pTRS1 specifically 
stimulates the translation of m6A modified mRNAs. While the exact function of YTHDC2 
and YTHDF3 is unknown, YTDHF2 has been shown to promote mRNA degradation of 
its bound mRNAs (59). Perhaps pTRS1 binds YTHDF2 and prevents degradation of 
m6A modified mRNAs. This could be an additional means by which pTRS1 modulates 
mRNA stability and therefore mRNA translation. 
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 On a larger scale, the role of mRNA modifications in translation regulation during 
HCMV infection has not been examined. RNA methylation affects both mRNA decay 
and translation initiation (57), however it is not known if HCMV mRNAs contain RNA 
modifications. HCMV mRNAs are processed similarly to cellular mRNAs, which often 
contain multiple RNA modifications. Thus it seems likely that HCMV RNAs contain 
similar RNA modifications. Recently, cap-independent translation was shown to require 
m6A modification of 5’UTRs (60, 61). Perhaps m6A modification of HCMV mRNAs 
enhances their translation in conditions that limit eIF4F abundance. We could test this 
by depleting m6A methyltransferases prior to infection and determining if HCMV mRNAs 
maintain the ability to translate in the absence of a complete eIF4F complex. If m6A 
modifications were necessary for HCMV mRNAs to translate in an eIF4F-independent 
manner, it would be interesting to see if the interaction of pTRS1 with m6A readers 
would be necessary for this phenotype. It is possible that m6A modifications on viral 
mRNAs are bound by the same m6A readers that pTRS1 binds, and thus could target 
pTRS1 to viral mRNAs to promote their translation. In any case, the continued 
translation of HCMV mRNAs in the face of cellular stress is a hallmark of HCMV 
translation regulation. Inclusion of mRNA modifications that promote stress-resistant 
translation on viral mRNAs may be another strategy utilized by HCMV to ensure 
efficient synthesis of viral proteins. 
 How are mRNAs translated in the presence of eIF2α phosphorylation during 
HCMV infection? Many viruses inhibit the translation of cellular mRNAs to free 
ribosomes to translate viral mRNAs (62, 63). However both host and viral mRNAs are 
translated throughout the HCMV replicative cycle, even though phosphorylated eIF2α 
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accumulates later in infection (48, 64). Phosphorylation of eIF2α increases its affinity for 
the guanine nucleotide exchange factor (GEF) eIF2B. Tight binding of phosphorylated 
eIF2α inhibits the ability of eIF2B to exchange GDP for GTP on eIF2, preventing the 
formation of new ternary complexes and leading to a global inhibition of protein 
synthesis (65, 66). Thus an outstanding question is how are host and viral mRNAs 
efficiently translated in the presence of phosphorylated eIF2α? Even a small amount of 
eIF2α phosphorylation significantly inhibits protein synthesis, as eIF2α is present at 
much greater levels than eIF2B (eIF2α is ~10X more abundant) (67). Therefore even 
low levels of phosphorylated eIF2α can sequester all available eIF2B and prevent 
ternary complex formation. A potential mechanism to circumvent eIF2α phosphorylation 
would be for HCMV to increase expression levels of eIF2B. However, this does not 
seem to be the case, as eIF2α and eIF2B levels increase proportionally during infection 
(68). An alternative would be for HCMV to encode a viral GEF, however a GEF domain 
has not been identified in an HCMV protein.  
 Another possible mechanism to maintain protein synthesis despite eIF2α 
phosphorylation would be for HCMV mRNAs to use an alternative translation initiation 
factor(s). The eIF2A and eIF2D initiation factors bind tRNAiMet, associate with 40S 
ribosomal subunits, and can substitute for eIF2 in ternary complex formation (69-72). 
eIF2A is important for viral protein synthesis during hepatitis C virus and alphavirus 
infection, which induce eIF2α phosphorylation (73, 74). The role of eIF2A and eIF2D 
during HCMV infection has not been determined. Cells lacking expression of eIF2A, 
eIF2D, or both, are viable (75). Thus overall levels of protein synthesis and HCMV 
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replication could be examined in cells lacking eIF2A and eIF2D expression to determine 
if these proteins contribute to mRNA translation at late times in HCMV replication. 
 Another possibility is that HCMV alters the composition of eIF2B to make it 
insensitive to eIF2α phosphorylation. eIF2B is a decameric complex consisting of two 
copies of a five protein subunit, eIF2Bα-ε. One subunit, the eIF2Bα protein, is not 
necessary for eIF2B GEF activity. In fact, loss of eIF2Bα renders eIF2B activity resistant 
to inactivation when eIF2α is phosphorylated (76). HCMV could alter eIF2Bα expression 
or binding to the eIF2B complex to allow for continued mRNA translation despite eIF2α 
phosphorylation. Whole cell proteomics analysis of HCMV infected cells found that 
eIF2Bα levels are relatively unchanged by infection (68), however it is not known if 
infection prevents inclusion of eIF2Bα into the eIF2B complex. If eIF2Bα was 
dissociated from the eIF2B complex, perhaps by an HCMV protein, this could facilitate 
GTP exchange on eIF2 despite eIF2α phosphorylation, allowing for overall levels of 
protein synthesis to remain unaffected. Proteomics analysis to define the components of 
the eIF2B complex during infection could identify changes to the eIF2B holoenzyme 
complex that potentially allow HCMV mRNAs to translate in the face of eIF2α 
phosphorylation. 
 It is also possible that HCMV specifically induces eIF2α phosphorylation late in 
infection for the benefit of the virus. As discussed above, eIF2α phosphorylation inhibits 
the translation of most mRNAs. However eIF2α phosphorylation also promotes 
translation initiation on mRNAs that contain short upstream ORFs (uORFs) in their 
5’UTR preceding the mRNA coding determinant sequence (cds). Under non-stressed 
conditions, translation initiation on 5’UTR uORFs inhibits the translation of the 
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downstream cds. When eIF2α is phosphorylated, 48S complexes are more likely to 
scan through uORFs to the translation start codon for the cds (39, 46). uORFs are 
common in cellular mRNAs encoding proteins involved in alleviating cellular stress (41). 
Virus replication and assembly induces significant cellular stress (77), thus the 
expression of cellular proteins needed to mitigate stress would likely be beneficial to the 
virus at this point of infection. Further HCMV ribosome profiling data identified several 
hundred short (<30 aa) peptide coding regions, which were often situated just upstream 
of known viral genes (48).  While the full-length transcriptome of HCMV is poorly 
defined, this data suggests that uORFs may be a common feature of HCMV mRNAs. 
Ribosome profiling data also showed that HCMV mRNAs are translated more efficiently 
than host mRNAs late in infection, when eIF2α is phosphorylated (64). I hypothesize 
that the inclusion of uORFs on HCMV mRNAs allows them to be translated more 
efficiently than host mRNAs when eIF2α is phosphorylated. This would allow for 
ongoing viral protein synthesis despite the harsh intracellular environment found late in 
infection, and could help HCMV mRNAs compete for host ribosomes by decreasing the 
translation of cellular mRNAs. To test this hypothesis, we could measure HCMV mRNA 
translation and replication in cells where the phosphorylation site of eIF2α (Ser51) has 
been mutated using CRISPR/Cas9. We could then compare the translation efficiency of 
host and viral mRNAs in control and eIF2α phosphosite mutant cells at different times 
after infection, and measure the impact on HCMV replication. No matter the 
mechanism, further work is needed to understand how HCMV mRNAs avoid translation 
inhibition in the presence of eIF2α phosphorylation, as this mechanism is likely 
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necessary for the efficient translation of viral mRNAs late in infection, and therefore 
necessary for efficient HCMV replication.	
 
Conclusion 
 In this thesis I defined the molecular mechanism of PKR antagonism by pTRS1, 
showed that pTRS1 stimulates cap-independent translation, and identified pTRS1-
interacting proteins that may contribute to the ability of pTRS1 to stimulate translation in 
a PKR-independent manner. These data add to a growing list of pTRS1 functions and 
also implicate a role for pTRS1 in the regulation of mRNA stability and mRNA 
modifications as a means to control protein synthesis during HCMV infection. Post-
transcriptional regulation of gene expression is a largely unexplored area of HCMV 
research. The role of mRNA modifications, mRNA stability, and cellular RNA binding 
proteins in translation regulation during HCMV, and most herpesvirus, infections has not 
been thoroughly characterized. As viruses are completely reliant on the host translation 
machinery for the synthesis of viral proteins, factors that are necessary for the synthesis 
of viral proteins are attractive antiviral drug targets. Thus studies identifying the cellular 
factors necessary for the translation of viral mRNAs are important for both our complete 
understanding of the HCMV replication cycle, and the development of novel antiviral 
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